PARP1 inhibitors, compositions comprising them, and uses thereof.
Patent Information
- Application Number
- BR122025009667
- Authority / Receiving Office
- BR · BR
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2022-09-20
- Filing Date
- 2023-01-20
- Publication Date
- 2026-11-10
- Estimated Expiration
- 2043-01-20
AI Technical Summary
There is an unmet medical need for effective and safe PARP inhibitors, particularly those with selectivity for PARP1, to address various diseases including cancer, inflammatory disorders, and retroviral infections.
The development of a compound of Formula (I) or its pharmaceutically acceptable salt, solvate, or stereoisomer, which exhibits improved selectivity for PARP1, thereby potentially enhancing efficacy and reducing toxicity in therapeutic applications.
The proposed compound is expected to effectively inhibit PARP1, leading to improved treatment outcomes for cancers with BRCA1 and BRCA2 mutations, as well as other conditions where PARP inhibition is beneficial, while minimizing side effects.
Description
CROSS-REFERENCE
[001] This application claims the benefit of U.S. Provisional Patent Application Serial No. 63 / 301,907, filed January 21, 2022, and U.S. Provisional Patent Application Serial No. 63 / 376,338, filed September 20, 2022, which are incorporated herein by reference in their entirety. BACKGROUND OF THE INVENTION
[002] Poly(ADP-ribose)polymerase (PARP) or poly(ADP-ribose)synthase (PARS) plays an essential role in facilitating DNA repair, controlling RNA transcription, mediating cell death, and regulating the immune response. These actions make PARP inhibitors targets for a broad spectrum of disorders. PARP inhibitors have demonstrated efficacy in several disease models, particularly in models of ischemic reperfusion injury, inflammatory disease, degenerative diseases, protection against adverse effects of cytotoxic compounds, and potentiation of cytotoxic cancer therapy. PARP has also been indicated in retroviral infection, and therefore, inhibitors may have use in antiretroviral therapy. PARP inhibitors have been effective in preventing ischemic reperfusion injury in models of myocardial infarction, stroke, other neural trauma, organ transplantation, as well as reperfusion of the eyes, kidney, intestine, and skeletal muscle.PARP inhibitors have been effective in inflammatory diseases such as arthritis, gout, inflammatory bowel disease, CNS inflammation such as MS and allergic encephalitis, sepsis, septic shock, hemorrhagic shock, pulmonary fibrosis, and uveitis. PARP inhibitors have also shown benefit in several models of degenerative disease including diabetes (as well as complications) and Parkinson's disease. PARP inhibitors may improve liver toxicity after acetaminophen overdose, cardiac and renal toxicities from doxorubicin and platinum-based antineoplastic agents, as well as skin damage secondary to sulfur mustards. In several cancer models, PARP inhibitors have been shown to potentiate radiation and chemotherapy by increasing cell death of cancer cells, limiting tumor growth, decreasing metastasis, and prolonging the survival of tumor-bearing animals.
[003] PARP1 and PARP2 are the most widely studied PARPs for their role in DNA damage repair. PARP1 is activated by DNA breaks and damage and functions to catalyze the addition of poly(ADP-ribose) (PAR) chains to target proteins. This post-translational modification, known as PArilation, mediates the recruitment of additional DNA repair factors to DNA lesions.
[004] After the completion of this recruitment function, PARP auto-replication triggers the release of bound PARP from DNA to allow access to other DNA repair proteins to complete the repair. Thus, PARP binding to damaged sites, its catalytic activity, and its eventual release from DNA are all important steps for a cancer cell to respond to DNA damage caused by chemotherapeutic agents and radiotherapy.
[005] Inhibition of PARP family enzymes has been explored as a strategy to selectively exterminate cancer cells by inactivating complementary DNA repair pathways. Several preclinical and clinical studies have demonstrated that tumor cells with deleterious alterations of BRCA1 or BRCA2, key tumor suppressor proteins involved in double-strand DNA break ("DSB") repair by homologous recombination ("HR"), are selectively sensitive to small molecule inhibitors of the PARP family of DNA repair enzymes. Such tumors have deficient homologous recombination repair ("HRR") pathways and depend on the function of PARP enzymes for survival.Although PARP inhibitor therapy predominantly targets cancers with SRCA mutations, PARP inhibitors have been clinically tested in tumors without SRCA mutations, those exhibiting homologous recombination deficiency ("HRD").
[006] It is believed that PARP inhibitors with improved selectivity for PARP1 may have improved efficacy and reduced toxicity compared to other clinical PARP1 / 2 inhibitors. It is also believed that strong selective inhibition of PARP1 would lead to PARP1 trapping in DNA, resulting in DNA double-strand breaks (DSBs) through the collapse of replication forks in the S phase. It is also believed that PARP1-DNA trapping is an effective mechanism for selectively eliminating tumor cells that have HRD. There is, therefore, an unmet medical need for effective and safe PARP inhibitors. Especially, PARP inhibitors with selectivity for PARP1. SUMMARY OF THE INVENTION
[007] A compound of Formula (I), or a salt, solvate or pharmaceutically acceptable stereoisomer thereof, is described herein: wherein: R1 is hydrogen, deuterium, halogen, -CN, -ORa, -NRcRd, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl or heterocycloalkyl; wherein alkyl, alkenyl, alkynyl, cycloalkyl and heterocycloalkyl are optionally substituted by one or more R; R2 is hydrogen, deuterium, halogen, -CN, -ORa, -NRcRd, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 deuteroalkyl; X is N or CR3; Y is N or CR4; Z is N or CR5; R3 is hydrogen, deuterium, halogen, -CN, -ORa, -NRcRd, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl or heterocycloalkyl; wherein alkyl, alkenyl, alkynyl, cycloalkyl and heterocycloalkyl are optionally substituted by one or more R;R4 is hydrogen, deuterium, halogen, -CN, -ORa, -NRcRd, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl or heterocycloalkyl; wherein alkyl, alkenyl, alkynyl, cycloalkyl and heterocycloalkyl are optionally substituted by one or more R; R5 is hydrogen, deuterium, halogen, -CN, -ORa, -NRcRd, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl or heterocycloalkyl; wherein alkyl, alkenyl, alkynyl, cycloalkyl and heterocycloalkyl are optionally substituted by one or more R; each R6 is independently hydrogen, deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, cycloalkyl or heterocycloalkyl;wherein the alkyl, cycloalkyl and heterocycloalkyl groups are optionally substituted by one or more R groups; or two R groups are combined to form a cycloalkyl or a heterocycloalkyl group; each optionally substituted by deuterium, halogen, -CN, -OH, -ORa, -NRcRd, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, or C1-C6 heteroalkyl; each R group is independently deuterium, halogen, -CN, -OH, -ORa, -NRcRd, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, or C2-C6 alkynyl; or two R7s on the same carbon are combined to form an oxo; or two R7s on the same carbon or on different carbons are combined to form a cycloalkyl or a heterocycloalkyl; each optionally substituted by one or more R; n is 0 to 4; T is N or CR8; U is N or CR9;R8 is hydrogen, deuterium, halogen, -CN, -OH, -ORa, -NRcRd, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl or heterocycloalkyl; wherein alkyl, alkenyl, alkynyl, cycloalkyl and heterocycloalkyl are optionally substituted by one or more R; R9 is hydrogen, deuterium, halogen, -CN, -OH, -ORa, -NRcRd, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl or heterocycloalkyl; wherein alkyl, alkenyl, alkynyl, cycloalkyl and heterocycloalkyl are optionally substituted by one or more R; R10 is hydrogen, deuterium, halogen, -CN, -OH, -ORa, -NRcRd, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl or heterocycloalkyl;where alkyl, alkenyl, alkynyl, cycloalkyl and heterocycloalkyl are optionally substituted by one or more R; R11é hydrogen, deuterium, halogenium, -CN, -OH, -ORa, - NRcRd, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C1-C6heteroalkyl, C2- C6alkenyl, C2-C6alkynyla, cycloalkyl or heterocycloalkyl; where alkyl, alkenyl, alkynyl, cycloalkyl and heterocycloalkyl are optionally substituted by one or more R; R12é cyano or halogenium; each Ra is independently C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C1-C6heteroalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6alkylene(cycloalkyl), C1-C6alkylene(heterocycloalkyl), C1-C6alkylene(aryl), or C1-C6alkylene(heteroaryl);sendo que cada alkyla, alkylene, alkenyl, alkynyl, cycloalkyla, heterocicloalkyla, aryl e heteroaryla é independente e opciónmente substituída por um ou mais R; cada Rbé independentemente hidrogênio, C1-C6alkyla, C1-C6haloalkyla, C1-C6deuteroalkyla, C1-C6hydroxyalkyla, C1-C6aminoalkyla, C1-C6heteroalkyla, C2-C6alkenyl, C2-C6alkynyl, cicloalkyla, heterocicloalkyla, aryl, heteroaryla, C1-C6alkyleno(cicloalkyla), C1-C6alkyleno(heterocicloalkyla), C1-C6alkyleno(aryla), ou C1-C6alkyleno(heteroaryla); sendo que cada alquila, alkylene, alkenyl, alkynyl, cicloalquila, heterocicloalquila, aryl e heteroaryl é independente e opciónmente substituída por um ou mais R;and each Rc and Rd are independently hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkylene (cycloalkyl), C1-C6 alkylene (heterocycloalkyl), C1-C6 alkylene (aryl), or C1-C6 alkylene (heteroaryl); wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently and optionally substituted by one or more R; or Rc and Rd are considered together with the atom to which they are attached to form a heterocycloalkyl optionally substituted by one or more R;each R is independently deuterium, halogen, -CN, -OH, -OC1-C6alkyl, -NH2, -NHC1-C6alkyl, -N(C1-C6alkyl)2, -NHC(=O)OC1-C6alkyl, -C(=O)C1-C6alkyl, -C(=O)OH, -C(=O)OC1-C6alkyl, -C(=O)NH2, -C(=O)N(C1-C6alkyl)2, -C(=O)NHC1-C6alkyl, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, or C1-C6heteroalkyl; or two R on the same atom are combined to form an oxo; provided that when X is CR3, Y is CR4 and Z is CR5; Therefore, one of R3, R4, and R5 is not hydrogen, and R4 is not -OMe; and since when X is CH, Y is CH, and Z is CH, then R2 is not hydrogen.
[008] Also described herein is a pharmaceutical composition comprising a compound described herein, or a salt, a solvate or a pharmaceutically acceptable stereoisomer thereof and a pharmaceutically acceptable excipient.
[009] Also described herein is a method of treating a cancer comprising a BRCA1 and / or BRCA2 mutation in an individual in need thereof, the method comprising administering a compound described herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. Also described herein is a method of treating a cancer comprising a mutation in a gene conferring homologous repair deficiency in an individual in need thereof, the method comprising administering a compound described herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. In some embodiments, the mutation in a gene conferring homologous repair deficiency comprises ATM, BRCA1, BRCA2, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, RAD51B, RAD51C, RAD51D, or RAD54L, or any combination thereof.In some modalities, the cancer is bladder cancer, brain and CNS cancer, breast cancer, cervical cancer, colorectal cancer, esophageal cancer, Hodgkin's lymphoma, non-Hodgkin's lymphoma, kidney cancer, leukemia, lung cancer, melanoma, myeloma, oral cavity cancer, ovarian cancer, pancreatic cancer, prostate cancer, skin cancer, stomach cancer, thyroid cancer, or uterine cancer. In some modalities, the cancer is metastatic. In some modalities, the cancer will have metastases in the brain.
[0010] Also described herein is a method of treating brain cancer in an individual in need thereof, the method comprising administering a compound described herein, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof. Also described herein is a method of treating brain cancer in an individual in need thereof, the method comprising administering a compound described herein, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof. Incorporation by Reference
[0011] All publications, patents and patent applications mentioned in this descriptive report are incorporated into the present invention by reference to the same extent as if each individual publication, patent or patent application were specifically and individually indicated for incorporation by reference. DETAILED DESCRIPTION OF THE INVENTION Definitions
[0012] In the following description, certain specific details are set forth to provide a complete understanding of various embodiments. However, one skilled in the art will understand that the invention can be practiced without these details. In other cases, well-known structures have not been shown or described in detail to avoid descriptions that unnecessarily confuse embodiments. Unless the context requires otherwise, throughout the descriptive report and claims that follow, the word "comprise" and variations thereof, such as "comprises" and "comprising," shall be interpreted in an open, inclusive sense, that is, "including but not limited to." Furthermore, the headings given herein are for convenience only and do not interpret the scope or meaning of the claimed invention.
[0013] The reference throughout this descriptive report to "some modalities" means that a specific feature, structure, or characteristic described in connection with the modality is included in at least one modality. Thus, the appearance of the phrase "in a modality" in various places throughout this descriptive report does not necessarily refer to the same modality. Furthermore, specific features, structures, or characteristics may be combined in any suitable manner in one or more modalities. Additionally, as used in this descriptive report and the attached claims, the singular forms "a," "an," "the," and "the" include plural references unless the content clearly indicates otherwise. It should also be noted that the term "or" is generally used in its inclusive sense of "and / or," unless the content clearly indicates otherwise.
[0014] The terms below, as used herein, have the following meanings unless otherwise indicated: "oxo" refers to =O. "carboxyl" refers to -COOH. "cyano" refers to -CN.
[0015] "Alkyl" refers to a saturated hydrocarbon monoradical with a linear or branched chain having from one to about ten carbon atoms, more preferably from one to six carbon atoms. Examples include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, 2-methyl-1-propyl, 2-methyl-2-propyl, 2-methyl-1-butyl, 3-methyl-1-butyl, 2-methyl-3-butyl, 2,2-dimethyl-1-propyl, 2-methyl-1-pentyl, 3-methyl-1-pentyl, 4-methyl-1-pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2,2-dimethyl-1-butyl, 3,3-dimethyl-1-butyl, 2-ethyl-1-butyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl, isopentyl, ne-pentyl, ter-amyl and hexyl, and longer alkyl groups such as Heptyl, octyl and similar types.Whenever a numerical range such as "C1-C6 alkyl" or "C1-6alkyl" appears here, it means that the alkyl group may consist of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms, or 6 carbon atoms, although the present definition also covers the occurrence of the term "alkyl" where no numerical range is designated. In some embodiments, the alkyl is a C1-10 alkyl. In some embodiments, the alkyl is a C1-6 alkyl. In some embodiments, the alkyl is a C1-5 alkyl. In some embodiments, the alkyl is a C1-4 alkyl. In some embodiments, the alkyl is a C1-3 alkyl. Unless otherwise specifically indicated in the descriptive report, an alkyl group may optionally be replaced, for example, by oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl and the like.In some embodiments, the alkyl group is optionally replaced by an oxo group, a halogen group, -CN, -COOH, -COOMe, -OH, -OMe, -NH2, or -NO2. In some embodiments, the alkyl group is optionally replaced by a halogen group, -CN, -OH, or -OMe. In some embodiments, the alkyl group is optionally replaced by a halogen group.
[0016] "Alkenyl" refers to a linear or branched chain hydrocarbon monoradical having one or more carbon-carbon double bonds and having from two to about ten carbon atoms, more preferably from two to about six carbon atoms. The group may be in the cis or trans conformation with respect to the double bond(s), and should be understood as including both isomers. Examples include, but are not limited to, ethenyl (-CH=CH2), 1-propenyl (-CH2CH=CH2), isopropenyl [-C(CH3)=CH2], butenyl, 1,3-butadienyl and the like. Whenever a numerical range such as "C2-C6 alkenyl" or "C2-6 alkenyl" appears here, it means that the alkenyl group may consist of 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms, or 6 carbon atoms, although the present definition also covers the occurrence of the term "alkenyl" where no numerical range is designated.Unless otherwise specifically indicated in the descriptive report, an alkenyl group may be optionally substituted, for example, by oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like. In some embodiments, the alkenyl is optionally substituted by oxo, halogen, -CN, -COOH, -COOMe, -OH, -OMe, -NH2, or -NO2. In some embodiments, the alkenyl is optionally substituted by halogen, -CN, -OH, or -OMe. In some embodiments, the alkenyl is optionally substituted by halogen.
[0017] "Alkynyl" refers to a linear or branched chain hydrocarbon monoradical having one or more carbon-carbon triple bonds and having from two to about ten carbon atoms, more preferably from two to about six carbon atoms. Examples include, but are not limited to, ethynyl, 2-propynyl, 2-butynyl, 1,3-butadiynyl and the like. Wherever a numerical range such as "C2-C6 alkynyl" or "C2-6 alkynyl" appears herein, it means that the alkynyl group may consist of 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms or 6 carbon atoms, although the present definition also covers the occurrence of the term "alkynyl" where no numerical range is designated.Unless otherwise specifically indicated in the descriptive report, an alkynyl group may be optionally replaced, for example, by oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like. In some embodiments, the alkynyl is optionally replaced by oxo, halogen, -CN, -COOH, -COOMe, -OH, -OMe, -NH2, or -NO2. In some embodiments, the alkynyl is optionally replaced by halogen, -CN, -OH, or -OMe. In some embodiments, the alkynyl is optionally replaced by halogen.
[0018] "Alkylene" refers to a linear or branched divalent hydrocarbon chain. Unless otherwise indicated, specifically in the descriptive report, an alkylene group may be optionally substituted, for example, by oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl and the like. In some embodiments, the alkylene is optionally substituted by oxo, halogen, -CN, -COOH, COOMe, -OH, -OMe, -NH2 or -NO2. In some embodiments, the alkylene is optionally substituted by halogen, -CN, -OH or -OMe. In some embodiments, the alkylene is optionally substituted by halogen.
[0019] "Alkoxy" refers to a radical with the formula -ORa where Ra is an alkyl radical as defined. Unless otherwise indicated, specifically in the descriptive report, an alkoxy group may be optionally substituted, for example, by oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl and the like. In some embodiments, the alkoxy is optionally substituted by halogen, -CN, -COOH, COOMe, -OH, -OMe, -NH2 or -NO2. In some embodiments, the alkoxy is optionally substituted by halogen, -CN, -OH or -OMe. In some embodiments, the alkoxy is optionally substituted by halogen.
[0020] "Aryl" refers to a radical derived from a hydrocarbon ring system comprising 6 to 30 carbon atoms and at least one aromatic ring. The aryl radical may be a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which may include bridging or fused ring systems (when fused with a cycloalkyl or heterocycloalkyl ring, the aryl is linked through an aromatic ring atom). In some embodiments, the aryl is a 6- to 10-membered aryl. In some embodiments, the aryl is a 6-membered aryl (phenyl). Aryl radicals include, but are not limited to, aryl radicals derived from the hydrocarbon ring systems of anthrylene, naphthylene, phenanthrylene, anthracene, azulene, benzene, chrysene, fluoroanthene, fluorene, as-indacene, s-indacene, indane, indene, naphthalene, phenalene, phenanthrene, pleiadene, pyrene, and triphenylene.Unless otherwise indicated, specifically in the descriptive report, an aryl group may be optionally replaced, for example, by halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl and the like. In some embodiments, the aryl group is optionally replaced by halogen, methyl, ethyl, -CN, -COOH, COOMe, -CF3, -OH, -OMe, -NH2 or -NO2. In some embodiments, the aryl group is optionally replaced by halogen, methyl, ethyl, -CN, -CF3, -OH or -OMe. In some embodiments, the aryl group is optionally replaced by halogen.
[0021] "Cycloalkyl" refers to a partially or fully saturated carbocyclic, monocyclic, or polycyclic ring, which may include bridging or fused ring systems (when fused with an aryl or heteroaryl ring, the cycloalkyl is linked through a non-aromatic ring atom). In some embodiments, the cycloalkyl is fully saturated. Representative cycloalkyls include, but are not limited to, cycloalkyls having from three to fifteen carbon atoms (C3-C15 cycloalkyl or C3-C15 cycloalkenyl), from three to ten carbon atoms (C3-C10 cycloalkyl or C3-C10 cycloalkenyl), from three to eight carbon atoms (C3-C8 cycloalkyl or C3-C8 cycloalkenyl), from three to six carbon atoms (C3-C6 cycloalkyl or C3-C6 cycloalkenyl), from three to five carbon atoms (C3-C5 cycloalkyl or C3-C5 cycloalkenyl), or from three to four carbon atoms (C3-C4 cycloalkyl or C3-C4 cycloalkenyl).In some embodiments, the cycloalkyl is a 3- to 10-membered cycloalkyl or a 3- to 10-membered cycloalkenyl. In some embodiments, the cycloalkyl is a 3- to 6-membered cycloalkyl or a 3- to 6-membered cycloalkenyl. In some embodiments, the cycloalkyl is a 5- to 6-membered cycloalkyl or a 5- to 6-membered cycloalkenyl. Monocyclic cycloalkyls include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Polycyclic cycloalkyls include, for example, adamantyl, norbornyl, decalinyl, bicyclo[3,3,0]octane, bicyclo[4,3,0]nonane, cisdecalin, trans-decalin, bicyclo[2,1,1]hexane, bicyclo[2,2,1]heptane, bicyclo[2,2,2]octane, bicyclo[3,2,2]nonane and bicyclo[3,3,2]decane and 7,7-dimethyl-bicyclo[2,2,1]heptanyl. Partially saturated cycloalkyls include, for example, cyclopentenyl, cyclohexenyl, cycloheptenyl and cyclooctenyl.Unless otherwise indicated, specifically in the descriptive report, a cycloalkyl group is optionally substituted, for example, by oxo, halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like. In some embodiments, a cycloalkyl group is optionally substituted by oxo, halogen, methyl, ethyl, -CN, -COOH, COOMe, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, a cycloalkyl group is optionally substituted by oxo, halogen, methyl, ethyl, -CN, -CF3, -OH, or -OMe. In some embodiments, the cycloalkyl group is optionally substituted by halogen.
[0022] "Halo" or "halogen" refers to bromine, chlorine, fluorine, or iodine. In some embodiments, the halogen is fluorine or chlorine. In some embodiments, the halogen is fluorine.
[0023] "Haloalkyl" refers to an alkyl radical, as defined above, which is substituted by one or more halo radicals, as defined above, for example, trifluoromethyl, difluoromethyl, fluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 1,2-difluoroethyl, 3-bromo-2-fluoropropyl, 1,2-dibromoethyl and the like.
[0024] "Hydroxyalkyl" refers to an alkyl radical, as defined above, that is substituted by one or more hydroxyl groups. In some embodiments, the alkyl is substituted by a hydroxyl group. In some embodiments, the alkyl is substituted by one, two, or three hydroxyl groups. Hydroxyalkyl includes, for example, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, or hydroxypentyl. In some embodiments, the hydroxyalkyl is hydroxymethyl.
[0025] "Aminoalkyl" refers to an alkyl radical, as defined above, that is substituted by one or more amines. In some embodiments, the alkyl is substituted by an amine. In some embodiments, the alkyl is substituted by one, two, or three amines. Aminoalkyl includes, for example, aminomethyl, aminoethyl, aminopropyl, aminobutyl, or aminopentyl. In some embodiments, the aminoalkyl is aminomethyl.
[0026] "Deuteroalkyl" refers to an alkyl radical, as defined above, that is substituted by one or more deuteriums. In some embodiments, the alkyl is substituted by a deuterium. In some embodiments, the alkyl is substituted by one, two, or three deuteriums. In some embodiments, the alkyl is substituted by one, two, three, four, five, or six deuteriums. Deuteroalkyl includes, for example, CD3, CH2D, CHD2, CH2CD3, CD2CD3, CHDCD3, CH2CH2D, or CH2CHD2. In some embodiments, the deuteroalkyl is CD3.
[0027] "Heteroalkyl" refers to an alkyl group in which one or more atoms of the alkyl backbone are selected from an atom other than carbon, for example, oxygen, nitrogen (e.g., -NH-, -N(alkyl)-), sulfur, phosphorus, or combinations thereof. A heteroalkyl is attached to the rest of the molecule at a carbon atom of the heteroalkyl. In one aspect, a heteroalkyl is a C1-C6 heteroalkyl wherein the heteroalkyl comprises 1 to 6 carbon atoms and one or more atoms other than carbon, for example, oxygen, nitrogen (e.g., -NH-, -N(alkyl)-), sulfur, phosphorus, or combinations thereof, wherein the heteroalkyl is attached to the rest of the molecule at a carbon atom of the heteroalkyl. Examples of such heteroalkyl groups are, for example, -CH2OCH3, -CH2CH2OCH3, -CH2CH2OCH2CH2OCH3, -CH(CH3)OCH3, -CH2NHCH3, -CH2N(CH3)2, -CH2CH2NHCH3 or -CH2CH2N(CH3)2.Unless otherwise indicated, specifically in the descriptive report, a heteroalkyl group is optionally substituted, for example, by oxo, halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like. In some embodiments, a heteroalkyl group is optionally substituted by oxo, halogen, methyl, ethyl, -CN, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, a heteroalkyl group is optionally substituted by oxo, halogen, methyl, ethyl, -CN, -CF3, -OH, or -OMe. In some embodiments, the heteroalkyl group is optionally substituted by halogen.
[0028] "Heterocycloalkyl" refers to a partially or fully saturated 3- to 24-membered ring radical comprising 2 to 23 carbon atoms and one to eight heteroatoms selected from the group consisting of nitrogen, oxygen, phosphorus, and sulfur. In some embodiments, the heterocycloalkyl is fully saturated. In some embodiments, the heterocycloalkyl comprises one to three heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur. In some embodiments, the heterocycloalkyl comprises one to three heteroatoms selected from the group consisting of nitrogen and oxygen. In some embodiments, the heterocycloalkyl comprises one to three nitrogens. In some embodiments, the heterocycloalkyl comprises one or two nitrogens. In some embodiments, the heterocycloalkyl comprises one nitrogen. In some embodiments, the heterocycloalkyl comprises one nitrogen and one oxygen.Unless otherwise indicated, specifically in the descriptive report, the heterocycloalkyl radical may be a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which may include bridging or fused ring systems (when fused with an aryl or heteroaryl ring, the heterocycloalkyl is linked through a non-aromatic ring atom); and the nitrogen, carbon, or sulfur atoms in the heterocycloalkyl may optionally be oxidized; the nitrogen atom may optionally be quaternized.Representative heterocycloalkyls include, but are not limited to, heterocycloalkyls having from two to fifteen carbon atoms (C2-C15 heterocycloalkyl or C2-C15 heterocycloalkenyl), from two to ten carbon atoms (C2-C10 heterocycloalkyl or C2-C10 heterocycloalkenyl), from two to eight carbon atoms (C2-C8 heterocycloalkyl or C2-C8 heterocycloalkenyl), from two to seven carbon atoms (C2-C7 heterocycloalkyl or C2-C7 heterocycloalkenyl), from two to six carbon atoms (C2-C6 heterocycloalkyl or C2-C6 heterocycloalkenyl), from two to five carbon atoms (C2-C5 heterocycloalkyl or C2-C5 heterocycloalkenyl), or from two to four carbon atoms (C2-C4 heterocycloalkyl or C2-C4 heterocycloalkenyl).Examples of such heterocycloalkyl radicals include, but are not limited to, aziridinyl, azetidinyl, oxetanyl, dioxolanyl, thienyl[1,3]dithyanyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl, 1-oxo- thiomorpholinyl, 1,1-dioxo-thiomorpholinyl, 1,3-dihydroisobenzofuran-1-yl, 3-oxo-1,3-dihydroisobenzofuran-1-yl, methyl-2-oxo-1,3-dioxol-4-yl and 2-oxo-1,3-dioxol-4-yl. The term heterocycloalkyl also includes all ring forms of carbohydrates, including but not limited to monosaccharides, disaccharides and oligosaccharides.Unless otherwise indicated, heterocycloalkyls have from 2 to 10 carbons in the ring. It is understood that, when referring to the number of carbon atoms in a heterocycloalkyl, the number of carbon atoms in the heterocycloalkyl is not the same as the total number of atoms (including heteroatoms) that constitute the heterocycloalkyl (i.e., atoms of the heterocycloalkyl ring backbone). In some embodiments, the heterocycloalkyl is a 3- to 8-membered heterocycloalkyl. In some embodiments, the heterocycloalkyl is a 3- to 7-membered heterocycloalkyl. In some embodiments, the heterocycloalkyl is a 3- to 6-membered heterocycloalkyl. In some embodiments, the heterocycloalkyl is a 4- to 6-membered heterocycloalkyl. In some embodiments, the heterocycloalkyl is a 5- to 6-membered heterocycloalkyl. In some embodiments, the heterocycloalkyl group is a 3- to 8-membered heterocycloalkenyl group.In some embodiments, the heterocycloalkyl is a 3- to 7-membered heterocycloalkenyl. In some embodiments, the heterocycloalkyl is a 3- to 6-membered heterocycloalkenyl. In some embodiments, the heterocycloalkyl is a 4- to 6-membered heterocycloalkenyl. In some embodiments, the heterocycloalkyl is a 5- to 6-membered heterocycloalkenyl. Unless otherwise indicated, specifically in the descriptive report, a heterocycloalkyl may optionally be substituted as described below, for example, by oxo, halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl and the like. In some embodiments, the heterocycloalkyl group is optionally replaced by oxo, halogen, methyl, ethyl, -CN, -COOH, COOMe, -CF3, -OH, -OMe, -NH2, or -NO2.In some embodiments, the heterocycloalkyl group is optionally replaced by a halogen, methyl, ethyl, -CN, -CF3, -OH, or -OMe. In some embodiments, the heterocycloalkyl group is optionally replaced by a halogen.
[0029] "Heteroaryl" refers to a 5- to 14-membered ring system radical comprising one to thirteen carbon atoms, one to six heteroatoms selected from the group consisting of nitrogen, oxygen, phosphorus, and sulfur, and at least one aromatic ring. In some embodiments, the heteroaryl comprises one to three heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur. In some embodiments, the heteroaryl comprises one to three heteroatoms selected from the group consisting of nitrogen and oxygen. In some embodiments, the heteroaryl comprises one to three nitrogens. In some embodiments, the heteroaryl comprises one or two nitrogens. In some embodiments, the heteroaryl comprises one nitrogen. The heteroaryl radical may be a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which may include bridging or fused ring systems (when fused with a cycloalkyl or heterocycloalkyl ring).The heteroaryl group is linked through an aromatic ring atom; and the nitrogen, carbon, or sulfur atoms in the heterocycloalkyl radical may optionally be oxidized; the nitrogen atom may optionally be quaternized. In some embodiments, the heteroaryl group is a 5- to 10-membered heteroaryl group. In some embodiments, the heteroaryl group is a 5- to 6-membered heteroaryl group. In some embodiments, the heteroaryl group is a 6-membered heteroaryl group. In some embodiments, the heteroaryl group is a 5-membered heteroaryl group. Examples include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzothiazolyl, benzindolyl, benzodioxolyl, benzofuranyl, benzooxazolyl, benzothiazolyl, benzothiadiazolyl, benzo[b][1,4]dioxepinyl, 1,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzofuranonyl, benzothienyl (benzothiophenyl), benzotriazolyl, benzo[4,6]imidazo[1,2-a]pyridinyl, carbazolyl,cinolinyl, dibenzofuranyl, dibenzothiophenyl, furanyl, furanonyl, isothiazolyl, imidazolyl, indazolyl, indolyl, isoindolyl, indolinyl, isoindolinyl, isoquinolyl, indolizinyl, isoxazolyl, naphthyridinyl, oxadiazolyl, 2-oxoazepinyl, oxazolyl, oxiranyl, 1-oxidopyridinyl, 1-oxidopyrimidinyl, 1- oxidopyrazinyl, 1-oxidopyridazinyl, 1-phenyl-1H-pyrrolyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, pyrrolyl, pyrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, quinazolinyl, quinoxalinyl, quinolinyl, quinuclidinyl, isoquinolinyl, tetrahydroquinolinyl, thiazolyl, thiadiazolyl, triazolyl, tetrazolyl, triazinyl, and thiophenyl (i.e., thienyl). Unless otherwise indicated, specifically in the descriptive report, a heteroaryl group may optionally be substituted, for example, by halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl,Cycloalkyl, heterocycloalkyl, heteroaryl and the like. In some embodiments, the heteroaryl is optionally replaced by halogen, methyl, ethyl, -CN, -COOH, COOMe, -CF3, -OH, -OMe, -NH2 or -NO2. In some embodiments, the heteroaryl is optionally replaced by halogen, methyl, ethyl, -CN, -CF3, -OH or -OMe. In some embodiments, the heteroaryl is optionally replaced by halogen.
[0030] The term "optional" or "optionally" means that the event or circumstance subsequently described may or may not occur, and that the description includes instances where said event or circumstance occurs, and instances where it does not occur. For example, "optionally substituted alkyl" means "alkyl" or "substituted alkyl," as defined above. Furthermore, an optionally substituted group may be unsubstituted (e.g., -CH2CH3), fully substituted (e.g., -CF2CF3), monosubstituted (e.g., -CH2CH2F), or substituted at a level anywhere between fully substituted and monosubstituted (e.g., -CH2CHF2, -CH2CF3, -CF2CH3, -CFHCHF2, etc.).It will be understood by those skilled in the art with respect to any group containing one or more substituents, that such groups are not intended to introduce any substitution or replacement patterns (e.g., substituted alkyl includes optionally substituted cycloalkyl groups, which in turn are defined as including optionally substituted alkyl groups, potentially ad infinitum) that are sterically impractical and / or synthetically unfeasible. Thus, any substituents described should, in general, be understood as having a maximum molecular weight of about 1000 daltons and, more typically, up to about 500 daltons.
[0031] The term "one or more" when referring to an optional substitute means that the group in question is optionally replaced by one, two, three, or four substitutes. In some embodiments, the group in question is optionally replaced by one, two, or three substitutes. In some embodiments, the group in question is optionally replaced by one or two substitutes. In some embodiments, the group in question is optionally replaced by one substitute. In some embodiments, the group in question is optionally replaced by two substitutes.
[0032] An "effective amount" or "therapeutically effective amount" refers to an amount of a compound administered to a mammalian individual, either as a single dose or as part of a series of doses, that is effective in producing a desired therapeutic effect.
[0033] The terms "treat," "treated," "treatment," or "treating," as used herein, refer to therapeutic treatment, the objective of which is to slow down (reduce) an undesirable physiological condition, disorder, or disease, or to obtain beneficial or desired clinical outcomes. For the purposes described herein, beneficial or desired clinical outcomes include, but are not limited to, relief of symptoms; reduction in the extent of the condition, disorder, or disease; stabilization (i.e., non-aggravation) of the condition, disorder, or disease state; delay in the onset or slowing of the progression of the condition, disorder, or disease; improvement of the condition, disorder, or disease state; and remission (whether partial or total), whether detectable or undetectable, or enhancement or improvement of the condition, disorder, or disease. Treatment includes inducing a clinically significant response without excessive levels of side effects.Treatment also includes prolonging survival compared to the expected survival if you do not receive treatment. The terms "treat," "treated," "treatment," or "treating," as well as words derived from them, as used herein, do not necessarily imply complete or 100% treatment. Instead, there are different degrees of treatment that one skilled in the art recognizes as having a potential benefit or therapeutic effect. In this respect, the methods described can provide any amount of any level of treatment of the disorder in a mammal. For example, a disorder, including symptoms or conditions thereof, can be reduced by, for example, about 100%, about 90%, about 80%, about 70%, about 60%, about 50%, about 40%, about 30%, about 20%, or about 10%. "Synergy" or "synergize" refers to an effect of a combination that is greater than the additive effect of each component alone at the same doses.
[0034] As used herein, a "PARP-associated disease or disorder" or, alternatively, "a PARP-mediated disease or disorder" means any disease or other detrimental condition in which PARP, or a PARP mutant, is known or suspected to play a role.
[0035] As used herein, a "PARP1-associated disease or disorder" or, alternatively, "a PARP1-mediated disease or disorder" means any disease or other detrimental condition in which PARP1, or a mutant thereof, is known or suspected to play a role. Compounds
[0036] Compounds, or a salt, solvate or stereoisomer thereof, pharmaceutically acceptable, useful in the treatment of cancer are described herein.
[0037] A compound of Formula (I), or a salt, solvate or pharmaceutically acceptable stereoisomer thereof, is described herein: wherein: R1 is hydrogen, deuterium, halogen, -CN, -ORa, -NRcRd, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl or heterocycloalkyl; wherein alkyl, alkenyl, alkynyl, cycloalkyl and heterocycloalkyl are optionally substituted by one or more R; R2 is hydrogen, deuterium, halogen, -CN, -ORa, -NRcRd, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 deuteroalkyl; X is N or CR3; Y is N or CR4; Z is N or CR5; R3 is hydrogen, deuterium, halogen, -CN, -ORa, -NRcRd, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl or heterocycloalkyl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl and heterocycloalkyl groups are optionally substituted by one or more R groups;R4 is hydrogen, deuterium, halogen, -CN, -ORa, -NRcRd, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl or heterocycloalkyl; wherein alkyl, alkenyl, alkynyl, cycloalkyl and heterocycloalkyl are optionally substituted by one or more R; R5 is hydrogen, deuterium, halogen, -CN, -ORa, -NRcRd, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl or heterocycloalkyl; wherein alkyl, alkenyl, alkynyl, cycloalkyl and heterocycloalkyl are optionally substituted by one or more R; each R6 is independently hydrogen, deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, cycloalkyl or heterocycloalkyl;wherein the alkyl, cycloalkyl and heterocycloalkyl groups are optionally substituted by one or more R groups; or two R groups are combined to form a cycloalkyl or a heterocycloalkyl group; each optionally substituted by deuterium, halogen, -CN, -OH, -ORa, -NRcRd, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, or C1-C6 heteroalkyl; each R group is independently deuterium, halogen, -CN, -OH, -ORa, -NRcRd, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, or C2-C6 alkynyl; or two R7s on the same carbon are combined to form an oxo; or two R7s on the same carbon or on different carbons are combined to form a cycloalkyl or a heterocycloalkyl; each optionally substituted by one or more R; n is 0 to 4; T is N or CR8; U is N or CR9;R8 is hydrogen, deuterium, halogen, -CN, -OH, -ORa, -NRcRd, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl or heterocycloalkyl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl and heterocycloalkyl groups are optionally substituted by one or more R groups; R9 is hydrogen, deuterium, halogen, -CN, -OH, -ORa, -NRcRd, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl or heterocycloalkyl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl and heterocycloalkyl groups are optionally substituted by one or more R groups; R10 is hydrogen, deuterium, halogen, -CN, -OH, -ORa, -NRcRd, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl or heterocycloalkyl;where alkyl, alkenyl, alkynyl, cycloalkyl and heterocycloalkyl are optionally substituted by one or more R; R11é hydrogen, deuterium, halogenium, -CN, -OH, -ORa, - NRcRd, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C1-C6heteroalkyl, C2- C6alkenyl, C2-C6alkynyla, cycloalkyl or heterocycloalkyl; where alkyl, alkenyl, alkynyl, cycloalkyl and heterocycloalkyl are optionally substituted by one or more R; R12é cyano or halogenium; each Ra is independently C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C1-C6heteroalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6alkylene(cycloalkyl), C1-C6alkylene(heterocycloalkyl), C1-C6alkylene(aryl), or C1-C6alkylene(heteroaryl);sendo que cada alkyla, alkylene, alkenyl, alkynyl, cycloalkyla, heterocicloalkyla, aryl e heteroaryla é independente e opciónmente substituída por um ou mais R; cada Rbé independentemente hidrogênio, C1-C6alkyla, C1-C6haloalkyla, C1-C6deuteroalkyla, C1-C6hydroxyalkyla, C1-C6aminoalkyla, C1-C6heteroalkyla, C2-C6alkenyl, C2-C6alkynyl, cicloalkyla, heterocicloalkyla, aryl, heteroaryla, C1-C6alkyleno(cicloalkyla), C1-C6alkyleno(heterocicloalkyla), C1-C6alkyleno(aryla), ou C1-C6alkyleno(heteroaryla); sendo que cada alquila, alkylene, alkenyl, alkynyl, cicloalquila, heterocicloalquila, aryl e heteroaryl é independente e opciónmente substituída por um ou mais R;and each Rc and Rd are independently hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkylene (cycloalkyl), C1-C6 alkylene (heterocycloalkyl), C1-C6 alkylene (aryl), or C1-C6 alkylene (heteroaryl); wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently and optionally substituted by one or more R; or Rc and Rd are considered together with the atom to which they are attached to form a heterocycloalkyl optionally substituted by one or more R;each R is independently deuterium, halogen, -CN, -OH, -OC1-C6alkyl, -NH2, -NHC1-C6alkyl, -N(C1-C6alkyl)2, -NHC(=O)OC1-C6alkyl, -C(=O)C1-C6alkyl, -C(=O)OH, -C(=O)OC1-C6alkyl, -C(=O)NH2, -C(=O)N(C1-C6alkyl)2, -C(=O)NHC1-C6alkyl, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, or C1-C6heteroalkyl; or two R on the same atom are combined to form an oxo; provided that when X is CR3, Y is CR4 and Z is CR5; Therefore, one of R3, R4, and R5 is not hydrogen, and R4 is not -OMe; and since when X is CH, Y is CH, and Z is CH, then R2 is not hydrogen.
[0038] In some embodiments of a compound of Formula (I), the compound is not 7-(1-(4-(2,4-difluorophenyl)piperazin-1-yl)ethyl)-3-methylquinolin-2(1H)-one.
[0039] In some embodiments of a compound of Formula (I), the compound is not 7-((4-(3,4-dichlorophenyl)piperazin-1-yl)methyl)-3-ethylquinolin-2(1H)-one.
[0040] In some embodiments of a compound of Formula (I), the compound is not 7-((5-(4-chlorophenyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)methyl)-3-ethylquinolin-2(1H)-one.
[0041] In some embodiments of a compound of Formula (I), the compound is not 6-(4-(cyclohexyl(3-methyl-2-oxo-1,2-dihydroquinolin-7-yl)methyl)piperazin-1-yl)nicotinonitrile.
[0042] In some embodiments of a compound of Formula (I), the compound is not 6-(4-((3-ethyl-5-methoxy-2-oxo-1,2-dihydroquinolin-7-yl)methyl)piperazin-1-yl)nicotinonitrile.
[0043] In some embodiments of a compound of Formula (I), the compound is not 6-(4-(2-methyl-1-(3-methyl-2-oxo-1,2-dihydroquinolin-7-yl)propyl)piperazin-1-yl)nicotinonitrile.
[0044] In some embodiments of a compound of Formula (I), the compound is not 6-(4-((3-ethyl-2-oxo-1,2-dihydroquinolin-7-yl)methyl)piperazin-1-yl)nicotinonitrile.
[0045] In some embodiments of a compound of Formula (I), the compound is not 6-(4-(1-(3-ethyl-2-oxo-1,2-dihydroquinolin-7-yl)-2-methylpropyl)piperazin-1-yl)nicotinonitrile.
[0046] In some embodiments of a compound of Formula (I), X is N. In some embodiments of a compound of Formula (I), X is CR3.
[0047] In some embodiments of a compound of Formula (I), Y is N. In some embodiments of a compound of Formula (I), Y is CR4.
[0048] In some embodiments of a compound of Formula (I), Z is N. In some embodiments of a compound of Formula (I), Z is CR5.
[0049] In some embodiments of a compound of Formula (I), X is N. Y is N or CR4; and Z is N or CR5; In some embodiments of a compound of Formula (I), X is N or CR3; Y is N; and Z is N or CR5; In some embodiments of a compound of Formula (I), X is N or CR3; Y is N or CR4; and Z is N. In some embodiments of a compound of Formula (I), one of X, Y, or Z is N. In some embodiments of a compound of Formula (I), two of X, Y, or Z are N. In some embodiments of a compound of Formula (I), X is CR3; Y is CR4; and Z is CR5. In some embodiments of a compound of Formula (I), X is CH; Y is CH; and Z is CH. In some embodiments of a compound of Formula (I), X is CR3; Y is N; and Z is CR5. In some embodiments of a compound of Formula (I), X is CH; Y is N; and Z is CH. In some embodiments of a compound of Formula (I), X is N. Y is CR4; and Z is CR5. In some embodiments of a compound of Formula (I), X is N. Y is CH; and Z is CH.
[0050] In some embodiments of a compound of Formula (I), the compound is of Formula (Ia): Formula (Ia).
[0051] In some embodiments of a compound of Formula (I), the compound is of Formula (Ib):
[0052] In some embodiments of a compound of Formula (I), the compound is of Formula (Ic):
[0053] In some embodiments of a compound of Formula (I), the compound is of Formula (Id): Given that one of R3, R4, and R5 is not hydrogen, and R4 is not -OMe.
[0054] In some embodiments of a compound of Formula (I), the compound is of Formula (Ie): where R2 is deuterium, halogen, -CN, -ORa, -NRcRd, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 deuteroalkyl.
[0055] In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R1 is hydrogen, deuterium, halogen, -CN, -ORa, -NRcRd, C1-C6haloalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C1-C6heteroalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl or heterocycloalkyl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl and heterocycloalkyl are optionally replaced by one or more R;
[0056] In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R1 is hydrogen, deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C2-C6 alkynyl, cycloalkyl or heterocycloalkyl; wherein the alkyl, alkynyl, cycloalkyl and heterocycloalkyl are optionally replaced by one or more R. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R1 is hydrogen, deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkynyl, cycloalkyl or heterocycloalkyl; wherein the alkyl, alkynyl, cycloalkyl and heterocycloalkyl groups are optionally replaced by one or more R groups. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R1 is a halogen, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkynyl or cycloalkyl group; wherein the alkyl, alkynyl and cycloalkyl groups are optionally replaced by one or more R groups.In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R1 is halogen, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkynyl or cycloalkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R1 is C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkynyl or cycloalkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R1 is C1-C6 alkyl, or cycloalkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R1 is C1-C6 alkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R1 is methyl or ethyl. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R1 is methyl. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R1 is ethyl. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R1 is cycloalkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R1 is cyclopropyl. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R1 is heterocycloalkyl.In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R1 is C1-C6 haloalkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R1 is difluoromethyl. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R1 is halogen, C1-C6 haloalkyl, or cycloalkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R1 is halogen or cycloalkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R1 is halogen. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R1 is fluorine or chlorine. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R1 is chlorine.
[0057] In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R2 is hydrogen, deuterium, halogen, -ORa, C1-C6 alkyl, or C1-C6 haloalkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R2 is hydrogen, halogen, -ORa, or C1-C6 alkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R2 is hydrogen or halogen. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R2 is halogen. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R2 is fluorine. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R2 is methyl. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R2 is -ORa. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R2 is -OCF3. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R2 is hydrogen, deuterium, halogen, -CN, -ORa, -NRcRd, C1-C2 alkyl, C1-C2 haloalkyl, or C1-C2 deuteroalkyl.In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R2 is hydrogen, halogen, -ORa, or C1-C2 alkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R2 is halogen, -ORa, or C1-C2 alkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R2 is halogen or C1-C2 alkyl.
[0058] In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R3 is hydrogen, deuterium, halogen, -ORa, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 deuteroalkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R3 is hydrogen, halogen, -ORa, or C1-C6 alkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R3 is hydrogen, or halogen, or C1-C6 alkyl.
[0059] In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R3 is hydrogen or halogen.
[0060] In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R3 is a halogen. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R3 is hydrogen. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R3 is not hydrogen.
[0061] In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R4 is hydrogen, deuterium, halogen, -CN, -NRcRd, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C1-C6heteroalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl or heterocycloalkyl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl and heterocycloalkyl are optionally substituted by one or more R. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R4 is hydrogen, deuterium, halogen, -ORa, C1-C6alkyl, C1-C6haloalkyl, or C1-C6deuteroalkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R4 is hydrogen, halogen, -ORa or C1-C6 alkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R4 is hydrogen, or halogen, or C1-C6 alkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R4 is hydrogen or halogen. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R4 is halogen.In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R4 is hydrogen. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R4 is not hydrogen.
[0062] In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R5 is hydrogen, deuterium, halogen, -ORa, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 deuteroalkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R5 is hydrogen, halogen, -ORa, or C1-C6 alkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R5 is hydrogen, halogen, or C1-C6 alkyl.
[0063] In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R5 is hydrogen or halogen. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R5 is halogen. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R5 is hydrogen. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R5 is not hydrogen.
[0064] In some embodiments of a compound of Formula (I) or (Ia)-(Ie), each R6 is independently hydrogen, deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 deuteroalkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), each R6 is independently hydrogen, deuterium, or C1-C6 alkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), one R6 is hydrogen, and the other R6 is C1-C6 alkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), each R6 is deuterium. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), each R6 is independently C1-C6 alkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), each R6 is hydrogen. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), two R6 are combined to form a cycloalkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), two R6 are combined to form a cyclopropyl.
[0065] In some embodiments of a compound of Formula (I) or (Ia)-(Ie), each R7 is independently C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 deuteroalkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), each R7 is independently C1-C6 alkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), two R7 on the same carbon or different carbons are combined to form a cycloalkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), two R7 on the same carbon or different carbons are combined to form a cyclopropyl.
[0066] In some embodiments of a compound of Formula (I) or (Ia)-(Ie), n is 0 or 1. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), n is 0 to 2. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), n is 1 or 2. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), n is 1. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), n is 2. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), n is 3. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), n is 4.
[0067] In some embodiments of a compound of Formula (I) or (Ia)-(Ie), T is N. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), T is CR8.
[0068] In some embodiments of a compound of Formula (I) or (Ia)-(Ie), U is N. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), U is CR9.
[0069] In some embodiments of a compound of Formula (I)
[0070] In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R8 is hydrogen, deuterium, halogen, -CN, -OH, -ORa, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, or cycloalkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R8 is hydrogen, halogen, -CN, -ORa, C1-C6 alkyl, or C1-C6 haloalkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R8 is hydrogen, halogen, -CN, -ORa, or C1-C6 haloalkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R8 is hydrogen, halogen, or C1-C6 haloalkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R8 is hydrogen or halogen. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R8 is hydrogen.
[0071] In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R9 is hydrogen, deuterium, halogen, -CN, -OH, -ORa, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, or cycloalkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R9 is hydrogen, deuterium, halogen, -CN, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, or cycloalkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R9 is hydrogen, halogen, -C1-C6 alkyl, C1-C6 haloalkyl, or cycloalkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R9 is hydrogen, halogen, or cycloalkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R9 is hydrogen or halogen. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R9 is hydrogen.
[0072] In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R10 is hydrogen, deuterium, halogen, -CN, -OH, -ORa, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, or cycloalkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R10 is hydrogen, deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, or cycloalkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R10 is hydrogen, halogen, C1-C6 alkyl, or C1-C6 haloalkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R10 is hydrogen or halogen. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R10 is hydrogen.
[0073] In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R11 is hydrogen, deuterium, halogen, -CN, -OH, -ORa, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, or cycloalkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R11 is hydrogen, deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, or cycloalkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R11 is hydrogen, halogen, C1-C6 alkyl or C1-C6 haloalkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R11 is hydrogen or halogen. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R11 is hydrogen.
[0074] In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R12 is cyano. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R12 is halogen. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R12 is fluorine or chlorine. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R12 is fluorine. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R12 is chlorine. In some embodiments of a compound of Formula (I) or (Ia)-(Ie), R12 is fluorine or bromine.
[0075] In some embodiments of a compound described herein, each Ra is independently C1-C6alkyl, C1-C6haloalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C1-C6heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6alkylene(cycloalkyl), C1-C6alkylene(heterocycloalkyl), C1-C6alkylene(aryl), or C1-C6alkylene(heteroaryl); wherein each alkyl, alkylene, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is independently and optionally substituted by one or more R. In some embodiments of a compound described herein, each Ra is independently C1-C6alkyl, C1-C6haloalkyl or cycloalkyl, heterocycloalkyl; whereby each alkyl, cycloalkyl, and heterocycloalkyl group is independently and optionally substituted by one or more R groups.In some embodiments of a compound described herein, each Ra is independently C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkylene (cycloalkyl), C1-C6 alkylene (heterocycloalkyl), C1-C6 alkylene (aryl), or C1-C6 alkylene (heteroaryl). In some embodiments of a compound described herein, each Ra is independently C1-C6 alkyl, C1-C6 haloalkyl or cycloalkyl, heterocycloalkyl. In some embodiments of a compound described herein, each Ra is independently C1-C6 alkyl, C1-C6 haloalkyl. In some embodiments of a compound described herein, each Ra is independently C1-C6 alkyl. In some embodiments of a compound described herein, each Rae is independently C1-C6 haloalkyl.
[0076] In some embodiments of a compound described herein, each Rbé independently hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkylene (cycloalkyl), C1-C6 alkylene (heterocycloalkyl), C1-C6 alkylene (aryl), or C1-C6 alkylene (heteroaryl); wherein each alkyl, alkylene, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently and optionally substituted by one or more R. In some embodiments of a compound described herein, each Rbé independently hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, or cycloalkyl, heterocycloalkyl; whereby each alkyl, cycloalkyl and heterocycloalkyl group is independently and optionally substituted by one or more R groups.In some embodiments of a compound described herein, each Rbé independently represents hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkylene (cycloalkyl), C1-C6 alkylene (heterocycloalkyl), C1-C6 alkylene (aryl), or C1-C6 alkylene (heteroaryl). In some embodiments of a compound described herein, each Rbé independently represents hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, or cycloalkyl, heterocycloalkyl. In some embodiments of a compound described herein, each Rbé independently represents hydrogen, C1-C6 alkyl, or C1-C6 haloalkyl. In some embodiments of a compound described herein, each Rbé independently represents hydrogen, or C1-C6 alkyl. In some embodiments of a compound described herein, each Rbé is hydrogen. In some embodiments of a compound described herein, each Rbé is independently C1-C6 alkyl.In some embodiments of a compound described herein, each Rbé independently represents a C1-C6 haloalkyl group.
[0077] In some embodiments of a compound described herein, each Rc and Rd are independently hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkylene (cycloalkyl), C1-C6 alkylene (heterocycloalkyl), C1-C6 alkylene (aryl), or C1-C6 alkylene (heteroaryl); wherein each alkyl, alkylene, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently and optionally substituted by one or more R. In some embodiments of a compound described herein, each Rc and Rd are independently hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, or cycloalkyl, heterocycloalkyl; whereby each alkyl, cycloalkyl and heterocycloalkyl group is independently and optionally substituted by one or more R groups.In some embodiments of a compound described herein, each Rc and Rd are independently hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkylene (cycloalkyl), C1-C6 alkylene (heterocycloalkyl), C1-C6 alkylene (aryl), or C1-C6 alkylene (heteroaryl). In some embodiments of a compound described herein, each Rc and Rd are independently hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, or cycloalkyl, heterocycloalkyl. In some embodiments of a compound described herein, each Rc and Rd are independently hydrogen, C1-C6 alkyl, or C1-C6 haloalkyl. In some embodiments of a compound described herein, each Rc and Rd is independently hydrogen or C1-C6 alkyl. In some embodiments of a compound described herein, each Rc and Rd is hydrogen. In some embodiments of a compound described herein, each Rc and Rd is independently C1-C6 alkyl.In some embodiments of a compound described herein, each Rc and Rd are independently C1-C6 haloalkyl.
[0078] In some embodiments of a compound described herein, Rc and Rd are combined with the atom to which they are attached to form a heterocycloalkyl group optionally substituted by one or more R.
[0079] In some embodiments of a compound described herein, each R is independently deuterium, halogen, -CN, -OH, -OC1-C6alkyl, -NH2, -NHC1-C6alkyl, -N(C1-C6alkyl)2, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, or C1-C6heteroalkyl; or two R on the same atom are combined to form an oxo. In some embodiments of a compound described herein, each R is independently deuterium, halogen, -CN, -OH, -OC1-C6alkyl, -NH2, -NHC1-C6alkyl, -N(C1-C6alkyl)2, C1-C6alkyl, C1-C6haloalkyl or C1-C6deuteroalkyl; In some embodiments of a compound described herein, each R is independently deuterium, halogen, -CN, -OH, -OC1-C6alkyl, -NH2, C1-C6alkyl, or C1-C6haloalkyl; or two R on the same atom are combined to form an oxo.
[0080] Any combination of the groups described above for the various variables is contemplated herein. Throughout the descriptive report, groups and their substituents are chosen by a person skilled in the art to provide stable moieties and compounds.
[0081] In some embodiments, the compound described herein, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, is selected from a compound in Table 1.
[0082] The absolute marker (abs) is added to a chiral center to denote that it is unequivocally a pure sample of the extracted stereoisomer.
[0083] The OR (or) marker denotes a pure substance, but the absolute configuration of the stereochemical center is unknown. After chiral separation with isolated pure structures, multiple OR (OR indicates purity) markers with the same numerical value will indicate that a sample is one of a pair of pure enantiomers (but the absolute configuration of the stereochemical center is unknown).
[0084] The E (e) label denotes that both isomers are present at the represented stereochemical center. Assigning different numerical values to the E labels denotes that they are independent of each other. The use of E labels with the same values indicates that the two stereocenters are relative to each other and can only change together.
[0085] In some embodiments, the compound described herein, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, is selected from Additional forms of compounds described here Isomers / Stereoisomers
[0086] In some embodiments, the compounds described herein exist as geometric isomers. In some embodiments, the compounds described herein possess one or more double bonds. The compounds presented herein include all cis, trans, syn, anti, entgegen (E) and zusammen (Z) isomers, as well as corresponding mixtures thereof. In some situations, the compounds described herein possess one or more chiral centers, and each center exists in the R configuration or the S configuration. The compounds described herein include all diastereomeric, enantiomeric and epimeric forms, as well as corresponding mixtures thereof. In additional embodiments of the compounds and methods provided herein, mixtures of enantiomers and / or diastereomers, resulting from a single preparatory step, combination or interconversion, are useful for the applications described herein.In some embodiments, the compounds described herein are prepared as their individual stereoisomers by reacting a racemic mixture of the compound with an optically active resolving agent to form a pair of diastereomeric compounds, separating the diastereomers and recovering the optically pure enantiomers. In some embodiments, dissociable complexes are preferred. In some embodiments, the diastereomers have distinct physical properties (e.g., melting points, boiling points, solubilities, reactivity, etc.) and are separated by exploiting these dissimilarities. In some embodiments, the diastereomers are separated by chiral chromatography or, preferably, by separation / resolution techniques based on differences in solubility. In some embodiments, the optically pure enantiomer is then recovered, along with the resolving agent, by any practical means that does not result in racemization. Labeled compounds.
[0087] In some embodiments, the compounds described herein exist in their isotopically labeled forms. In some embodiments, the methods described herein include methods of treating diseases by administering such isotopically labeled compounds. In some embodiments, the methods described herein include methods of treating diseases by administering such isotopically labeled compounds as pharmaceutical compositions. Thus, in some embodiments, the compounds described herein include isotopically labeled compounds that are identical to those mentioned herein, but in that one or more atoms are replaced by an atom with an atomic mass or mass number different from the atomic mass or mass number generally found in nature.Examples of isotopes that can be incorporated into the compounds described herein include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, and chloride, such as 2H, 3H, 13C, 14C, 15N, 18O, 17O, 31P, 32P, 35S, 18F, and 36Cl, respectively. The compounds described herein and pharmaceutically acceptable salts, solvates, or stereoisomers thereof containing the aforementioned isotopes and / or other isotopes of other atoms are within the scope of this invention. Certain isotopically labeled compounds, for example, those in which radioactive isotopes such as 3H and 14C are incorporated, are useful in assays of drug and / or substrate distribution in tissues. Tritiated isotopes, i.e., 3H, and carbon-14, i.e., 14C, are particularly preferred due to their ease of preparation and detectability.Additionally, substitution with heavy isotopes such as deuterium, i.e., 2H, produces certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements.
[0088] In some embodiments, the compounds described herein are labeled by other means, including, but not limited to, the use of chromophores or fluorescent moieties, bioluminescent markers or chemiluminescent markers. Pharmaceutically acceptable salts
[0089] In some embodiments, the compounds described herein exist as their pharmaceutically acceptable salts. In some embodiments, the methods described herein include methods of treating diseases by administering such pharmaceutically acceptable salts. In some embodiments, the methods described herein include methods of treating diseases by administering such pharmaceutically acceptable salts as pharmaceutical compositions.
[0090] In some embodiments, the compounds described herein possess acidic or basic groups and therefore react with any of a series of inorganic or organic bases, and inorganic and organic acids, to form a pharmaceutically acceptable salt. In some embodiments, these salts are prepared in situ during the final isolation and purification of the compounds described herein, or a solvate, or stereoisomer thereof, or by separately reacting a purified compound in its free form with a suitable acid or base, and isolating the salt thus formed.
[0091] Examples of pharmaceutically acceptable salts include those salts prepared by reacting the compounds described herein with a mineral, organic acid or inorganic base, such as salts including acetate, acrylate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, bisulfite, bromide, butyrate, butin-1,4-dioate, camphor, camphorsulfonate, caproate, caprylate, chlorobenzoate, chloride, citrate, cyclopentanopropionate, decanoate, digluconate, dihydrogen phosphate, dinitrobenzoate, dodecyl sulfate, ethanesulfonate, formate, fumarate, glucoheptanoate, glycerophosphate, glycolate, hemisulfate, heptanoate, hexanoate, hexin-1,6-dioate, hydroxybenzoate, γ-hydroxybutyrate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, iodide, isobutyrate, lactate, maleate, malonate, methanesulfonate, mandelate, metaphosphate, methanesulfonate, methoxybenzoate, methylbenzoate, monohydrogen phosphate, 1-naphthalenesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate,palmoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, pyrosulfate, pyrophosphate, propiolate, phthalate, phenylacetate, phenylbutyrate, propanesulfonate, salicylate, succinate, sulfate, sulfite, succinate, suberate, sebacate, sulfonate, tartrate, thiocyanate, tosylate, undecanoate and xylenesulfonate.
[0092] Additionally, the compounds described herein can be prepared as pharmaceutically acceptable salts formed by reacting the free base form of the compound with a pharmaceutically acceptable inorganic or organic acid, including, but not limited to, inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, metaphosphoric acid, phosphoric acid and the like; and organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanopropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, p-toluenesulfonic acid, tartaric acid, dotrifluoroacetic acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, arylsulfonic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 2-naphthalenesulfonic acid,4-methylbicyclo-[2,2,2]oct-2-ene-1-carboxylic acid, glucoheptonic acid, 4,4'-methylenebis-(3-hydroxy-2-ene-1-carboxylic acid), 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, and muconic acid. In some embodiments, other acids, such as oxalic acid, although not themselves pharmaceutically acceptable, are employed in the preparation of salts useful as intermediates in obtaining the compounds described herein, solvate or stereoisomer thereof, and their pharmaceutically acceptable acid addition salts.
[0093] In some embodiments, the compounds described herein comprising a free acid group react with a suitable base, such as hydroxide, carbonate, bicarbonate, sulfate, of a pharmaceutically acceptable metal cation, with ammonia, or with a pharmaceutically acceptable primary, secondary, tertiary or quaternary organic amine. Representative salts include alkaline or alkaline-earth salts, such as lithium, sodium, potassium, calcium and magnesium, and aluminum salts and the like. Illustrative examples of bases include sodium hydroxide, potassium hydroxide, choline hydroxide, sodium carbonate, N+(C1-4 alkyl)4 and the like.
[0094] Representative organic amines useful for the formation of base addition salts include ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, and the like. It should be understood that the compounds described herein also include the quaternization of any nitrogen-containing basic groups they contain. In some embodiments, products soluble or dispersible in water or oil are obtained by such quaternization. Solvatos
[0095] In some embodiments, the compounds described herein exist as solvates. The invention provides methods of treating diseases by administering such solvates. The invention further provides methods of treating diseases by administering such solvates as pharmaceutical compositions.
[0096] Solvates contain stoichiometric or non-stoichiometric amounts of a solvent and, in some embodiments, are formed during the crystallization process with pharmaceutically acceptable solvents such as water, ethanol, and the like. Hydrates are formed when the solvent is water, or alcoholates are formed when the solvent is alcohol. The solvates of the compounds described herein may be conveniently prepared or formed during the processes described herein. By way of example only, hydrates of the compounds described herein may be conveniently prepared by recrystallization from an aqueous / organic solvent mixture, using organic solvents including, but not limited to, dioxane, tetrahydrofuran, or methanol. Furthermore, the compounds provided herein may exist in non-solvated as well as solvated forms.In general, solvated forms are considered equivalent to non-solvated forms for the purposes of the compounds and methods provided herein. Tautomers
[0097] In some situations, compounds exist as tautomers. The compounds described here include all possible tautomers within the formulas described herein. Tautomers are compounds that are interconvertible by the migration of a hydrogen atom, accompanied by an exchange of a single bond and an adjacent double bond. In bonding arrangements where tautomerization is possible, a chemical equilibrium of the tautomers exists. All tautomeric forms of the compounds described herein are contemplated. The exact ratio of tautomers depends on several factors, including temperature, solvent, and pH. Treatment method
[0098] Methods of treating a disease in which PARP inhibition is beneficial are described herein, wherein the method comprises administering a compound described herein. Methods of treating a disease in which PARP1 inhibition is beneficial are also described herein, wherein the method comprises administering a compound described herein. In some embodiments, the disease is cancer. In some embodiments, the cancer is breast cancer, ovarian cancer, pancreatic cancer, prostate cancer, a hematologic cancer, a gastrointestinal cancer such as gastric cancer and colorectal cancer, or lung cancer. In some embodiments, the cancer is breast cancer, ovarian cancer, pancreatic cancer, or prostate cancer. In some embodiments, the cancer is leukemia, colon cancer, glioblastoma, lymphoma, melanoma, or cervical cancer.In some modalities, the cancer is bladder cancer, brain and CNS cancer, breast cancer, cervical cancer, colorectal cancer, esophageal cancer, Hodgkin's lymphoma, non-Hodgkin's lymphoma, kidney cancer, leukemia, lung cancer, melanoma, myeloma, oral cavity cancer, ovarian cancer, pancreatic cancer, prostate cancer, skin cancer, stomach cancer, thyroid cancer, or uterine cancer.
[0099] In some forms, the cancer is metastatic. In some forms, the cancer will have metastases in the brain.
[00100] In some forms, the cancer involves a BRCA1 and / or BRCA2 mutation.
[00101] In some forms, cancer that includes a BRCA1 and / or BRCA2 mutation is bladder cancer, brain and CNS cancers, breast cancer, cervical cancer, colorectal cancer, esophageal cancer, Hodgkin's lymphoma, non-Hodgkin's lymphoma, kidney cancer, leukemia, lung cancer, melanoma, myeloma, oral cavity cancer, ovarian cancer, pancreatic cancer, prostate cancer, skin cancer, stomach cancer, thyroid cancer, or uterine cancer.
[00102] In some forms, the cancer is a cancer deficient in homologous recombination (HR)-dependent DNA DSB repair activity. The HR-dependent DNA DSB repair pathway corrects double-strand breaks (DSBs) in DNA through homologous mechanisms to reform a continuous DNA helix. The components of the HR-dependent DNA DSB repair pathway include, but are not limited to, ATM (NM_000051), RAD51 (NM_002875), RAD51 L1 (NM_002877), RAD51 C (NM_002876), RAD51 L3 (NM_002878), DMC1 (NM_007068), XRCC2 (NM_005431), XRCC3 (NM_005432), RAD52 (NM_002879), RAD54L (NM_003579), RAD54B (NM_012415), BRCA1 (NM_007295), BRCA2 (NM_000059), RAD50 (NM_005732), MRE1 1 A (NM_005590), and NBS1 (NM_002485). Other proteins involved in the HR-dependent DNA DSB repair pathway include regulatory factors such as EMSY.In some forms, cancer that is deficient in HR-dependent DNA DSB repair comprises one or more cancer cells that have a reduced or eliminated capacity to repair DNA DSBs through this pathway, compared to normal cells; that is, the activity of the HR-dependent DNA DSB repair pathway may be reduced or abolished in one or more cancer cells.
[00103] In some embodiments, the activity of one or more components of the HR-dependent DNA DSB repair pathway is abolished in one or more cancer cells of an individual who has a cancer that is deficient in HR-dependent DNA DSB repair.
[00104] In some modalities, cancer cells have a BRCA1 and / or BRCA2 deficient phenotype, that is, BRCA1 and / or BRCA2 activity is reduced or abolished in cancer cells. Cancer cells with this phenotype may be BRCA1 and / or BRCA2 deficient, that is, the expression and / or activity of BRCA1 and / or BRCA2 may be reduced or abolished in cancer cells, for example, through mutation or polymorphism in the coding nucleic acid or through amplification, mutation, or polymorphism in a gene encoding a regulatory factor, for example, the EMSY gene encoding a BRCA2 regulatory factor. BRCA1 and BRCA2 are known tumor suppressors whose wild-type alleles are frequently lost in tumors of heterozygous carriers. Amplification of the EMSY gene, which encodes a BRCA2 binding factor, is also known to be associated with breast and ovarian cancer.Individuals with BRCA1 and / or BRCA2 mutations are also at increased risk for certain cancers, including breast cancer, ovarian cancer, pancreatic cancer, prostate cancer, hematological cancer, gastrointestinal cancer, and lung cancer.
[00105] Also described herein is a method of treating cancer comprising a mutation in a gene that confers homologous repair deficiency in an individual in need thereof, the method comprising administering a compound described herein, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof. In some embodiments, the mutation in a gene that confers homologous repair deficiency comprises ATM, BRCA1, BRCA2, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, RAD51B, RAD51C, RAD51D, or RAD54L, or any combination thereof.
[00106] Also described here is a method of treating a cancer that is present in the brain, the method comprising administering a compound described herein, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof.
[00107] In some forms, the cancer present in the brain arises from primary peripheral tumors that have metastasized to the brain. In some forms, the cancer present in the brain arises from primary brain tissue.
[00108] Also described here is a method of treating brain cancer, the method comprising administering a compound described herein, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof.
[00109] In some forms, brain cancer is a primary brain tumor that starts in the brain and tends to remain there.
[00110] In some forms, brain cancer is a secondary brain tumor. These cancers start elsewhere in the body and travel to the brain. Lung, breast, kidney, colon, and skin cancers are among the most common cancers that spread to the brain.
[00111] In some embodiments, the compound described herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, is capable of penetrating the blood-brain barrier (BBB). In some embodiments, the BBB penetration ratio is > 0.1, where 1 is complete BBB penetration and 0 is no penetration. In some embodiments, the BBB penetration ratio is > 0.2. In some embodiments, the BBB penetration ratio is > 0.3. In some embodiments, the BBB penetration ratio is measured using the rat kp,uu assay. In some embodiments, the compound has a ratio of >0.3 (i.e., 0.3 to 1), as determined in the rat kp,uu assay. Dosage
[00112] In certain embodiments, compositions containing the compound(s) described herein are administered for prophylactic and / or therapeutic treatments. In certain therapeutic applications, the compositions are administered to a patient already suffering from a disease or condition, in a quantity sufficient to cure or at least partially interrupt at least one of the symptoms of the disease or condition. Effective amounts for this use depend on the severity and course of the disease or condition, prior therapy, the patient's health status, weight and response to drugs, and the conduct of the attending physician. Therapeutically effective amounts are optionally determined by methods that include, but are not limited to, a dose-escalation and / or dose-determination clinical trial.
[00113] In prophylactic applications, compositions containing the compounds described herein are administered to a patient susceptible to, or otherwise at risk of, a specific disease, disorder, or condition. This amount is defined as a "prophylactically effective amount or dose." In this use, the precise amounts also depend on the patient's health status, weight, and similar factors. When used in patients, the effective amounts for this use will depend on the severity and course of the disease, disorder, or condition, prior therapy, the patient's health status and response to drugs, and the attending physician's conduct.In one aspect, prophylactic treatments include administering to a mammal that has previously experienced at least one symptom of, or risk factor for, the disease to be treated and is currently in remission, a pharmaceutical composition comprising a compound described herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, in order to prevent the return of symptoms of the disease or condition.
[00114] In certain modalities where the patient's condition does not improve, at the physician's discretion, the administration of the compounds is carried out on a continuous basis, that is, for a prolonged period of time, including throughout the patient's life, to improve or otherwise control or limit the symptoms of the patient's disease or condition.
[00115] In certain modalities where a patient's condition improves, the administered drug dose is temporarily reduced or temporarily suspended for a certain period of time (i.e., a "drug rest"). In specific modalities, the duration of the drug rest ranges from 2 days to 1 year, including, by way of example only, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 10 days, 12 days, 15 days, 20 days, 28 days or more than 28 days. Dose reduction during a drug break is, by way of example only, from 10% to 100%, including by way of example only 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% and 100%.
[00116] Once the patient's condition has improved, a maintenance dose is administered if necessary. Subsequently, in specific modalities, the dosage or frequency of administration, or both, is reduced as a function of the symptoms, to a level at which improvement in the disease, disorder, or condition is maintained. In certain modalities, however, the patient requires long-term intermittent or daily treatment after any recurrence of symptoms.
[00117] The amount of a given agent that corresponds to such quantity varies depending on factors such as the specific compound, the disease condition and its severity, the identity (e.g., weight, sex) of the individual or host requiring treatment, but is nevertheless determined according to the specific circumstances surrounding the case, including, for example, the specific agent administered, the route of administration, the condition being treated, and the individual or host being treated.
[00118] In general, however, the doses used for the treatment of adult humans are typically in the range of 0.01 mg to 5000 mg per day. In one aspect, the doses used for the treatment of adult humans are from about 1 mg to about 1000 mg per day. In one embodiment, the desired dose is conveniently presented as a single dose or in divided doses administered simultaneously or at appropriate intervals, for example, as two, three, four or more subdoses per day.
[00119] In one embodiment, the appropriate daily dosages for the compound described herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, are from about 0.01 to about 50 mg / kg of body weight. In some embodiments, the daily dosage or the amount of active ingredient in the dosage form is lower or higher than the ranges indicated herein, based on a number of variables relating to an individual treatment regimen. In several embodiments, the daily and unit dosages are altered depending on a number of variables including, but not limited to, the activity of the compound used, the disease or condition being treated, the mode of administration, the individual's needs, the severity of the disease or condition being treated, and the professional's judgment.
[00120] The toxicity and therapeutic efficacy of such therapeutic regimens are determined by standard pharmaceutical procedures in cell cultures or experimental animals, including, but not limited to, the determination of LD10 and ED90. The dose ratio between toxic and therapeutic effects is the therapeutic index and is expressed as the ratio between LD50 and ED50. In certain embodiments, data obtained from cell culture assays and animal studies are used in formulating the therapeutically effective daily dosage range and / or the therapeutically effective unit dosage amount for use in mammals, including humans. In some embodiments, the daily dosage amount of the compounds described herein is within a range of circulating concentrations that include the ED50 with minimal toxicity.In certain dosage forms, the daily dosage range and / or the unit dosage amount varies within this range depending on the dosage form employed and the route of administration used.
[00121] In any of the aspects mentioned above, there are additional embodiments in which the effective amount of the compound described herein, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, is: (a) administered systemically to the mammal; and / or (b) administered orally to the mammal; and / or (c) administered intravenously to the mammal; and / or (d) administered by injection to the mammal; and / or (e) administered topically to the mammal; and / or (f) administered non-systemically or locally to the mammal.
[00122] In any of the above-mentioned aspects are additional embodiments comprising single administrations of the effective amount of the compound, including other embodiments in which (i) the compound is administered once daily; or (ii) the compound is administered to the mammal multiple times during the period of one day.
[00123] In any of the aforementioned aspects are additional embodiments comprising multiple administrations of the effective amount of the compound, including additional embodiments in which (i) the compound is administered continuously or intermittently, as in a single dose; (ii) the time between multiple administrations is every 6 hours; (iii) the compound is administered to the mammal every 8 hours; (iv) the compound is administered to the individual every 12 hours; (v) the compound is administered to the individual every 24 hours. In additional or alternative embodiments, the method comprises a "drug rest," whereby administration of the compound is temporarily suspended or the dose of the compound administered is temporarily reduced; at the end of the drug rest, the dosage of the compound is resumed. In one embodiment, the duration of the drug rest ranges from 2 days to 1 year. Routes of administration
[00124] Suitable routes of administration include, but are not limited to, oral, intravenous, rectal, aerosol, parenteral, ophthalmic, pulmonary, transmucosal, transdermal, vaginal, otic, nasal, and topical administration. In addition, by way of example only, parenteral administration includes intramuscular, subcutaneous, intravenous, intramedullary injections, as well as intrathecal, direct intraventricular, intraperitoneal, intralymphatic, and intranasal injections.
[00125] In certain embodiments, a compound as described herein is administered locally rather than systemically, for example, by injecting the compound directly into an organ, often in a depot preparation or sustained-release formulation. In specific embodiments, long-acting formulations are administered by implantation (e.g., subcutaneous or intramuscular) or by intramuscular injection. Furthermore, in other embodiments, the drug is applied in a targeted drug delivery system, for example, in an organ-specific antibody-coated liposome. In such embodiments, liposomes are targeted and selectively absorbed by the organ. In still other embodiments, the compound as described herein is provided in the form of a rapid-release formulation, in the form of a sustained-release formulation, or in the form of an intermediate-release formulation.In other forms, the compound described here is administered topically. Pharmaceutical Compositions / Formulations.
[00126] The compounds described herein are administered to an individual in need thereof, alone or in combination with pharmaceutically acceptable vehicles, excipients or diluents, in a pharmaceutical composition, in accordance with standard pharmaceutical practice. In one embodiment, the compounds of this invention may be administered to animals. The compounds may be administered orally or parenterally, including intravenous, intramuscular, intraperitoneal, subcutaneous, rectal and topical routes of administration.
[00127] In another aspect, pharmaceutical compositions are provided herein comprising a compound described herein, or a salt, a solvate or a pharmaceutically acceptable stereoisomer thereof and at least one pharmaceutically acceptable excipient. The pharmaceutical compositions are formulated in a conventional manner using one or more pharmaceutically acceptable excipients that facilitate the processing of the active compounds into preparations that can be used pharmaceutically. The appropriate formulation depends on the chosen route of administration. A summary of the pharmaceutical compositions described herein can be found, for example, in Remington: The Science and Practice of Pharmacy, Nineteenth Edition (Easton, Pa.: Mack Publishing Company, 1995); Hoover, John E., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pennsylvania 1975; Liberman, HA and Lachman, L., Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, NY, 1980; and Pharmaceutical Dosage Forms and Drug Delivery Systems, Seventh Ed. (Lippincott Williams & Wilkins 1999), incorporated herein by reference for such disclosure.
[00128] In some embodiments, the pharmaceutically acceptable excipient is selected from vehicles, binders, bulking agents, suspending agents, flavoring agents, sweetening agents, disintegrating agents, dispersing agents, surfactants, lubricants, colorants, diluents, solubilizers, humectants, plasticizers, stabilizers, penetration enhancers, wetting agents, antifoaming agents, antioxidants, preservatives and any combinations thereof.
[00129] The pharmaceutical compositions described herein are administered to an individual by appropriate routes of administration, including, but not limited to, oral, parenteral (e.g., intravenous, subcutaneous, intramuscular), intranasal, buccal, topical, rectal or transdermal routes of administration. The pharmaceutical formulations described herein include, but are not limited to, aqueous liquid dispersions, liquids, gels, syrups, elixirs, aqueous pastes, suspensions, self-emulsifying dispersions, solid solutions, liposomal dispersions, aerosols, oral solid dosage forms, powders, immediate-release formulations, controlled-release formulations, rapid-melting formulations, tablets, capsules, pills, powders, dragees, effervescent formulations, lyophilized formulations, delayed-release formulations, prolonged-release formulations, pulsatile-release formulations, multiparticulate formulations, and mixed immediate-release and controlled-release formulations.
[00130] Pharmaceutical compositions, including the compounds described herein, or a salt, a solvate or a pharmaceutically acceptable stereoisomer thereof, are manufactured in a conventional manner, such as, by way of example only, by conventional processes of mixing, dissolving, granulating, coating, levigating, emulsifying, encapsulating, coating or compression.
[00131] Pharmaceutical compositions for oral use are obtained by mixing one or more solid excipients with one or more of the compounds described herein, optionally triturating the resulting mixture and processing the granule mixture, after adding suitable auxiliary agents, if desired, to obtain dragee or tablet cores. Suitable excipients include, for example, fillers such as sugars, including lactose, sucrose, mannitol or sorbitol; cellulose preparations such as, for example, corn starch, wheat starch, rice starch, potato starch, gelatin, tragacanth gum, methylcellulose, microcrystalline cellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose; or others such as polyvinylpyrrolidone (PVP or povidone) or calcium phosphate. If desired, disintegrating agents are added, such as cross-linked croscarmellose sodium, polyvinylpyrrolidone, agar, or alginic acid, or a salt thereof, such as sodium alginate.In some embodiments, dyes or pigments are added to the coatings of tablets or dragees for identification or to characterize different dose combinations of the active compound.
[00132] Pharmaceutical compositions administered orally include gelatin "push-fit" capsules, as well as sealed soft capsules made of gelatin and a plasticizer such as glycerol or sorbitol. Push-fit capsules contain the active ingredients mixed with fillers such as lactose, binders such as starches and / or lubricants such as talc or magnesium stearate, and optionally, stabilizers. In soft capsules, the active compounds are dissolved or suspended in suitable liquids such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In some embodiments, stabilizers are added.
[00133] Pharmaceutical compositions for parenteral use are formulated as infusions or injections. In some embodiments, the pharmaceutical composition suitable for injection or infusion includes sterile aqueous solutions, dispersions, or powders comprising a compound described herein, or a salt, a solvate, or a pharmaceutically acceptable stereoisomer thereof. In some embodiments, the pharmaceutical composition comprises a liquid vehicle. In some embodiments, the liquid vehicle is a solvent or liquid dispersion medium comprising, for example, water, saline solution, ethanol, a polyol (e.g., glycerol, propylene glycol, liquid polyethylene glycols and the like), vegetable oils, non-toxic glyceryl esters, and any combinations thereof. In some embodiments, the pharmaceutical compositions further comprise a preservative to prevent the growth of microorganisms. Combinations
[00134] Methods of treating cancer using a compound described herein, or a salt, solvate or pharmaceutically acceptable stereoisomer thereof, in combination with an additional therapeutic agent, are described herein.
[00135] In some modalities, the additional therapeutic agent is an anticancer agent.
[00136] In some embodiments, the additional therapeutic agent is administered at the same time as the compound described herein. In some embodiments, the additional therapeutic agent and the compound described herein are administered sequentially. In some embodiments, the additional therapeutic agent is administered less frequently than the compound described herein. In some embodiments, the additional therapeutic agent is administered more frequently than the compound described herein. In some embodiments, the additional therapeutic agent is administered before the administration of the compound described herein. In some embodiments, the additional therapeutic agent is administered after the administration of the compound described herein. Examples
[00137] The compounds described herein are synthesized as generally described in general scheme 1 and general scheme 2. Step 1: Preparation of 3-bromo-2-methoxy-6-methyl-5-nitropyridine:
[00138] To a stirred mixture of 3-bromo-2-chloro-6-methyl-5-nitropyridine (20.00 g, 79.54 mmol, 1.00 equiv.) in MeOH (50 ml), NaOMe (15.76 g, 87.49 mmol, 1.10 equiv., 30% by weight) was added dropwise at 0 °C under a nitrogen atmosphere. The resulting mixture was stirred overnight at room temperature under a nitrogen atmosphere. The reaction was monitored by TLC (Pet. Ether : EtOAc=1:1, Rf = 0.4). After completion, the reaction was concentrated under reduced pressure and water (100 ml) was added. The resulting mixture was extracted with EtOAc (3 x 100 ml). The combined organic layers were washed with brine (1x200 ml), dried over anhydrous Na2SO4, filtered and concentrated to produce 3-bromo-2-methoxy-6-methyl-5-nitropyridine (20 g, 99%). 1H NMR (400 MHz, DMSO-d6) d 8.66 (s, 1H), 4.04 (s, 3H), 2.70 (s, 3H). Step 2: Preparation of (E)-2-(5-bromo-6-methoxy-3-nitropyridin-2-yl)-N,N-dimethylethen-1-amine:
[00139] A mixture of 3-bromo-2-methoxy-6-methyl-5-nitropyridine (15.00 g, 60.72 mmol, 1.00 equiv.) in DMF-DMA (100 ml) and DMF (100 ml) was stirred overnight at 100 °C under a nitrogen atmosphere. The reaction was monitored by TLC (Pet. Ether : EtOAc = 1:1, Rf = 0.5). The mixture was allowed to cool to room temperature and then concentrated under reduced pressure to yield crude (E)-2-(5-bromo-6-methoxy-3-nitropyridin-2-yl)-N,N-dimethylethen-1-amine. The crude product was used in the next step directly without further purification. Step 3: Preparation of 5-bromo-6-methoxy-3-nitropiclinaldehyde:
[00140] To a stirred mixture of (E)-2-(5-bromo-6-methoxy-3-nitropyridin-2-yl)ethenyl]dimethylamine (18.01 g, gross) in THF (100 ml) and H2O (100 ml), NaIO4 (28.00 g, 131.07 mmol, 2.20 equiv.) was added in portions at 0 °C under a nitrogen atmosphere. The resulting mixture was stirred for 2 hours at room temperature under a nitrogen atmosphere. The reaction was monitored by TLC (Pet. Ether : EtOAc = 5:1, Rf = 0.2). The reaction was abruptly cooled by the addition of saturated (aqueous) sodium hyposulfite (100 ml) at room temperature. The resulting mixture was extracted with EtOAc (3 x 100 ml). The combined organic layers were washed with brine (2 x 100 ml), then dried with anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The crude product was used directly in the next step without further purification. 1H NMR (400 MHz, DMSO-d6) d 10.16 (s, 1H), 8.87 (s, 1H), 4.10 (s, 3H). Step 4: Preparation of ethyl 7-bromo-6-methoxy-1,5-naphthyridine-3-carboxylate:
[00141] To a stirred mixture of 5-bromo-6-methoxy-3-nitropyridine-2-carbaldehyde (7.00 g, gross) and ethyl 3,3-diethoxypropanoate (20.40 g, 107.27 mmol, 4.00 equiv.) in EtOH (100 ml), SnCl2 (26.25 g, 134.09 mmol, 5.00 equiv.) was added in portions at room temperature under a nitrogen atmosphere. The resulting mixture was stirred overnight at 90 °C under a nitrogen atmosphere. The reaction was monitored by LCMS. The mixture was allowed to cool to room temperature. The resulting mixture was concentrated under reduced pressure. The crude mixture was poured into saturated sodium bicarbonate (100 ml). The resulting mixture was extracted with EtOAc (3 x 100 ml). The combined organic layers were concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to produce the crude product.The crude product was purified by trituration with hexane (50 ml) to produce ethyl 7-bromo-6-methoxy-1,5-naphthyridine-3-carboxylate (3.50 g, 18.5 %, over three steps). LC-MS: (ES+H, m / z): [M+H]+=311.0. Step 5: Preparation of ethyl 7-bromo-6-oxo-5H-1,5-naphthyridine-3-carboxylate:
[00142] A solution of 7-bromo-6-methoxy-1,5-naphthyridine-3-carboxylate ethyl (5.00 g, 16.07 mmol, 1.00 equiv.) in ACN (400 mL) was added dropwise to TMSi (13.8 mL, 96.42 mmol, 6.00 equiv.) at room temperature. The resulting mixture was stirred for 2 hours at 80 °C under a nitrogen atmosphere. The mixture was allowed to cool to room temperature. The reaction was monitored by LCMS. The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to yield 7-bromo-6-oxo-5H-1,5-naphthyridine-3-carboxylate ethyl (3.8 g, 80%). LC-MS: (ES+H, m / z): [M+H]+ =296.95. Step 6: Preparation of 7-[2-(tert-butyldimethylsilyl)ethynyl]-6-oxo-5H-1,5-naphthyridine-3-carboxylate:
[00143] A mixture of ethyl 7-bromo-6-oxo-5H-1,5-naphthyridine-3-carboxylate (1.50 g, 5.05 mmol, 1.00 equiv.), tert-butyl(ethynyl)dimethylsilane (850 mg, 6.05 mmol, 1.20 equiv.), CuI (0.19 g, 1.01 mmol, 0.20 equiv.), Et3N (1.53 g, 15.15 mmol, 3 equiv.) and Pd(PPh3)2Cl2 (0.35 g, 0.51 mmol, 0.10 equiv.) in DMF (45 ml) was stirred for 2 ha at 50 °C under a nitrogen atmosphere. The mixture was allowed to cool to room temperature. The reaction was monitored by LCMS. The resulting mixture was diluted with water (450 ml). The resulting mixture was extracted with EtOAc (3 x 450 ml). The combined organic layers were washed with brine (3 x 450 ml), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to yield 7-[2-(tert-butyldimethylsilyl)ethynyl]-6-oxo-5H-1,5-naphthyridine-3-carboxylate (1.5 g, 83%). LC-MS: (ES+H, m / z): [M+H]+ = 357.2. Step 7: Preparation of 3-[2-(tert-butyldimethylsilyl)ethynyl]-7-(hydroxymethyl)-1H-1,5-naphthyridine-2-one:
[00144] To a stirred solution of ethyl 7-[2-(tert-butyldimethylsilyl)ethynyl]-6-oxo-5H-1,5-naphthyridine-3-carboxylate (1.20 g, 3.37 mmol, 1.00 equiv.) in THF (30 ml), LiEt3BH (13.46 ml, 13.46 mmol, 4.00 equiv., 1 M in THF) was added dropwise at 0 °C under a nitrogen atmosphere. The resulting mixture was stirred for 1 ha at 0 °C under a nitrogen atmosphere. The reaction was monitored by LCMS. The reaction was rapidly cooled by the addition of citric acid (5.05 ml, 5.05 mmol, 1.50 equiv., 1 M) at 0 °C. The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to yield 3-[2-(tert-butyldimethylsilyl)ethynyl]-7-(hydroxymethyl)-1H-1,5-naphthyridine-2-one (840 mg, 79%). LC-MS: (ES+H, m / z): [M+H]+ = 315.0. Step 8: Preparation of 3-[2-(tert-butyldimethylsilyl)ethynyl]-7-(chloromethyl)-1H-1,5-naphthyridine-2-one:
[00145] To a stirred mixture of 3-[2-(tert-butyldimethylsilyl)ethynyl]-7-(hydroxymethyl)-1H-1,5-naphthyridine-2-one (92 mg, 0.29 mmol, 1.00 equiv.) and DMF (1 mg, 0.01 mmol, 0.05 equiv.) in DCM (5 mL), SOCl2 (0.06 mL, 0.88 mmol, 3.00 equiv. 1.64 g / mL) was added dropwise at 0 °C under a nitrogen atmosphere. The resulting mixture was stirred overnight at room temperature under a nitrogen atmosphere. The reaction was monitored by LCMS. The resulting mixture was concentrated under reduced pressure to produce 3-[2-(tert-butyldimethylsilyl)ethynyl]-7-(chloromethyl)-1H-1,5-naphthyridine-2-one (97 mg, crude). The crude product was used directly in the next step without further purification. LC-MS: (ES+H, m / z): [M+H+MeCN] +=374.2. Step 9: Preparation of 5-[4-({7-[2-(terc-butyldimethylsilyl)ethynyl]-6-oxo-5H- 1,5-naphthyridine-3-yl}methyl)piperazine-1-yl]pyridine-2-carbonitrile:
[00146] To a stirred mixture of 5-(piperazine-1-yl)pyridine-2-carbonitrile hydrochloride (119 mg, 0.53 mmol, 1.48 equiv.), DIEA (232 mg, 1.80 mmol, 5.00 equiv.) and 3-[2-(tert-butyldimethylsilyl)ethynyl]-7-(chloromethyl)-1H-1,5-naphthyridine-2-one (120 mg, 0.36 mmol, 1.00 equiv.) in MeCN (5 ml), KI (11 mg, 0.07 mmol, 0.20 equiv.) was added in portions at room temperature under a nitrogen atmosphere. The resulting mixture was stirred for 2 hours at 80 °C under a nitrogen atmosphere. The reaction was monitored by LCMS. The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to yield 5-[4-({7-[2-(tert-butyldimethylsilyl)ethynyl]-6-oxo-5H-1,5-naphthyridine-3-yl}methyl)piperazine-1-yl]pyridine-2-carbonitrile (120 mg, 69%). Step 10: Preparation of 5-[4-({7-[2-(tert-butyldimethylsilyl)ethynyl]-6-oxo-5H-1,5-naphthyridine-3-yl}methyl)piperazine-1-yl]pyridine-2-carbonitrile:
[00147] To a stirred mixture of 5-[4-({7-[2-(tert-butyldimethylsilyl)ethynyl]-6-oxo-5H-1,5-naphthyridine-3-yl}methyl)piperazine-1-yl]pyridine-2-carbonitrile (120 mg, 0.24 mmol, 1.00 equiv.) in THF (2.5 mL) was added TBAF (0.27 mL, 0.27 mmol, 1.10 equiv.) by drop at room temperature under a nitrogen atmosphere. The resulting mixture was stirred for 1 h at room temperature under a nitrogen atmosphere. The reaction was monitored by LCMS. The resulting mixture was concentrated under reduced pressure. The resulting mixture was diluted with water (50 mL). The resulting mixture was extracted with EtOAc (3 x 25 mL). The combined organic layers were washed with brine (1 x 50 ml), dried with anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure.The crude product (120 mg) was purified by preparative HPLC to yield 5-[4-({7-[2-(tert-butyldimethylsilyl)ethynyl]-6-oxo-5H-1,5-naphthyridine-3-yl}methyl)piperazine-1-yl]pyridine-2-carbonitrile (31.3 mg, 34%). LC-MS: (ES-H, m / z): [MH]- =369.1. 1H NMR (300 MHz, DMSO-d6) d 12.17 (s, 1H), 8.48 (d, 1H), 8.42 (d, 1H), 8.15 (s, 1H), 7.75 (d, 1H), 7.64 (d, 1H), 7.36 (dd, 1H), 4.51 (s, 1H), 3.67 (s, 2H), 3.47 - 3.38 (m, 4H), 2.60 - 2.52 (m, 4H). Example 2. Step 1: Preparation of methyl 5-nitro-6-(prop-1-en-2-yl)pyridine-3-carboxylate:
[00148] A mixture of methyl 6-chloro-5-nitropyridine-3-carboxylate (10.00 g, 46.17 mmol, 1.00 equiv.), 4,4,5,5-tetramethyl-2-(prop-1-en-2-yl)-1,3,2-dioxaborolane (15.52 g, 92.34 mmol, 2.00 equiv.), K2CO3 (12.76 g, 92.34 mmol, 2.00 equiv.) and Pd(dppf)Cl2 (3.38 g, 4.62 mmol, 0.10 equiv.) in dioxane (150 ml) and water (15 ml) was stirred for 3 h at 100 °C under a nitrogen atmosphere. The reaction was monitored by LCMS. The mixture was allowed to cool to room temperature. The resulting mixture was diluted with water (300 ml) and extracted with EtOAc (3 x 300 ml). The combined organic layers were washed with saturated aqueous NaCl solution (3 x 100 ml), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / EA (1:1) to yield methyl 5-nitro-6-(prop-1-en-2-yl)pyridine-3-carboxylate (5.00 g, 48.74%) as a light yellow oil.LC-MS: (ES+H, m / z): [M+H] + =222.95; 1H NMR (300 MHz, DMSO-d6) d 9.25 (d, 1H), 8.74 (d, 1H), 5.41 - 5.47 (m, 1H), 5.13 - 5.21 (m, 1H), 3.94 (s, 3H), 2.16 (dd, 3H). Step 2: Preparation of methyl 5-nitro-6-(prop-1-en-2-yl)pyridine-3-carboxylate:
[00149] To a stirred solution of methyl 5-nitro-6-(prop-1-en-2-yl)pyridine-3-carboxylate (5.00 g, 22.50 mmol, 1.00 equiv.) in MeOH (100 ml) were added NH4Cl (25 ml, sat. aq.) and Fe (5.03 g, 90.01 mmol, 4.00 equiv.). The reaction was stirred at 80 °C for 4 h under a nitrogen atmosphere. The reaction was monitored by LCMS. The mixture was cooled to room temperature and then concentrated under reduced pressure. The residue was diluted with CH2Cl2 / 2-propanol (5:1, 200 ml) and washed with water (250 ml) and brine (250 ml). The combined organic layers were dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. This resulted in methyl 5-amino-6-(prop-1-en-2-yl)pyridine-3-carboxylate (3.90 g, 90.17%) which was used directly without further purification. LC-MS: (ES+H, m / z): [M+H]+ = 193.15; 1H NMR (300 MHz, DMSO-d6) d 8.29 (s, 1H), 7.60 (d, 1H), 5.51-5.47 (m, 1H), 5.41 (s, 2H), 5.39-5.36 (m, 1H), 3.84 (s, 3H), 2.08 (t, 3H). Step 3: Preparation of methyl 8-methyl-6-oxo-5H-1,5-naphthyridine-3-carboxylate:
[00150] A solution of triphosgene (1.54 g, 5.20 mmol, 0.50 equiv.) in toluene (20 ml) was added to a solution of methyl 5-amino-6-(prop-1-en-2-yl)pyridine-3-carboxylate (3.90 g, 20.29 mmol, 1.00 equiv.) and Et3N (6.16 g, 60.87 mmol, 3.00 equiv.) in toluene (40 ml) at 0 °C under a nitrogen atmosphere. The resulting mixture was stirred overnight at 60 °C under a nitrogen atmosphere. The reaction was monitored by LCMS. The reaction was rapidly cooled with MeOH (30 ml) at 0 °C. The resulting mixture was diluted with water (200 ml) and extracted with CH2Cl2 / 2-Propanol (5:1, 3 x 200 ml). The combined organic layers were washed with water (3 x 100 ml), dried with anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to yield methyl 8-methyl-6-oxo-5H-1,5-naphthyridine-3-carboxylate (1.80 g, 40.66%).LC-MS: (ES+H, m / z): [M+H]+=219.1; 1H NMR (400 MHz, DMSO-d6) d 11.92 (s, 1H), 8.92 (d, 1H), 8.15 (d, 1H), 6.79 (s, 1H), 3.93 (s, 3H), 2.48 (s, 3H). Step 4: Preparation of 7-chloro-8-methyl-6-oxo-5H-1,5-naphthyridine-3-methylcarboxylate:
[00151] To a stirred mixture of methyl 8-methyl-6-oxo-5H-1,5-naphthyridine-3-carboxylate (600 mg, 2.75 mmol, 1.00 equiv.) and NCS (587 mg, 4.40 mmol, 1.60 equiv.) in CH3COOH (7 ml), 2,2-dichloroacetic acid (71 mg, 0.55 mmol, 0.20 equiv.) was added dropwise at room temperature under a nitrogen atmosphere. The resulting mixture was stirred overnight at 100 °C under a nitrogen atmosphere. The reaction was monitored by LCMS. The mixture was allowed to cool to room temperature. The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to yield methyl 7-chloro-8-methyl-6-oxo-5H-1,5-naphthyridine-3-carboxylate (650 mg, 93.5%). LC-MS: (ES+H, m / z): [M+H]+ = 253.0; 1H NMR (300 MHz, DMSO-d6) d 8.90 (d, 1H), 8.13 (d, 1H), 3.93 (s, 3H), 2.60 (s, 3H). Step 5: Preparation of 3-chloro-7-(hydroxymethyl)-4-methyl-1H-1,5-naphthyridine-2-one:
[00152] To a stirred mixture of methyl 7-chloro-8-methyl-6-oxo-5H-1,5-naphthyridine-3-carboxylate (600 mg, 2.38 mmol, 1.00 equiv.) in THF (5 ml), LiAlH4 (2 ml, 2.5 M in THF, 4.75 mmol, 2.00 equiv.) was added dropwise at 0 °C under a nitrogen atmosphere. The resulting mixture was stirred for 1 h at room temperature under a nitrogen atmosphere. The reaction was monitored by LCMS. The reaction was rapidly cooled by the addition of HCl (1 ml, 12 M) at 0 °C. The resulting mixture was concentrated under reduced pressure. The residue was purified by silica-gel column chromatography to yield 3-chloro-7-(hydroxymethyl)-4-methyl-1H-1,5-naphthyridine-2-one (230 mg, 43.1%). LC-MS: (ES+H, m / z): [M+H]+ = 225.1; 1H NMR (300 MHz, DMSO-d6) d 12.24 (br, 1H), 8.48 (d, 1H), 7.77 (d, 1H), 5.69 (s, 1H), 4.63 (s, 2H), 2.63 (s, 3H). Step 6: Preparation of 3-chloro-7-(chloromethyl)-4-methyl-1H-1,5-naphthyridine-2-one:
[00153] To a stirred mixture of 3-chloro-7-(hydroxymethyl)-4-methyl-1H-1,5-naphthyridine-2-one (200 mg, 0.89 mmol, 1.00 equiv.) and DMF (7 mg, 0.09 mmol, 0.10 equiv.) in DCM (10 ml), SOCl2 (318 mg, 2.67 mmol, 3.00 equiv.) was added dropwise at 0 °C under a nitrogen atmosphere. The resulting mixture was stirred for 10 h at room temperature. The reaction was monitored by LCMS. The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to yield 3-chloro-7-(chloromethyl)-4-methyl-1H-1,5-naphthyridine-2-one (98 mg, 45.2%). LC-MS: (ES+H, m / z): [M+H]+ =243.0. Step 7: Preparation of 4-{4-[(7-chloro-8-methyl-6-oxo-5H-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}benzonitrile:
[00154] A mixture of 3-chloro-7-(chloromethyl)-4-methyl-1H-1,5-naphthyridine-2-one (25 mg, 0.10 mmol, 1.00 equiv.), DIEA (66 mg, 0.51 mmol, 5.00 equiv.), KI (4 mg, 0.02 mmol, 0.20 equiv.) and 4-(piperazin-1-yl)benzonitrile (19 mg, 0.10 mmol, 1.00 equiv.) in MeCN (2 ml) was stirred for 2 h at 80 °C under a nitrogen atmosphere. The mixture was allowed to cool to room temperature. The reaction was monitored by LCMS. The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography. The resulting mixture was concentrated under reduced pressure. The pure fraction was concentrated and then lyophilized to produce 4-{4-[(7-chloro-8-methyl-6-oxo-5H-1,5-naftiridin-3-yl)methyl]piperazin-1-yl}benzonitrile (12 mg, 29.6%).LC-MS: (ES-H, m / z): [MH]-=392.15; 1H NMR (400 MHz, DMSO-d6) d 12.30 (s, 1H), 8.51 (d, J = 1.8 Hz, 1H), 7.69 (d, J = 1.9 Hz, 1H), 7.58 (d, J = 8.7 Hz, 2H), 7.02 (d, J = 8.7 Hz, 2H), 3.67 (s, 2H), 3.38 - 3.34(m, 4H), 2.64 (s, 3H), 2.57-2.54 (m, 4H). Example 3. Step 1: Preparation of methyl 6-methyl-5-nitropyridine-3-carboxylate:
[00155] To a stirred solution of methyl 6-chloro-5-nitropyridine-3-carboxylate (5 g, 273.08 mmol, 1.00 equiv) and methylboronic acid (2.75 g, 46.17 mmol, 2.00 equiv) in toluene (60 ml) and H2O (3 ml) was added Pd(dppf)Cl2 (0.83 g, 1.15 mmol, 0.05 equiv) and CsF (7 g, 46.17 mmol, 2.00 equiv) at room temperature under a nitrogen atmosphere. The resulting mixture was stirred overnight at 100 °C under a nitrogen atmosphere. The resulting mixture was added to 500 ml of water and extracted with EtOAc (3 x 200 ml). The combined organic layers were washed with brine (200 mL), dried with anhydrous Na2SO4, filtered, and concentrated. The crude product was purified by silica gel column chromatography to yield methyl 6-methyl-5-nitropyridine-3-carboxylate (2.9 g, 64%). LC-MS: (ES+H, m / z): [M+H]+ = 197.0; 1H NMR (400 MHz, Chloroform-d) d 9.29 (s, 1H), 8.84 (d, 1H), 4.01 (s, 3H), 2.94 (s, 3H). Step 2: Preparation of methyl 6-formyl-5-nitropyridine-3-carboxylate:
[00156] A mixture of methyl 6-methyl-5-nitropyridine-3-carboxylate (35 g, 178.42 mmol, 1.00 equiv.) and SeO2 (30 g, 267.64 mmol, 1.50 equiv.) in dioxane (200 ml) was stirred overnight at 110 °C under a nitrogen atmosphere. The resulting mixture was then filtered, and the filter cake was washed with EtOAc (5 x 200 ml). The filtrate was concentrated under reduced pressure, and then the crude product was dissolved in THF (200 ml). The resulting mixture was filtered, and the filter cake was washed with THF (3 x 100 ml). The filtrate was concentrated under reduced pressure to yield nitropyridine-3-carboxylate (40 g, crude). LC-MS: (ES+H, m / z): [M+H]+ =211.1. Step 3: Preparation of (Z)-6-(2-(ethoxycarbonyl)but-1-en-1-yl)-5-methyl nitronicotinate:
[00157] To a stirred mixture of NaH (11.42 g, 285.52 mmol, 1.50 equiv., 60 wt. %) in THF (500 ml), ethyl 2-(diethoxyphosphoryl)butanoate (72 g, 285.52 mmol, 1.50 equiv.) in THF (50 ml) was added dropwise at 0 °C under a nitrogen atmosphere. The resulting mixture was stirred for 10 min at 0 °C and then heated to 40 °C and stirred for 10 min under a nitrogen atmosphere. The resulting mixture was cooled to -78 °C and then methyl 6-formyl-5-nitropyridine-3-carboxylate (40 g, 190.35 mmol, 1.00 equiv.) in THF (50 ml) was added dropwise. The resulting mixture was stirred for 30 min at -78 °C under a nitrogen atmosphere. The reaction was monitored by LCMS. The reaction was rapidly cooled by the addition of 100 ml of saturated NH4Cl (aq) at 0 °C. 400 ml of water was added to the resulting mixture and it was extracted with 3 x 500 ml of EtOAc. The combined organic layers were washed with brine (1 x 500 ml), dried with anhydrous Na2SO4, filtered, and concentrated.The residue was purified by silica gel column chromatography to give (Z)-6-(2-(ethoxycarbonyl)but-1-en-1-yl)-5-methyl nitronicotinate (20 g, 36%, two-step) and (E)-6-(2-(ethoxycarbonyl)but-1-en-1-yl)-5-methyl nitronicotinate (8.8 g). Data for (Z)-6-(2-(ethoxycarbonyl)but-1-en-1-yl)-5-methyl nitronicotinate: LC-MS: (ES+H, m / z): [M+H]+ = 309.1; 1H NMR (300 MHz, Chloroform-d) d 9.27 (d, 1H), 8.88 (d, 1H), 7.10 (t, 1H), 4.22 - 4.16 (m, 2H), 4.03 (s, 3H), 2.59 (qd, 2H), 1.25 (t, 3H), 1.19 (t, 3H). Data for methyl (E)-6-(2-(ethoxycarbonyl)but-1-en-1-yl)-5-nitronicotinate: LC-MS: (ES+H, m / z): [M+H] + =309.1; 1H NMR (300 MHz, Chloroform-d6) d 9.45 (d, 1H), 8.88 (d, 1H), 7.87 (s, 1H), 4.34 (q, 2H), 4.05 (s, 3H), 2.67 (q, 2H), 1.39 (t, 3H), 1.15 (t, 3H). Step 4: Preparation of ethyl 7-ethyl-6-oxo-5H-1,5-naphthyridine-3-carboxylate:
[00158] To a stirred mixture of methyl 6-[(1Z)-3-ethoxy-2-ethyl-3-oxoprop-1-en-1-yl]-5-nitropyridine-3-carboxylate (9.00 g, 29.19 mmol, 1.00 equiv.) and Fe (16.30 g, 291.93 mmol, 10.00 equiv.) in EtOH (200 mL), CaCl2 (19.44 g, 175.16 mmol, 6.00 equiv.) was added at room temperature under a nitrogen atmosphere. The resulting mixture was stirred overnight at 90 °C under a nitrogen atmosphere. The reaction was monitored by LCMS. The resulting mixture was filtered, the filter cake was washed with EtOAc (5 x 100 mL), and the combined filtrate was concentrated. The mixture was added to 250 ml of water and extracted with EtOAc (3 x 250 ml). The combined organic layers were washed with brine (1 x 250 ml) and dried with anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure to yield ethyl 7-ethyl-6-oxo-5H-1,5-naphthyridine-3-carboxylate (5.2 g, 72%).LC- MS: (ES+H, m / z): [M+H]+=247,1; RMN de 1H (400 MHz, DMSO-d6) d 12,06 (s, 1H), 8,90 (s, 1H), 8,16 (s, 1H), 7,83 (s, 1H), 4,38 (q, 2H), 2,58 (q, 2H), 1,36 (t, 3H), 1,20 (t, 3H). Etapa 5: Preparação de 3-etil-7-(hidroximetil)-1H-1,5-naftiridina-2-ona:
[00159] To a stirred solution of 7-ethyl-6-oxo-5H-1,5-naphthyridine-3-ethyl carboxylate (4.00 g, 16.24 mmol, 1.00 equiv.) in THF (50 ml), LiAlH4 (13 ml, 32.49 mmol, 2.00 equiv., 2.5 M in THF) was added dropwise at 0 °C under a nitrogen atmosphere. The resulting mixture was stirred for 1 h at 0 °C. The reaction was monitored by LCMS. The reaction was rapidly cooled by the addition of 1 M aqueous HCl (16 ml) at 0 °C. The resulting mixture was concentrated under reduced pressure and the crude product was purified by silica gel column chromatography to yield 3-ethyl-7-(hydroxymethyl)-1H-1,5-naphthyridin-2-one (2.00 g, 60%). LC-MS: (ES+H, m / z): [M+H]+=204.8; 1H NMR (400 MHz, DMSO-d6) d 11.91 (s, 1H), 8.38 (d, 1H), 7.74 (s, 1H), 7.62 (d, 1H), 5.49 (t, 1H), 4.62 (d, 2H), 2.55 (dd, 2H), 1.18 (t, 3H). Step 6: Preparation of 7-(chloromethyl)-3-ethyl-1H-1,5-naphthyridin-2-one:
[00160] To a stirred mixture of 3-ethyl-7-(hydroxymethyl)-1H-1,5-naphthyridine-2-one (300 mg, 1.47 mmol, 1.00 equiv.) and DMF (11 mg, 0.15 mmol, 0.10 equiv.) in DCM (10 ml), SOCl2 (1.05 g, 8.81 mmol, 6.00 equiv.) was added dropwise at 0 °C under a nitrogen atmosphere. The resulting mixture was stirred overnight at room temperature and then concentrated under vacuum. The residue was purified by silica gel column chromatography to yield 7-(chloromethyl)-3-ethyl-1H-1,5-naphthyridine-2-one (300 mg, 92%). LC-MS: (ES+H, m / z): [M+H]+=222.8; 1H NMR (400 MHz, DMSO-d6) d 11.99 (s, 1H), 8.50 (d, 1H), 7.76 (s, 1H), 7.70 (d, 1H), 4.93 (s, 2H), 2.56 (td, 2H), 1.19 (t, 3H). Step 7: Preparation of 5-{4-[(7-ethyl-6-oxo-5H-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}pyridine-2-carbonitrile:
[00161] To a stirred mixture of 5-(piperazin-1-yl)pyridine-2-carbonitrile, HCl salt (600 mg) and 7-(chloromethyl)-3-ethyl-1H-1,5-naphthyridin-2-one (500 mg, 2.25 mmol, 1.00 equiv.) in ACN (4 ml), DIEA (1.45 g, 11.25 mmol, 5.00 equiv.) and KI (75 mg, 0.45 mmol, 0.20 equiv.) were added in portions at room temperature. The resulting mixture was stirred for 1 h at 80 °C under a nitrogen atmosphere. The reaction was monitored by LCMS. The mixture was allowed to cool to room temperature. The reaction was poured into water (20 ml). The aqueous layer was extracted with EtOAc (3 x 20 ml). The combined organic layers were concentrated under reduced pressure. The residue was purified by silica gel column chromatography to yield 5-{4-[(7-ethyl-6-oxo-5H-1,5-naphtiridine-3-yl)methyl]piperazine-1-yl}pyridine-2-carbonitrile (650 mg, 77%).LC-MS: (ES+H, m / z): [M+H]+ = 375.2; 1H NMR (300 MHz, DMSO-d6) d 11.86 (s, 1H), 8.41-8.35 (m, 2H), 7.75 (t, 2H), 7.61 (s, 1H), 7.36 (dd, 1H), 3.64 (s, 2H), 3.52-3.42 (m, 4H), 2.61-2.54 (m, 6H), 1.18 (t, 3H). Example 5. Step 1: Preparation of methyl 2-[(4-bromo-2-fluoro-6-nitrophenyl)amino]butanoate:
[00162] To a stirred mixture of 5-bromo-1,2-difluoro-3-nitrobenzene (10.00 g, 42.02 mmol, 1.00 equiv) and methyl 2-aminobutanoate hydrochloride (6.43 g, 42.02 mmol, 1.00 equiv) in MPN (200 ml) was added DIEA (27.15 g, 210.10 mmol, 5.00 equiv) by drop at room temperature. The resulting mixture was diluted with water (500 ml). The resulting mixture was extracted with EtOAc (3 x 500 ml). The combined organic layers were washed with brine (8 x 300 ml), dried with anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, and the pure fraction was concentrated under vacuum to yield methyl 2-[(4-bromo-2-fluoro-6-nitrophenyl)amino]butanoate (13.00 g, 92%). LC-MS: (ES+H, m / z): [M+H]+ = 334.9; 1H NMR (400 MHz, DMSO-d6) d 8.09 (s, 1H), 7.88 (dd, 1H), 7.79 (dd, 1H), 4.56 (dtd, 1H), 3.69 (s, 3H), 1.97 - 1.79 (m, 2H), 0.91 (t, 3H). Step 2: Preparation of 7-bromo-3-ethyl-5-fluoro-3,4-dihydro-1H-quinoxaline-2-one:
[00163] To a stirred mixture of Fe (5.00 g, 89.52 mmol, 5.00 equiv) in AcOH (100 ml) was added 2-[(4-bromo-2-fluoro-6-nitrophenyl)amino]butanoate methyl (6.00 g, 17.90 mmol, 1.00 equiv) in AcOH (20 ml) by dropwise at 80 °C under a nitrogen atmosphere. The resulting mixture was stirred for 2 h at 80 °C under a nitrogen atmosphere. The reaction was monitored by TLC (CH2Cl2 / MeOH=10 / 1). The mixture was allowed to cool to room temperature. The resulting mixture was filtered, the filter cake was washed with EtOAc (3 x 50 ml). The filtrate was concentrated under reduced pressure. The residue was purified by trituration with water (3 x 100 ml). The precipitated solids were collected by filtration and washed with water (3 x 20 ml). This resulted in 7-bromo-3-ethyl-5-fluoro-3,4-dihydro-1H-quinoxalin-2-one (4.5 g, 92%). 1H NMR (400 MHz, DMSO-d6) d 10.52 (s, 1H), 6.99 (d, 1H), 6.72 (s, 1H), 6.17 (s, 1H), 3.78 (d, 1H), 1.72-1.62 (m, 2H), 0.88 (t, 3H). Step 3: Preparation of 7-bromo-3-ethyl-5-fluoro-1H-quinoxalin-2-one:
[00164] To a stirred solution of 7-bromo-3-ethyl-5-fluoro-1H-quinoxalin-2-one (4.40 g, 16.11 mmol, 1.00 equiv) in DCM (100 ml) was added DDQ (4.39 g, 19.33 mmol, 1.20 equiv) in portions at room temperature under a nitrogen atmosphere. The resulting mixture was stirred for 2 h at room temperature under a nitrogen atmosphere. The reaction was monitored by LCMS. The reaction was rapidly cooled by the addition of saturated NaHCO3 (aq.) (100 ml) at 0 °C. The residue was purified by trituration with saturated NaHCO3 (aq.) (5 x 100 ml). The precipitated solids were collected by filtration and washed with water (3 x 100 ml) to yield 7-bromo-3-ethyl-5-fluoro-1H-quinoxalin-2-one (3.50 g, 80%). LC-MS: (ES-H, m / z): (MH)- = 269.0; 1H NMR (400 MHz, DMSO-d6) d 12.51 (s, 1H), 7.44 (d, 1H), 7.24 (s, 1H), 2.79 (q, 2H), 1.21 (t, 3H). Step 4: Preparation of 2-ethyl-8-fluoro-3-oxo-4H-quinoxaline-6-carbaldehyde:
[00165] To a solution of 7-bromo-3-ethyl-5-fluoro-1H-quinoxalin-2-one (2.90 g, 10.70 mmol, 1.00 equiv) in toluene (100 ml) was added TMEDA (1.49 g, 12.84 mmol, 1.20 equiv), bis(adamantan-1-yl)(butyl)phosphane (0.77 g, 2.14 mmol, 0.20 equiv), Pd(OAc)2 (0.24 g, 1.07 mmol, 0.10 equiv) in a pressure tank. The mixture was purged with nitrogen for 5 min and then pressurized to 30 atm with (CO:H2=1:1). The mixture was stirred overnight at 100 °C. The reaction was monitored by LCMS. The reaction mixture was cooled to room temperature and filtered to remove insoluble solids. The resulting mixture was concentrated under vacuum. The residue was purified by column chromatography on silica gel, and the pure fraction was concentrated under vacuum to yield 2-ethyl-8-fluoro-3-oxo-4H-quinoxaline-6-carbaldehyde (1.40 g, 59%). LC-MS: (ES-H, m / z): [MH]- = 219.0; 1H NMR (300 MHz, DMSO-d6) d 12.74 (s, 1H), 10.01 (d, 1H), 7.65 - 7.47 (m, 2H), 2.86 (q, 2H), 1.24 (t, 3H). Step 5: Preparation of 6-(4-((2-ethyl-8-fluoro-3-oxo-3,4- dihydroquinoxalin-6-yl)methyl)piperazine-1-yl)nicotinonitrile:
[00166] To a stirred solution of 6-(piperazin-1-yl)pyridine-3-carbonitrile (200 mg, 1.06 mmol, 1.00 equiv) and 2-ethyl-8-fluoro-3-oxo-3,4-dihydroquinoxaline-6-carbaldehyde (304 mg, 1.38 mmol, 1.30 equiv) in THF (10 ml) was added Ti(OiPr)4 (453 mg, 1.60 mmol, 1.50 equiv) at room temperature under a nitrogen atmosphere. After 2 h, NaBH(AcO)3 (901 mg, 4.25 mmol, 4.00 equiv) was added at 0 °C and the reaction was heated to room temperature. After 2 h, the reaction was abruptly cooled by the addition of water (10 ml) at 0 °C. The aqueous layer was extracted with EtOAc (5 x 30 ml). The combined organic phase was concentrated under reduced pressure and the crude product was purified by preparation HPLC to yield 6-(4-((2-ethyl-8-fluoro-3-oxo-3,4-dihydroquinoxalin-6-yl)methyl)piperazin-1-yl)nicotinonitrile (56.1 mg, 13%).LC-MS: (ES+H, m / z): [M+H] + =393.2; 1H NMR (300 MHz, DMSO-d6) d 12.43(s,1H), 8.48(d,1H), 7.85(dd,1H), 7.16–7.04(m,2H), 6.93(d,1H), 3.77–3.52(m,6H), 2.87–2.75 (m, 2H), 2.50–2.43 (m, 4H), 1.22 (t, 3H); 19F NMR (282 MHz, DMSO-d6) d -125.38. Example 12. Step 1: Preparation of 2-fluoro-4-[(1-methoxy-1-oxobutan-2-yl)amino]-5- methyl nitrobenzoate:
[00167] To a stirred mixture of methyl 2,4-difluoro-5-nitrobenzoate (10.00 g, 46.06 mmol, 1.00 equiv.) and methyl 2-aminobutanoate, HCl salt (5.40 g, 46.06 mmol, 1.00 equiv.) in MPN (100 ml), DIEA (48.1 ml, 276.34 mmol, 6.00 equiv.) was added dropwise at room temperature under a nitrogen atmosphere. The resulting mixture was stirred for 4 hours at room temperature under a nitrogen atmosphere. The reaction was monitored by LCMS. The reaction was abruptly cooled by the addition of water (200 ml) at room temperature. The resulting mixture was extracted with EtOAc (3 x 100 ml). The combined organic layers were washed with brine (8 x 200 ml), dried with anhydrous Na2SO4, filtered, and concentrated. The crude product was purified by silica gel column chromatography to yield methyl 2-fluoro-4-[(1-methoxy-1-oxobutan-2-yl)amino]-5-nitrobenzoate (12 g, 83%).LC-MS: (ES+H, m / z): [M+H]+ = 315.1; 1H NMR (400 MHz, DMSO-d6) d 8.80-8.56 (m, 2H), 7.21-6.99 (m, 1H), 4.84-4.74 (m, 1H), 3.85-3.81 (s, 3H), 3.77-3.74 (s, 3H), 2.05-1.82 (m, 2H), 0.91-0.85 (m, 3H). Step 2: Preparation of methyl 2-ethyl-7-fluoro-3-oxo-2,4-dihydro-1H-quinoxaline-6-carboxylate:
[00168] To a stirred mixture of methyl 2-fluoro-4-[(1-methoxy-1-oxobutan-2-yl)amino]-5-nitrobenzoate (12.00 g, 38.18 mmol, 1.00 equiv) in MeOH (180 ml) and EtOAc (30 ml) was added Pd(OH)2 / C (2.40 g) in portions at room temperature under a nitrogen atmosphere. The resulting mixture was stirred overnight at room temperature under a hydrogen atmosphere. The reaction was monitored by LCMS. After completion, the resulting mixture was filtered, and the filter cake was washed with EtOAc (3 x 300 ml). The filtrate was concentrated and purified by silica gel column chromatography (Pet. Ether / EtOAc) to yield methyl 2-ethyl-7-fluoro-3-oxo-2,4-dihydro-1H-quinoxaline-6-carboxylate (8 g, 83%). LC-MS: (ES+H, m / z): [M+H]+ = 253.0; 1H NMR (400 MHz, DMSO-d6) d 10.44 (s, 1H), 7.25-7.20 (m, 1H), 7.19-7.14 (s, 1H), 4.00-3.91 (m, 1H), 3.75 (s, 3H), 1.76 - 1.60 (m, 2H), 0.94-0.86 (m, 3H). Step 3: Preparation of 2-ethyl-7-fluoro-3-oxo-4H-quinoxaline-6-methyl carboxylate:
[00169] To a stirred mixture of methyl 2-ethyl-7-fluoro-3-oxo-2,4-dihydro-1H-quinoxaline-6-carboxylate (7.00 g, 27.75 mmol, 1.00 equiv) in DCM (70 ml) at room temperature, DDQ (7.56 g, 33.30 mmol, 1.20 equiv) in DCM (70 ml) was added. The resulting mixture was stirred for 2 h at room temperature under a nitrogen atmosphere. The reaction was monitored by LCMS. The residue was then dissolved in saturated aqueous NaHCO3 (200 ml). The precipitated solids were collected by filtration and washed with saturated aqueous NaHCO3 (3 x 200 ml) and water (3 x 200 ml). The solids were purified by grinding with EtOAc (30 ml) / hexane (100 ml). The resulting mixture was filtered, and the filter cake was washed with hexane (3 x 100 ml). The filter cake was dried under reduced pressure to yield methyl 2-ethyl-7-fluoro-3-oxo-4H-quinoxaline-6-carboxylate (6 g, 86%).LC-MS: (ES+H, m / z): [M+H] + =251,1; RMN de 1H (400 MHz, DMSO-d6) d 12,44 (s, 1H), 7,78 (d, 1H), 7,63 (d, 1H), 3,89 (s, 3H), 2,82 (q, 2H), 1,23 (t, 3H). Etapa 4: Preparação de 3-etil-6-fluoro-7-(hidroximetil)-1H-quinoxalin-2- ona:
[00170] To a stirred solution of methyl 2-ethyl-7-fluoro-3-oxo-4H-quinoxaline-6-carboxylate (5.00 g, 19.98 mmol, 1.00 equiv.) in THF (100 ml), LiAlH4 (40 ml, 39.96 mmol, 2.00 equiv., 1 mol / L in THF) was added dropwise at 0 °C under a nitrogen atmosphere. The reaction was monitored by LCMS. The reaction was rapidly cooled by the addition of water (1.5 ml), 15% NaOH (1.5 ml), and water (4.5 ml) at 0 °C. The precipitated solids were collected by filtration and washed with water (3 x 30 ml). The solids were dissolved in water (500 ml) and EtOAc (200 ml). The resulting mixture was extracted with EtO-Ac (8 x 200 ml). The filtrate was concentrated under reduced pressure. The residue was purified by trituration with MeOH (5 ml) and EtOAc (20 ml). The resulting mixture was filtered, and the filter cake was washed with EtOAc (3 x 10 ml). The solid was dried under reduced pressure to yield 3-ethyl-6-fluoro-7-(hydroxymethyl)-1H-quinoxalin-2-one (1.2 g, 27%).LC-MS: (ES+H, m / z): [M+H] + =223.2; 1H NMR (400 MHz, DMSO-d6) d 12.38 (s, 1H), 7.48 (d, 1H), 7.41 (d, 1H), 5.52 (brs, 1H), 4.64 (s, 2H), 2.80 (q, 2H), 1.18 (t, 3H). Step 5: Preparation of 7-(bromomethyl)-3-ethyl-6-fluoro-1H-quinoxaline-2-one:
[00171] A stirred solution of 3-ethyl-6-fluoro-7-(hydroxymethyl)-1H-quinoxalin-2-one (150 mg, 0.68 mmol, 1.00 equiv) in HBr (4 ml, 33% by weight in AcOH) at room temperature under a nitrogen atmosphere. The resulting mixture was stirred for 1 h at 80 °C under a nitrogen atmosphere. The reaction was monitored by LC-MS. The mixture was allowed to cool to room temperature. The resulting mixture was concentrated under reduced pressure. The crude product was used in the next step directly without further purification. LC-MS: (ES+H, m / z): [M+H]+ = 285.0. Step 6: Preparation of 6-{4-[(2-ethyl-7-fluoro-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl}pyridine-3-carbonitrile:
[00172] A mixture of 7-(bromomethyl)-3-ethyl-6-fluoro-1H-quinoxalin-2-one (190 mg, 0.67 mmol, 1.00 equiv), 6-(piperazin-1-yl)pyridine-3-carbonitrile (150 mg, 0.80 mmol, 1.20 equiv) and DIEA (431 mg, 3.33 mmol, 5.00 equiv) in NMP (5 ml) was stirred for 1 ha at 80°C under a nitrogen atmosphere. The mixture was allowed to cool to room temperature. The reaction was poured into water (30 ml) and the aqueous layer was extracted with EtOAc (3 x 20 ml). The combined organic layers were concentrated under reduced pressure. The crude product (200 mg) was purified by preparative HPLC to yield 6-{4-[(2-ethyl-7-fluoro-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl}pyridine-3-carbonitrile (100.2 mg, 38%). LC-MS: (ES+H, m / z): [M+H] + =393.1; 1H NMR (300 MHz, DMSO-d6) d 12.31 (s, 1H), 8.48 (d, 1H), 7.85 (dd, 1H), 7.54 (d, 1H), 7.38 (d, 1H), 6.94 (d, 1H), 3.75-3.67 (m, 6H), 2.81 (q, 2H), 2.56-2.51 (m, 4H), 1.21 (t, 3H); 19F NMR (282 MHz, DMSO-d6) d -124.28. Example 16 Step 1: Preparation of ethyl 2-bromo-2-cyclopropylacetate:
[00173] To a stirred solution of ethyl 2-cyclopropylacetate (10.00 g, 78.02 mmol, 1.00 equiv.) in THF (100 ml), LDA (42.9 ml, 85.82 mmol, 1.10 equiv., 2.0 M in THF) was added dropwise at -78 °C under a nitrogen atmosphere. The reaction was stirred for 1 hour, then TMSCl (8.48 g, 78.02 mmol, 1.00 equiv.) was added dropwise, and the reaction was stirred for 3 hours as it was heated to room temperature. The reaction was cooled to -78 °C, and NBS (15.28 g, 85.82 mmol, 1.10 equiv.) in 50 ml of THF was added dropwise. The reaction was then stirred for 2 hours and allowed to warm to room temperature. The reaction was monitored by LCMS. The reaction was rapidly cooled by the addition of 50 ml of 0 °C saturated NH4Cl (aq). The resulting mixture was extracted with 3 x 200 ml of Et2O. The combined organic layers were washed with brine (3 x 200 ml) and dried with anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure.The residue was purified by reverse combi-flash chromatography to yield ethyl 2-bromo-2-cyclopropylacetate (5.00 g, 31%). 1H NMR (300 MHz, Chloroform-d) d 4.25 (q, 2H), 3.58 (d, 1H), 1.65 - 1.55 (m, 1H), 1.31 (t, 3H), 0.92 - 0.76 (m, 2H), 0.61 - 0.53 (m, 1H), 0.48 - 0.40 (m, 1H). Step 2: Preparation of ethyl 2-cyclopropyl-2-(diethoxyphosphoryl)acetate:
[00174] A solution of ethyl 2-bromo-2-cyclopropylacetate (5.00 g, 24.14 mmol, 1.00 equiv.) and triethyl phosphite (5.22 g, 31.39 mmol, 1.30 equiv.) was stirred for 24 ha at 130 °C under a nitrogen atmosphere. The residue was purified by reverse combi-flash chromatography to yield ethyl 2-cyclopropyl-2-(diethoxyphosphoryl)acetate (2.40 g, 38%). 1H NMR (300 MHz, Chloroform-d) d 4.26 - 4.07 (m, 6H), 2.19 (dd, 1H), 1.30 (dt, 10H), 0.71 (dddd, 1H), 0.60 (dddd, 1H), 0.47 - 0.37 (m, 1H), 0.24 (ddtd, 1H). Step 3: Preparation of methyl 6-[(1Z)-2-cyclopropyl-3-ethoxy-3-oxoprop-1-en-1-yl]-5-nitropyridine-3-carboxylate:
[00175] To a stirred mixture of NaH (0.29 g, 7.14 mmol, 1.50 equiv., 60 wt.%) in THF (20 ml), 2-cyclopropyl-2-(diethoxyphosphoryl)acetate (1.89 g, 7.14 mmol, 1.50 equiv.) was added dropwise at 0 °C under a nitrogen atmosphere. The resulting mixture was stirred for 10 min at 0 °C and then warmed to 40 °C and stirred for 10 min under a nitrogen atmosphere. The resulting mixture was cooled to -78 °C followed by the addition of methyl 6-formyl-5-nitropyridine-3-carboxylate (1.00 g, 4.76 mmol, 1.00 equiv.) in THF (20 ml) by dropwise. The resulting mixture was stirred for 30 min at -78 °C under a nitrogen atmosphere. The reaction was monitored by LCMS. The reaction was rapidly cooled by the addition of 5 ml of saturated NH4Cl (aq) at 0 °C. 20 ml of water was added to the resulting mixture and it was extracted with EtOAc (3 x 20 ml). The combined organic layers were washed with brine (1 x 50 ml) and dried with anhydrous Na2SO4.After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to yield methyl 6-[(1Z)-2-cyclopropyl-3-ethoxy-3-oxoprop-1-en-1-yl]-5-nitropyridine-3-carboxylate (700 mg, 46%). LC-MS: (ES+H, m / z): [M+H]+=320.8. Step 4: Preparation of ethyl 7-cyclopropyl-6-oxo-5H-1,5-naphthyridine-3-carboxylate:
[00176] To a stirred mixture of methyl 6-[(1Z)-2-cyclopropyl-3-ethoxy-3-oxoprop-1-en-1-yl]-5-nitropyridine-3-carboxylate (600 mg, 1.87 mmol, 1.00 equiv.) and Fe (1.04 g, 18.73 mmol, 10.00 equiv.) in EtOH (10 ml), CaCl2 (1.24 g, 11.24 mmol, 6.00 equiv.) was added at room temperature under a nitrogen atmosphere. The resulting mixture was stirred overnight at 90 °C under a nitrogen atmosphere. The reaction was monitored by LCMS. The mixture was allowed to cool to room temperature. The resulting mixture was filtered, the filter cake was washed with EtOAc (2 x 50 ml). The filtrate was concentrated under reduced pressure. The resulting mixture was added to 50 ml of water and extracted with EtOAc (2 x 50 ml). The combined organic layers were washed with brine (2 x 50 ml) and dried with anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure.The residue was purified by silica gel column chromatography to yield ethyl 7-cyclopropyl-6-oxo-5H-1,5-naphthyridine-3-carboxylate (200 mg, 41%). LC-MS: (ES+H, m / z): [M+H]+=259.0. Step 5: Preparation of 3-cyclopropyl-7-(hydroxymethyl)-1H-1,5-naphthyridin-2-one:
[00177] To a stirred solution of ethyl 7-cyclopropyl-6-oxo-5H-1,5-naphthyridine-3-carboxylate (160 mg, 0.62 mmol, 1.00 equiv.), LiAlH4 (0.50 ml, 1.23 mmol, 2.00 equiv., 2.5 M in THF) was added dropwise at 0 °C under a nitrogen atmosphere. The resulting mixture was stirred for 1 h at 0 °C under a nitrogen atmosphere. The reaction was monitored by LCMS. The reaction was rapidly cooled by the addition of 1 M aqueous HCl (1 ml) at 0 °C. The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to yield 3-cyclopropyl-7-(hydroxymethyl)-1H-1,5-naphthyridin-2-one (100 mg, 75%). LC-MS: (ES+H, m / z): [M+H]+=217.2. Step 6: Preparation of 7-(chloromethyl)-3-cyclopropyl-1H-1,5-naphthyridin-2-one:
[00178] To a stirred mixture of 3-cyclopropyl-7-(hydroxymethyl)-1H-1,5-naphthyridin-2-one (80 mg, 0.37 mmol, 1.00 equiv.) and DMF (3 mg, 0.04 mmol, 0.10 equiv.) in DCM (10 ml), SOCl2 (264 mg, 2.22 mmol, 6.00 equiv.) was added dropwise at 0 °C under a nitrogen atmosphere. The resulting mixture was stirred overnight at room temperature under a nitrogen atmosphere. The reaction was monitored by LCMS. The resulting mixture was concentrated under reduced pressure to yield 7-(chloromethyl)-3-cyclopropyl-1H-1,5-naphthyridin-2-one. The crude product was used directly in the next step without further purification. LC-MS: (ES+H, m / z): [M+H]+=235.0. Step 7: Preparation of 3-cyclopropyl-7-{[4-(5-fluoropyridin-2-yl)piperazin-1-yl]methyl}-1H-1,5-naphthyridin-2-one:
[00179] To a stirred solution of 1-(5-fluoropyridin-2-yl)piperazine (100 mg, 0.55 mmol, 1.00 equiv) and 7-(chloromethyl)-3-cyclopropyl-1H-1,5-naphthyridin-2-one (130 mg, 0.55 mmol, 1.00 equiv.) in ACN (3 ml), DIEA (357 mg, 2.76 mmol, 5.00 equiv.) and KI (18 mg, 0.11 mmol, 0.20 equiv.) were added at room temperature. The resulting mixture was stirred for 1 h at 80 °C under a nitrogen atmosphere. The reaction was monitored by LCMS. The mixture was allowed to cool to room temperature and then poured into H2O (10 ml). The resulting mixture was extracted with EtOAc (3 x 10 ml). The combined organic layers were concentrated and the crude product was purified by preparative HPLC to yield 3-cyclopropyl-7-{[4-(5-fluoropyridin-2-yl)piperazin-1-yl]methyl}-1H-1,5-naphtiridin-2-one (122.8 mg, 58%). LC-MS: (ES+H, m / z): [M+H]+ = 380.3; 1H NMR (300 MHz, DMSO-d6) d 11.88 (s, 1H), 8.38 (d, 1H), 8.09 (d, 1H), 7.61 (d, 1H), 7.55-7.45 (m, 1H), 7.42 (s, 1H), 6.86 (dd, 1H), 3.62 (s, 2H), 3.49-2.38 (m, 4H), 2.50-2.45 (m, 4H), 2.20-2.08 (m, 1H), 1.02 - 0.92 (m, 2H), 0.86 - 0.78 (m, 2H); 19F NMR (282 MHz, DMSO-d6) d -143.41. Examples 28 and 29. Step 1: Preparation of 7-(1-ethoxyvinyl)-3-methyl-1,5-naphthyridin-2(1H)-one:
[00180] To a stirred solution of 7-bromo-3-methyl-1H-1,5-naphthyridin-2-one (3.00 g, 12.54 mmol, 1.00 equiv) and tributyl(1-ethoxyethenyl)estanane (13.60 g, 37.64 mmol, 3.00 equiv) in 1,4-dioxane (20 mL) Pd(PPh3)2Cl2 (0.44 g, 0.62 mmol, 0.05 equiv) were added at room temperature. The resulting mixture was stirred for 2 hours at 100 °C under a nitrogen atmosphere. After completion, the reaction was cooled to room temperature and the resulting solution was used in the next step directly without further purification. LC-MS: (ES+H, m / z): [M+H]+ = 231.1 Step 2: Preparation of 7-acetyl-3-methyl-1,5-naphthyridin-2(1H)-one:
[00181] The 7-(1-ethoxyvinyl)-3-methyl-1,5-naphthyridin-2(1H)-one solution from Step 1 was cooled to 0 °C and treated with concentrated HCl (4 ml) by drop. The resulting reaction mixture was stirred for 1 h at room temperature and then basified to pH 8 with saturated NaHCO3 (aq.). The resulting mixture was then diluted with water (100 ml) and extracted with CH2Cl2 (3 x 200 ml). The combined organic layers were washed with brine (1 x 300 ml), dried with anhydrous Na2SO4, filtered, and concentrated. The crude product was purified by silica gel column chromatography to yield 7-acetyl-3-methyl-1,5-naphthyridin-2-one (1.39 g, 55%, in two steps). LC-MS: (ES+H, m / z): [M+H]+ =203.2 Step 3: Preparation of 6-[(2R)-2-methyl-4-[1-(7-methyl-6-oxo-5H-1,5-naphthyridin-3-yl)ethyl]piperazin-1-yl]pyridine-3-carbonitrile:
[00182] 7-acetyl-3-methyl-1H-1,5-naphthyridin-2-one (350 mg, 1.73 mmol, 1.00 equiv) was added to a solution of 6-[(2R)-2-methylpiperazin-1-yl]pyridine-3-carbonitrile (455 mg, 2.25 mmol, 1.30 equiv) in CH2Cl2 (8 ml). The resulting mixture was concentrated under reduced pressure. Ti(OiPr)4 (4.6 ml, 15.58 mmol, 9.00 equiv) was added dropwise to the above mixture at room temperature. The resulting mixture was stirred for a further 4 hours at 80 °C and then cooled to room temperature. EtOH (5 ml) and NaBH3CN (217 mg, 3.46 mmol, 2.00 equiv) were added to the above mixture in portions at room temperature. The resulting mixture was stirred for 2 hours at 80 °C and then cooled to room temperature. The reaction mixture was poured into water (100 ml) and stirred for 1 hour, filtered through Celite buffer, and washed with DCM / MeOH (3 / 1; 300 ml).The aqueous layer was extracted with DCM / i-PrOH (5 / 1; 2 x 100 mL) and the combined organic layers were washed with brine (2 x 50 mL), dried with Na2SO4, filtered, and concentrated. The residue was purified by silica gel column chromatography to yield 6-[(2R)-2-methyl-4-[1-(7-methyl-6-oxo-5H-1,5-naftiridin-3-yl)ethyl]piperazin-1-yl]pyridine-3-carbonitrile (280 mg, 41.6%). LC-MS: (ES-H, m / z): [M+H]+ = 389.1. The diastereomers were separated by Chiral HPLC to yield rel-6-[(2R)-2-methyl-4-[(1R*)- 1-(7-methyl-6-oxo-5H-1,5-naphthyridin-3-yl)ethyl]piperazin-1-yl]pyridine-3-carbonitrile (Example 28 90.6 mg, de = 100%) and rel-6-[(2R)-2-methyl-4-[(1R*)-1-(7-methyl-6-oxo-5H-1,5-naphthyridin-3-yl)ethyl]piperazin-1-yl]pyridine-3-carbonitrile (Example 29, 69.5 mg, de = 100%).Data for Example 28: LC-MS: (ES+H, m / z): [M+H]+ = 389.2; 1H NMR (300 MHz, DMSO-d6) d 11.90 (s, 1H), 8.48 - 8.43 (dd, 2H), 7.85 - 7.82 (m, 2H), 7.65 - 7.64 (d, 1H), 6.86 - 6.83 (d, 1H), 4.51 (s, 1H), 4.26 - 4.22 (d, 1H), 3. 59 - 3.57 (q, 1H), 3.14 - 3.11 (m, 2H), 2.58 - 2.50 (d, 1H), 2.18 - 2.06 (m, 5H), 1.36 - 1.34 (d, 3H), 1.18 - 1.15 (d, 3H). Data for Example 29: LC-MS: (ES+H, m / z): [M+H]+ = 389.1; 1H NMR (300 MHz, DMSO-d6) d 11.85 (s, 1H), 8.48 - 8.46(dd, 2H), 7.85 - 7.81 (m, 2H), 7.66 (d, 1H), 6.86 - 6.83 (d, 1H), 4.62 (s, 1H), 4.16 - 4. 12 (d, 1H), 3.70 - 3.64 (q, 1H), 3.11 - 3.01 (td, 1H), 2.88 - 2.76 (dd, 2H), 2.26 - 2.03 (m, 5H), 1.34 (d, 3H), 1.22 (d, 3H). The relative stereochemistry for Examples 28 and 29 was assigned arbitrarily. Example 36. Step 1: Preparation of methyl 5-nitro-6-(prop-1-en-2-yl)pyridine-3-carboxylate:
[00183] A mixture of methyl 6-chloro-5-nitropyridine-3-carboxylate (10.00 g, 46.17 mmol, 1.00 equiv), 4,4,5,5-tetramethyl-2-(prop-1-en-2-yl)-1,3,2-dioxaborolane (15.52 g, 92.34 mmol, 2.00 equiv), K2CO3 (12.76 g, 92.34 mmol, 2.00 equiv) and Pd(dppf)Cl2 (3.38 g, 4.62 mmol, 0.10 equiv) in dioxane (150 ml) and water (15 ml) was stirred for 3 h at 100 °C under a nitrogen atmosphere. The reaction was monitored by LCMS. The mixture was then left at room temperature. The resulting mixture was diluted with water (300 ml) and extracted with EtOAc (3 x 300 ml). The combined organic layers were washed with saturated aqueous NaCl solution (3 x 100 ml), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The filtrate was concentrated under reduced pressure. The residue was purified by column chromatography on silica gel to yield methyl 5-nitro-6-(prop-1-en-2-yl)pyridine-3-carboxylate (5.00 g, 49%) as a light yellow oil. LC-MS: (ES+H, m / z): [M+H]+ = 222.95. Step 2: Preparation of methyl 5-nitro-6-(prop-1-en-2-yl)pyridine-3-carboxylate:
[00184] To a stirred solution of methyl 5-nitro-6-(prop-1-en-2-yl)pyridine-3-carboxylate (5.00 g, 22.50 mmol, 1.00 equiv) in MeOH (100 ml) were added NH4Cl (25 ml, sat. aq.) and Fe (5.03 g, 90.01 mmol, 4.00 equiv). The reaction was stirred at 80 °C for 4 h under a nitrogen atmosphere. The reaction was monitored by LCMS. The resulting mixture was left at room temperature and concentrated under reduced pressure. The residue was diluted with CH2Cl2 / 2-propanol (5:1, 200 ml) and washed with water (250 ml) and brine (250 ml). The combined organic layers were dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. This resulted in methyl 5-amino-6-(prop-1-en-2-yl)pyridine-3-carboxylate (3.90 g, 90%) which was used directly without further purification. LC-MS: (ES+H, m / z): [M+H]+ = 193.15. 1H NMR (300 MHz, DMSO-d6) d 8.29 (d, 1H), 7.60 (d, 1H), 5.51-5.47 (m, 1H), 5.41 (s, 2H), 5.39 - 5.36 (m, 1H), 3.84 (s, 3H), 2.08 (t, 3H). Step 3: Preparation of methyl 8-methyl-6-oxo-5H-1,5-naphthyridine-3-carboxylate:
[00185] A solution of triphosgene (1.54 g, 5.20 mmol, 0.50 equiv) in toluene (20 ml) was added to a solution of methyl 5-amino-6-(prop-1-en-2-yl)pyridine-3-carboxylate (3.90 g, 20.29 mmol, 1.00 equiv) and Et3N (6.16 g, 60.87 mmol, 3.00 equiv) in toluene (40 ml) at 0 °C under a nitrogen atmosphere. The resulting mixture was stirred overnight at 60 °C under a nitrogen atmosphere. The reaction was monitored by LCMS. The reaction was rapidly cooled with MeOH (30 ml) at 0 °C. The resulting mixture was diluted with water (200 ml) and extracted with CH2Cl2 / 2-Propanol (5:1, 3 x 200 ml). The combined organic layers were washed with water (3 x 100 ml), dried with anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to yield methyl 8-methyl-6-oxo-5H-1,5-naphthyridine-3-carboxylate (1.80 g, 41%).LC-MS: (ES+H, m / z): [M+H]+=219.1; 1H NMR (400 MHz, DMSO-d6) d 11.92 (s, 1H), 8.92 (d, 1H), 8.15 (d, 1H), 6.79 (s, 1H), 3.93 (s, 3H), 2.48 (s, 3H). Step 4: Preparation of 7-chloro-8-methyl-6-oxo-5H-1,5-naphthyridine-3-methylcarboxylate:
[00186] To a stirred mixture of methyl 8-methyl-6-oxo-5H-1,5-naphthyridine-3-carboxylate (600 mg, 2.75 mmol, 1.00 equiv.) and NCS (587 mg, 4.40 mmol, 1.60 equiv.) in CH3COOH (7 ml), 2,2-dichloroacetic acid (71 mg, 0.55 mmol, 0.20 equiv.) was added dropwise at room temperature under a nitrogen atmosphere. The resulting mixture was stirred overnight at 100 °C and then cooled to room temperature. The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to yield methyl 7-chloro-8-methyl-6-oxo-5H-1,5-naphthyridine-3-carboxylate (650 mg, 94%). LC-MS: (ES+H, m / z): [M+H]+ = 253.0; 1H NMR (300 MHz, DMSO-d6) d 8.90 (d, 1H), 8.13 (d, 1H), 3.93 (s, 3H), 2.60 (s, 3H). Step 5: Preparation of 3-chloro-7-(hydroxymethyl)-4-methyl-1H-1,5-naphthyridine-2-one:
[00187] To a stirred mixture of methyl 7-chloro-8-methyl-6-oxo-5H-1,5-naphthyridine-3-carboxylate (600 mg, 2.38 mmol, 1.00 equiv.) in THF (5 ml), LiAlH4 (2 ml, 2.5 M in THF, 4.75 mmol, 2.00 equiv.) was added dropwise at 0 °C under a nitrogen atmosphere. The resulting mixture was stirred for 1 h at room temperature under a nitrogen atmosphere. The reaction was monitored by LCMS. The reaction was rapidly cooled by the addition of HCl (1 ml, 12 M) at 0 °C. The resulting mixture was concentrated under reduced pressure. The residue was purified by silica-gel column chromatography to yield 3-chloro-7-(hydroxymethyl)-4-methyl-1H-1,5-naphthyridin-2-one (230 mg, 43%). LC-MS: (ES+H, m / z): [M+H]+ = 225.1; 1H NMR (300 MHz, DMSO-d6) d 12.24 (br, 1H), 8.48 (d, 1H), 7.77 (d, 1H), 5.69 (s, 1H), 4.63 (s, 2H), 2.63 (s, 3H). Step 6: Preparation of 3-chloro-7-(chloromethyl)-4-methyl-1H-1,5-naphthyridine-2-one:
[00188] To a stirred mixture of 3-chloro-7-(hydroxymethyl)-4-methyl-1H-1,5-naphthyridin-2-one (200 mg, 0.89 mmol, 1.00 equiv.) and DMF (7 mg, 0.09 mmol, 0.10 equiv.) in DCM (10 ml), SOCl2 (318 mg, 2.67 mmol, 3.00 equiv.) was added dropwise at 0 °C under a nitrogen atmosphere. The resulting mixture was stirred for 10 h at room temperature. The reaction was monitored by LCMS. The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to yield 3-chloro-7-(chloromethyl)-4-methyl-1H-1,5-naphthyridin-2-one (98 mg, 45%). LC-MS: (ES+H, m / z): [M+H]+ =243.0. Step 7: Preparation of 6-{4-[(7-chloro-8-methyl-6-oxo-5H-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}pyridine-3-carbonitrile:
[00189] To a stirred solution of 3-chloro-7-(chloromethyl)-4-methyl-1H-1,5-naphthyridin-2-one (85 mg, 0.35 mmol, 1.00 equiv) and 6-(piperazin-1-yl)pyridine-3-carbonitrile (66 mg, 0.35 mmol, 1.00 equiv) in ACN (1 ml), DIEA (136 mg, 1.05 mmol, 3.00 equiv) and KI (1 mg, 0.01 mmol, 0.10 equiv) were added at room temperature under a nitrogen atmosphere. The resulting mixture was stirred for 1 h at 80 °C. The reaction was monitored by LCMS. The mixture was allowed to cool to room temperature. The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to yield the crude product (90 mg), which was further purified by preparative HPLC to yield 6-{4-[(7-chloro-8-methyl-6-oxo-5H-1,5-naphtiridine-3-yl)methyl]piperazin-1-yl}pyridine-3-carbonitrile (52.5 mg, 28%).LC-MS: (ES+H, m / z): [M+H] + =395.10; 1H NMR (300 MHz, DMSO-d6) d 12.30 (br, 1H), 8.50 (m, 2H), 7.85 (dd, 1H), 7.69 (d, 1H), 6.94 (d, 1H), 3,673.62 (m, 6H), 2.65 (s, 3H), 2.50-2.49 (m, 4H). Example 42. Step 1: Preparation of 7-(difluoromethyl)-8-methyl-6-oxo-5H-1,5-naphthyridine-3-carboxylate methyl:
[00190] A mixture of methyl 8-methyl-6-oxo-5H-1,5-naphthyridine-3-carboxylate (800 mg, 3.67 mmol, 1.00 equiv), sodium difluoromethanesulfinic acid (1012 mg, 7.33 mmol, 2.00 equiv), 2-methylpropane-2-peroxol (991 mg, 11.00 mmol, 3.00 equiv) and TFA (418 mg, 3.67 mmol, 1.00 equiv) in CH2Cl2 / H2O (2.5:1, 120 ml) was stirred overnight at room temperature under a nitrogen atmosphere. The reaction was monitored by LCMS. The resulting mixture was then diluted with water (100 ml) and extracted with CH2Cl2 / 2-Propanol (5:1, 3 x 100 ml). The combined organic layers were washed with water (3 x 50 ml) and dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to yield methyl 7-(difluoromethyl)-8-methyl-6-oxo-5H-1,5-naphthyridine-3-carboxylate (650 mg, 66%). LC-MS: (ES+H, m / z): [M+H]+=269.1; 1H NMR (400 MHz, DMSO-d6) d 12.39 (s, 1H), 8.99 (d, 1H), 8.19 (m, 1H), 7.26 (t, 1H), 3.94 (s, 3H), 2.72 (s, 3H). Step 2: Preparation of 3-(difluoromethyl)-7-(hydroxymethyl)-4-methyl-1H-1,5-naphthyridin-2-one:
[00191] To a stirred mixture of methyl 7-(difluoromethyl)-8-methyl-6-oxo-5H-1,5-naphthyridine-3-carboxylate (650 mg, 2.42 mmol, 1.00 equiv.) in THF (65 ml), a solution of LiAlH4 (2.5 M in THF, 3.9 ml, 9.75 mmol, 4.00 equiv.) was added dropwise at 0 °C under a nitrogen atmosphere. The resulting mixture was stirred for 1 h at room temperature under a nitrogen atmosphere. The reaction was monitored by LCMS. The reaction was rapidly cooled by the addition of saturated aqueous NH4Cl (10 ml) at 0 °C and dried over anhydrous Na2SO4. The mixture was filtered and washed with CH2Cl2 / MeOH (10:1, 100 ml) and the combined organic layers were concentrated under reduced pressure. The residue was purified by silica gel column chromatography to yield 3-(difluoromethyl)-7-(hydroxymethyl)-4-methyl-1H-1,5-naphthyridin-2-one (520 mg, 89%). LC-MS: (ES+H, m / z): [M+H]+ = 241.1. 1H NMR (400 MHz, Methanol-d4) d 8.58 (d, 1H), 7.73 (d, 1H), 7.20 (t, 1H), 4.79 (s, 2H), 2.81 (t, 3H). Step 3: Preparation of 7-(chloromethyl)-3-(difluoromethyl)-4-methyl-1H-1,5-naphthyridin-2-one:
[00192] To a stirred mixture of 3-(difluoromethyl)-7-(hydroxymethyl)-4-methyl-1H-1,5-naphthyridin-2-one (320 mg, 1.33 mmol, 1.00 equiv.) and DMF (5 mg, 0.07 mmol, 0.05 equiv.) in CH2Cl2 (32 ml), SOCl2 (475 mg, 4.00 mmol, 3.00 equiv.) was added dropwise at 0 °C under a nitrogen atmosphere. The resulting mixture was stirred for 2 h at 50 °C under a nitrogen atmosphere. The reaction was monitored by LCMS. The mixture was allowed to reach room temperature, then concentrated under reduced pressure to yield 7-(chloromethyl)-3-(difluoromethyl)-4-methyl-1H-1,5-naphthyridin-2-one (crude, 400 mg). LC-MS: (ES+H, m / z): [M+H]+ =259.1 Step 4: Preparation of 6-(4-{[7-(difluoromethyl)-8-methyl-6-oxo-5H-1,5-naphthyridin-3-yl]methyl} piperazin-1-yl)pyridine-3-carbonitrile:
[00193] A mixture of 7-(chloromethyl)-3-(difluoromethyl)-4-methyl-1H-1,5-naphthyridin-2-one (380 mg, 1.47 mmol, 1.00 equiv.), 6-(piperazin-1-yl)pyridine-3-carbonitrile (415 mg, 2.20 mmol, 1.50 equiv.), KI (365 mg, 2.20 mmol, 1.50 equiv.) and DIEA (569 mg, 4.40 mmol, 3.00 equiv.) in MeCN (4 ml) was stirred for 1 h at 80 °C under a nitrogen atmosphere. The reaction was monitored by LCMS. The mixture was left at room temperature. The resulting mixture was diluted with water (50 ml) and extracted with EtOAc (3 x 50 ml). The combined organic layers were washed with water (3 x 10 ml), dried with anhydrous Na2SO4. The mixture was filtered and washed with EtOAc (50 ml) and the filtrate was concentrated under reduced pressure. The residue was purified by preparative HPLC to yield 6-(4-{[7-(difluoromethyl)-8-methyl-6-oxo-5H-1,5-naftiridin-3-yl]methyl}piperazin-1-yl)pyridine-3-carbonitrile (31 mg, 5%).LC-MS: (ES+H, m / z): [M+H]+=411.2; 1H NMR (300 MHz, DMSO-d6) d 12.17 (br, 1H), 8.57 (d, 1H), 8.41 (d, 1H), 7.85 (dd, 1H), 7.68 (d, 1H), 7.24 (t, 1H), 6.94 (d, 1H), 3.80-3.60 (m, 6H), 2.72 (s, 3H), 2.60-2.40 (m, 4H); 19F NMR (282 MHz, DMSO-d6) d -115.51. Example 47. Step 1: Preparation of 3-bromo-2-methoxy-6-methyl-5-nitropyridine:
[00194] To a stirred mixture of 3-bromo-2-chloro-6-methyl-5-nitropyridine (20.00 g, 79.54 mmol, 1.00 equiv.) in MeOH (50 ml), NaOMe (15.76 g, 87.49 mmol, 1.10 equiv., 30% by weight) was added dropwise at 0 °C under a nitrogen atmosphere. The resulting mixture was stirred overnight at room temperature under a nitrogen atmosphere. The reaction was monitored by TLC (Pet. Ether : EtOAc=1:1, Rf = 0.4). After completion, the reaction was concentrated under reduced pressure and water (100 ml) was added. The resulting mixture was extracted with EtOAc (3 x 100 ml). The combined organic layers were washed with brine (1x200 ml), dried over anhydrous Na2SO4, filtered and concentrated to produce 3-bromo-2-methoxy-6-methyl-5-nitropyridine (20 g, 99%). 1H NMR (400 MHz, DMSO-d6) d 8.66 (s, 1H), 4.04 (s, 3H), 2.70(s, 3H). Step 2: Preparation of (E)-2-(5-bromo-6-methoxy-3-nitropyridin-2-yl)-N,N-dimethylethen-1-amine:
[00195] A mixture of 3-bromo-2-methoxy-6-methyl-5-nitropyridine (15.00 g, 60.72 mmol, 1.00 equiv.) in DMF-DMA (100 ml) and DMF (100 ml) was stirred overnight at 100 °C under a nitrogen atmosphere. The reaction was monitored by TLC (Pet. Ether: EtOAc = 1:1, Rf = 0.5). The mixture was allowed to cool to room temperature and then concentrated under reduced pressure to yield crude (E)-2-(5-bromo-6-methoxy-3-nitropyridin-2-yl)-N,N-dimethylethen-1-amine. The crude product was used in the next step directly without further purification. Step 3: Preparation of 5-bromo-6-methoxy-3-nitropicolinalaldehyde:
[00196] To a stirred mixture of (E)-2-(5-bromo-6-methoxy-3-nitropyridin-2-yl)ethenyl]dimethylamine (18.01 g, gross) in THF (100 ml) and H2O (100 ml), NaIO4 (28.00 g, 131.07 mmol, 2.20 equiv.) was added in portions at 0 °C under a nitrogen atmosphere. The resulting mixture was stirred for 2 hours at room temperature under a nitrogen atmosphere. The reaction was monitored by TLC (Pet. Ether : EtOAc = 5:1, Rf = 0.2). The reaction was abruptly cooled by the addition of saturated (aqueous) sodium hyposulfite (100 ml) at room temperature. The resulting mixture was extracted with EtOAc (3 x 100 ml). The combined organic layers were washed with brine (2 x 100 ml), then dried with anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The crude product was used directly in the next step without further purification. 1H NMR (400 MHz, DMSO-d6) d 10.16 (s, 1H), 8.87 (s, 1H), 4.10 (s, 3H). Step 4: Preparation of ethyl 7-bromo-6-methoxy-1,5-naphthyridine-3-carboxylate:
[00197] To a stirred mixture of 5-bromo-6-methoxy-3-nitropyridine-2-carbaldehyde (7.00 g, gross) and ethyl 3,3-diethoxypropanoate (20.40 g, 107.27 mmol, 4.00 equiv.) in EtOH (100 ml), SnCl2 (26.25 g, 134.09 mmol, 5.00 equiv.) was added in portions at room temperature under a nitrogen atmosphere. The resulting mixture was stirred overnight at 90 °C under a nitrogen atmosphere. The reaction was monitored by LCMS. The mixture was allowed to cool to room temperature. The resulting mixture was concentrated under reduced pressure. The crude mixture was poured into saturated sodium bicarbonate (100 ml). The resulting mixture was extracted with EtOAc (3 x 100 ml). The combined organic layers were concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to produce the crude product.The crude product was purified by trituration with hexane (50 ml) to produce ethyl 7-bromo-6-methoxy-1,5-naphthyridine-3-carboxylate (3.50 g, 18.5 %, over three steps). LC-MS: (ES+H, m / z): [M+H]+=311.0. Step 5: Preparation of ethyl 7-chloro-6-methoxy-1,5-naphthyridine-3-carboxylate:
[00198] To a stirred mixture of ethyl 7-bromo-6-methoxy-1,5-naphthyridine-3-carboxylate (1.20 g, 3.85 mmol, 1.00 equiv.) in DMF (10 ml), CuCl (0.57 g, 5.78 mmol, 1.50 equiv.) was added at room temperature under a nitrogen atmosphere. The resulting mixture was stirred overnight at 120 °C. The reaction was monitored by LCMS. The mixture was allowed to cool to room temperature. The resulting mixture was diluted with EtOAc (20 ml). The resulting mixture was washed with 3 x 30 ml of water (NH3-H2O 10%). The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to yield ethyl 7-chloro-6-methoxy-1,5-naphthyridine-3-carboxylate (800 mg, 77.78%). LC-MS: (ES+H, m / z): [M+H]+ = 267.0; 1H NMR (300 MHz, DMSO-d6) d 9.27 (d, 1H), 8.63 (d, 1H), 8.57 (s, 1H), 4.41 (q, 2H), 4.12 (s, 3H), 1.37 (t, 3H). Step 6: Preparation of ethyl 7-chloro-6-oxo-5H-1,5-naphthyridine-3-carboxylate:
[00199] To a stirred mixture of ethyl 7-chloro-6-methoxy-1,5-naphthyridine-3-carboxylate (800 mg, 3.00 mmol, 1.00 equiv.) in CH3CN (8 ml), TMSI (1.80 g, 9.00 mmol, 3.00 equiv.) was added at room temperature under a nitrogen atmosphere. The resulting mixture was stirred for 2 h at 50 °C. The reaction was monitored by LCMS. The mixture was allowed to cool to room temperature. The resulting mixture was diluted with EtOAc (50 ml). The aqueous layer was washed with 3 x 50 ml of water (10% Et3N). The combined organic layers were washed with brine (50 ml), dried with anhydrous Na2SO4, filtered, and concentrated. The residue was purified by silica gel column chromatography to yield ethyl 7-chloro-6-oxo-5H-1,5-naphthyridine-3-carboxylate (740 mg, 97.64%). LC-MS: (ES+H, m / z): [M+H]+ = 252.9; 1H NMR (300 MHz, DMSO-d6) d12.61 (s, 1H), 8.94 (d, 1H), 8.37 (d, 1H), 8.20 (s, 1H), 4.39 (q, 2H), 1.36 (t, 3H). Step 7: Preparation of 3-chloro-7-(hydroxymethyl)-1H-1,5-naphthyridin-2-one:
[00200] To a stirred mixture of ethyl 7-chloro-6-oxo-5H-1,5-naphthyridine-3-carboxylate (740 mg, 2.92 mmol, 1.00 equiv.) in THF (6 ml), LiAlH4 (2.5 ml, 5.85 mmol, 2.00 equiv.) was added dropwise at 0 °C under a nitrogen atmosphere. The resulting mixture was stirred for a further 2 hours at 0 °C. The reaction was monitored by LCMS. The mixture was acidified to pH 5 with 1 M aqueous HCl. The resulting mixture was concentrated under reduced pressure and the residue was purified by silica gel column chromatography to yield 3-chloro-7-(hydroxymethyl)-1H-1,5-naphthyridine-2-one (250 mg, 40.53%). LC-MS: (ES+H, m / z): [M+H] + =211.0; 1H NMR (400 MHz, DMSO-d6) d12.49 (s, 1H), 8.45 (d, 1H), 8.28 (s, 1H), 7.69 (d, 1H), 5.53 (t, 1H), 4.64 (d, 2H). Step 4: Preparation of 3-chloro-7-(chloromethyl)-1H-1,5-naphthyridin-2-one:
[00201] To a stirred mixture of 3-chloro-7-(hydroxymethyl)-1H-1,5-naphthyridin-2-one (250 mg, 1.18 mmol, 1.00 equiv.) in CH2Cl2 (5 ml), SOCl2 (423 mg, 3.56 mmol, 3.00 equiv.) and DMF (8 mg, 0.11 mmol, 0.10 equiv.) were added dropwise at room temperature under a nitrogen atmosphere. The resulting mixture was stirred for 3 h at room temperature. The reaction was monitored by LCMS. The resulting mixture was concentrated under reduced pressure. This resulted in 3-chloro-7-(chloromethyl)-1H-1,5-naphthyridin-2-one (280 mg, crude). The crude product was used in the next step directly without further purification. LC-MS: (ES+H, m / z): [M+H]+ =228.95. Step 9: Preparation of 3-chloro-7-{[4-(5-fluoropyridin-2-yl)piperazin-1-yl]methyl}-1H-1,5-naphthyridin-2-one:
[00202] To a stirred mixture of 3-chloro-7-(chloromethyl)-1H-1,5-naphthyridin-2-one (200 mg, 0.87 mmol, 1.00 equiv) and 1-(5-fluoropyridin-2-yl)piperazine (126 mg, 0.69 mmol, 0.80 equiv.) in CH3CN (5 ml) were added DIEA (564 mg, 4.36 mmol, 5 equiv.) and KI (14 mg, 0.08 mmol, 0.10 equiv.) at room temperature. The resulting mixture was stirred for 2 hours at 50 °C. The reaction was monitored by LCMS. The resulting mixture was cooled to room temperature and poured into 20 ml of water. The resulting mixture was extracted with EtOAc (3 x 20 ml). The combined organic layers were washed with brine (50 ml) and dried with anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The crude product was purified by preparative HPLC to yield 3-chloro-7-{[4-(5-fluoropyridin-2-yl)piperazin-1-yl]methyl}-1H-1,5-naphtiridin-2-one (42.7 mg, 13.08%).LC-MS: (ES+H, m / z): [M+H] + =374.0; 1H NMR (300 MHz, DMSO-d6) d 12.48 (s, 1H), 8.48 (d, 1H), 8.29 (s, 1H), 8.09 (d, 1H), 7.70 (d, 1H), 7.55 - 7.47 (m, 1H), 6.87 (dd, 1H), 3.66 (s, 2H), 3.46 - 3.42 (m, 4H), 2,532.50 (m, 4H); 19F NMR (282 MHz, DMSO-d6) d -143.39. Example 48. Step 1: Preparation of 7-(difluoromethyl)-6-methoxy-1,5-naphthyridine-3-ethyl carboxylate:
[00203] A solution of ethyl 7-bromo-6-methoxy-1,5-naphthyridine-3-carboxylate (300 mg, 0.96 mmol, 1.00 equiv), [1,3-Bis[2,6-bis(i-propyl)phenyl]-2-imidazolidinylidene]difluoromethylsilver(I) (97 mg, 0.17 mmol, 1.10 equiv), [2-[2-(diphenylphosphanyl)phenoxy]phenyl]diphenylphosphane (181 mg, 0.33 mmol, 0.35 equiv) and Pd(dba)2 (177 mg, 0.30 mmol, 0.32 equiv) in toluene (5 ml) was stirred for 1.5 ha at 80 °C under a nitrogen atmosphere. The reaction was monitored by LCMS. The mixture was allowed to cool to room temperature. The resulting mixture was diluted with EtOAc (50 ml). The resulting mixture was filtered, and the filter cake was washed with EtOAc (3 x 50 ml). The filtrate was concentrated under reduced pressure. The residue was purified by preparative TLC (Pet. Ether / EtOAc 5:1) to yield ethyl 7-(difluoromethyl)-6-methoxy-1,5-naphthyridine-3-carboxylate (235 mg, 86%).LC-MS: (ES+H, m / z): [M+H]+=283.1; 1H NMR (300 MHz, DMSO-d6) d 9.25 (d, 1H), 8.59 (d, 1H), 8.53 (s, 1H), 7.24 (t, 1H), 4.42 (q, 2H), 4.12 (s, 3H), 1.40 (t, 3H); 19F NMR (282 MHz, DMSO-d6) d -117.83. Step 2: Preparation of 7-(difluoromethyl)-6-oxo-5H-1,5-naphthyridine-3-ethyl carboxylate:
[00204] To a stirred mixture of 7-(difluoromethyl)-6-methoxy-1,5-naphthyridine-3-carboxylate ethyl (240 mg, 0.85 mmol, 1.00 equiv.) in ACN (7 ml), TMSI (680 mg, 3.40 mmol, 4.00 equiv.) was added dropwise at room temperature. The reaction mixture was then stirred for 5 h at 50°C under a nitrogen atmosphere, cooled to room temperature, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (Pet. Ether / EtOAc) to yield 7-(difluoromethyl)-6-oxo-5H-1,5-naphthyridine-3-carboxylate ethyl (225 mg, 99%). LC-MS: (ES+H, m / z): [M+H]+ =269.1. Step 3: Preparation of 3-(difluoromethyl)-7-(hydroxymethyl)-1H-1,5-naphthyridin-2-one:
[00205] To a stirred mixture of ethyl 7-(difluoromethyl)-6-oxo-5H-1,5-naphthyridine-3-carboxylate (230 mg, 0.85 mmol, 1.00 equiv.) in THF (5 ml), LiAlH4 (0.69 ml, 2.5 mol / L in THF, 2.00 equiv.) was added dropwise at 0 °C under a nitrogen atmosphere. The resulting mixture was stirred for 1 h at room temperature. The reaction was monitored by LCMS. The resulting mixture was rapidly cooled with MeOH (10 ml / L) and then DCM (50 ml) was added. The solution was filtered, the filter cake was washed with DCM / MeOH=(5:1) (3 x 50 ml). The filtrate was concentrated under reduced pressure. The residue was purified by silica-gel column chromatography to yield 3-(difluoromethyl)-7-(hydroxymethyl)-1H-1,5-naphthyridin-2-one (50 mg, 26%). LC-MS: (ES+H, m / z): [M+H]+ = 227.0; 1H NMR (400 MHz, DMSO- d6) d 12.36 (s, 1H), 8.50 (d, 1H), 8.16 (d, 1H), 7.70 (s, 1H), 6.98 (t, 1H), 5.57 (t, 1H), 4.67 (d, 2H). Step 4: Preparation of 7-(chloromethyl)-3-(difluoromethyl)-1H-1,5-naphthyridin-2-one:
[00206] To a stirred mixture of 3-(difluoromethyl)-7-(hydroxymethyl)-1H-1,5-naphthyridine-2-one (80 mg, 0.35 mmol, 1.00 equiv.) and DMF (1 mg, 0.02 mmol, 0.05 equiv.) in DCM (4 ml), SOCl2 (126 mg, 1.06 mmol, 3.00 equiv.) was added dropwise at room temperature under a nitrogen atmosphere. The resulting mixture was stirred for 5 h at room temperature. The reaction was monitored by LC-MS. The resulting mixture was concentrated under reduced pressure. The crude product was used directly in the next step without further purification. LC-MS: (ES+H, m / z): [M+H]+ = 245.0. Step 5: Preparation of 6-(4-{[7-(difluoromethyl)-6-oxo-5H-1,5-naphthyridine-3-yl]methyl}piperazine-1-yl)pyridine-3-carbonitrile:
[00207] To a stirred solution of 7-(chloromethyl)-3-(difluoromethyl)-1H-1,5-naphthyridin-2-one (86 mg, assumed 100% yield, 0.35 mmol, 1.00 equiv), 6-(piperazin-1-yl)pyridine-3-carbonitrile (66 mg, 0.35 mmol, 1.00 equiv), KI (11 mg, 0.07 mmol, 0.20 equiv) in ACN (5 ml) was added DIEA (227 mg, 1.76 mmol, 5.00 equiv) by drop at room temperature. The resulting solution was stirred for 1 hour at 80 °C. The reaction was monitored by LCMS. The mixture was allowed to cool to room temperature. The resulting mixture was diluted with water (50 ml). The solution was extracted with EtOAc (3 x 100 ml). The combined organic layers were concentrated under reduced pressure. The residue was purified by silica gel column chromatography to yield the crude product (80 mg). The crude product was purified by preparative HPLC to yield 6-(4-{[7-(difluoromethyl)-6-oxo-5H-1,5-naftiridin-3-yl]methyl}piperazin-1-yl)pyridine-3-carbonitrile (42.9 mg, 33% over two steps).LC-MS: (ES+H, m / z): [M+H]+ = 397.1; 1H NMR (300 MHz, DMSO-d6) d 12.33 (s, 1H), 8.54 (d, 1H), 8.48 (d, 1H), 8.16 (s, 1H), 7.85 (dd, 1H), 7.71 (d, 1H), 7.20 - 6.73 (m, 2H), 3.72 - 3.68 (m, 4H), 3.67 (s, 2H), 2.51 - 2.49 (m, 4H); 19F NMR (282 MHz, DMSO-d6) d -119.30. Example 49. Step 1: Preparation of methyl 2-[(4-bromo-2-fluoro-6-nitrophenyl)amino]propanoate:
[00208] To a stirred mixture of 5-bromo-1,2-difluoro-3-nitrobenzene (10.00 g, 42.01 mmol, 1 equiv) and methyl 2-aminopropanoate hydrochloride (2.93 g, 21.00 mmol, 1.00 equiv) in NMP (200 mL), DIEA (27.15 g, 210.09 mmol, 5.00 equiv) was added by drop at room temperature under a nitrogen atmosphere. The resulting mixture was stirred for 2 hours at 100 °C under a nitrogen atmosphere. The reaction was monitored by TLC (Pet. Ether / EtOAc=10 / 1). The mixture was allowed to cool to room temperature. The resulting mixture was diluted with EtOAc (1 L). The resulting mixture was washed with water (3 x 300 ml), dried with anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to yield methyl 2-[(4-bromo-2-fluoro-6-nitrophenyl)amino]propanoate (7.5 g, 56%) as a red oil.1H NMR (400 MHz, DMSO-d6) d 8.08 (t, 1H), 7.87 (dd, 1H), 7.77 (dd, 1H), 4.67 - 4.55 (m, 1H), 3.68 (s, 3H), 1.48 (dd, 3H); 19F NMR (377 MHz, DMSO-d6) d -122.19. Step 2: Preparation of 7-bromo-5-fluoro-3-methyl-3,4-diidro-1H- quinoxalin-2-one:
[00209] To a stirred mixture of methyl 2-[(4-bromo-2-fluoro-6-nitrophenyl)amino]propanoate (6.00 g, 18.68 mmol, 1.00 equiv.) in HOAc (200 ml), Fe (5.22 g, 93.43 mmol, 5.00 equiv.) was added at room temperature under a nitrogen atmosphere. The resulting mixture was stirred for 2 hours at 80 °C under a nitrogen atmosphere. The reaction was monitored by LCMS. The mixture was allowed to cool to room temperature. The resulting mixture was diluted with EtOAc (50 ml). The resulting mixture was filtered, the filter cake was washed with DCM:MeOH=4:1 (3 x 100 ml). The filtrate was concentrated under reduced pressure. The pH of the residue was adjusted to pH 7 with saturated NaHCO3 (aq.). The resulting mixture was then extracted with CH2Cl2 (3 x 300 ml). The combined organic layers were washed with brine (1 x 100 ml) and dried with anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure to yield 7-bromo-5-fluoro-3-methyl-3,4-dihydro-1H-quinoxalin-2-one (4.2 g, 87%).LC-MS: (ES-H, m / z): [MH]- =257,1; RMN de 1H (400 MHz, DMSO-d6) d 10,54 (s, 1H), 7,01 (dd, 1H), 6,76 (t, 1H), 6,20 (s, 1H), 3,90 - 3,80 (m, 1H), 1,28 (d, 3H). RMN de 19F (377 MHz, DMSO-d6) d -132,99. Etapa 3: Preparação de 7-bromo-5-fluoro-3-meil-1H-quinoxalin-2-ona:
[00210] To a stirred solution of 7-bromo-5-fluoro-3-methyl-3,4-dihydro-1H-quinoxalin-2-one (4.50 g, 17.36 mmol, 1.00 equiv) in DCM (500 ml) was added DDQ (4.34 g, 19.10 mmol, 1.10 equiv) at room temperature. The resulting mixture was stirred for 2 hours at room temperature under a nitrogen atmosphere. The reaction was monitored by LCMS. The resulting mixture was concentrated under reduced pressure. The resulting mixture was washed with saturated NaHCO3 (aq.) (500 ml). The mixture was stirred for 30 minutes at room temperature. The resulting mixture was filtered, the filter cake was washed with saturated NaHCO3 (aq.) (3 x 100 ml). The filter cake was dried under reduced pressure. The residue was purified by silica-gel column chromatography to yield 7-bromo-5-fluoro-3-methyl-1H-quinoxalin-2-one (3 g, 67%). LC-MS: (ES-H, m / z): [MH]- = 255.0. 1H NMR (400 MHz, DMSO-d6) d 12.52 (s, 1H), 7.49 - 7.40 (m, 1H), 7.24 (q, 1H), 2.40 (q, 3H). Step 4: Preparation of 8-fluoro-2-methyl-3-oxo-4H-quinoxaline-6-carbaldehyde:
[00211] To a solution of 7-bromo-5-fluoro-3-methyl-1H-quinoxalin-2-one (500 mg, 1.94 mmol, 1.00 equiv) in toluene (100 mL) was added bis(adamantan-1-yl)(butyl)phosphane (349 mg, 0.97 mmol, 0.50 equiv), TMEDA (1.13 g, 9.72 mmol, 5.00 equiv) and Pd(OAc)2 (218 mg, 0.97 mmol, 0.50 equiv) in a pressure tank. The mixture was purged with nitrogen for 5 min and then pressurized to 30 MPa with CO2:H2=1:1 at room temperature. The resulting mixture was stirred overnight at 100 °C. The reaction mixture was cooled to room temperature and filtered to remove insoluble solids. The reaction was monitored by LCMS. The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to yield 8-fluoro-2-methyl-3-oxo-4H-quinoxaline-6-carbaldehyde (300 mg, 74.8%). LC-MS: (ES-H, m / z): [MH]- = 205.2. 1H NMR (400 MHz, DMSO-d6) d 12.75 (s, 1H), 10.02 (q, 1H), 7.67 - 7.52 (m, 2H), 2.49 - 2.44 (m, 3H). Step 5: Preparation of 6-{4-[(8-fluoro-2-methyl-3-oxo-4H-quinoxalin-6- il)methyl]piperazine-1-yl}pyridine-3-carbonitrile:
[00212] To a stirred mixture of 8-fluoro-2-methyl-3-oxo-4H-quinoxaline-6-carbaldehyde (200 mg, 0.97 mmol, 1.00 equiv) and 6-(piperazin-1-yl)pyridine-3-carbonitrile (274 mg, 1.45 mmol, 1.50 equiv) in THF (20 mL) was added tetraquis(propan-2-yloxy)titanium (551 mg, 1.94 mmol, 2.00 equiv) at room temperature under a nitrogen atmosphere. The resulting mixture was stirred for 4 h at room temperature under a nitrogen atmosphere. To the above mixture, NaBH(OAc)3 (822 mg, 3.88 mmol, 4.00 equiv) was added at room temperature. The resulting mixture was stirred for a further 4 h at room temperature. The reaction was monitored by LCMS. The reaction was rapidly cooled by the addition of water (80 ml) at 0 °C. The resulting mixture was extracted with EtOAc (3 x 100 ml). The combined organic layers were washed with brine (1 x 50 ml), dried with anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure.The residue was purified by silica gel column chromatography followed by trituration with MeCN (5 mL) to yield 6-{4-[(8-fluoro-2-methyl-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl}pyridine-3-carbonitrile (51.1 mg, 14%). LC-MS: (ES+H, m / z): [M+H] + =379.2; 1H NMR (400 MHz, DMSO-d6) d 12.44 (s, 1H), 8.48 (d, 1H), 7.85 (dd, 1H), 7.09 (d, 2H), 6.93 (d, 1H), 3.68 (t, 4H), 3.60 - 3.55 (m,2H), 2.47 (d, 4H), 2.41 (s, 3H); 19F NMR (377 MHz, DMSO-d6) d -125.51. Example 60. Step 1: Preparation of 3-bromo-2-methoxy-6-methyl-5-nitropyridine:
[00213] To a stirred mixture of 3-bromo-2-chloro-6-methyl-5-nitropyridine (20.00 g, 79.54 mmol, 1.00 equiv.) in MeOH (50 ml), NaOMe (15.76 g, 87.49 mmol, 1.10 equiv., 30 wt.) was added dropwise at 0 °C under a nitrogen atmosphere. The resulting mixture was stirred overnight at room temperature under a nitrogen atmosphere. The reaction was monitored by TLC (PE:EA=1:1, Rf = 0.4). The resulting mixture was concentrated under reduced pressure, and water (100 ml) was added. The resulting mixture was extracted with EtOAc (3 x 100 ml). The combined organic layers were washed with brine (1 x 200 ml), then dried with anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure to produce 3-bromo-2-methoxy-6-methyl-5-nitropyridine (20 g, 99%). 1H NMR (400 MHz, DMSO-d6) d 8.66 (s, 1H), 4.04 (s, 3H), 2.70 (s, 3H). Step 2: Preparation of (E)-2-(5-bromo-6-methoxy-3-nitropyridin-2-yl)-N,N-dimethylethen-1-amine:
[00214] A mixture of 3-bromo-2-methoxy-6-methyl-5-nitropyridine (15.00 g, 60.72 mmol, 1.00 equiv.) in DMF-DMA (100 ml) and DMF (100 ml) was stirred overnight at 100 °C under a nitrogen atmosphere. The reaction was monitored by TLC (PE:EA=1:1, Rf = 0.5). The mixture was allowed to cool to room temperature. The resulting mixture was concentrated under reduced pressure. The crude product was used directly in the next step without further purification. Step 3: Preparation of 5-bromo-6-methoxy-3-nitropiclinaldehyde:
[00215] To a stirred mixture of (E)-2-(5-bromo-6-methoxy-3-nitropiridin-2-yl)ethenyl]dimethylamine (18.01 g, gross) in THF (100 ml) and H2O (100 ml), NaIO4 (28.00 g, 131.07 mmol, 2.20 equiv.) was added in portions at 0 °C under a nitrogen atmosphere. The resulting mixture was stirred for 2 h at room temperature under a nitrogen atmosphere. The reaction was monitored by TLC (PE:EA=5:1, Rf =0.2). The reaction was abruptly cooled by the addition of saturated (aqueous) sodium thiosulfate (100 ml) at room temperature. The resulting mixture was extracted with EtOAc (3 x 100 ml). The combined organic layers were washed with brine (2 x 100 ml), then dried with anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The crude product was used directly in the next step without further purification. 1H NMR (400 MHz, DMSO- d6) d 10.16 (s, 1H), 8.87 (s, 1H), 4.10 (s, 3H). Step 4: Preparation of ethyl 7-bromo-6-methoxy-1,5-naphthyridine-3-carboxylate:
[00216] To a stirred mixture of 5-bromo-6-methoxy-3-nitropyridine-2-carbaldehyde (7.00 g, gross) and ethyl 3,3-diethoxypropanoate (20.40 g, 107.27 mmol, 4.00 equiv.) in EtOH (100 ml), SnCl2 (26.25 g, 134.09 mmol, 5.00 equiv.) was added in portions at room temperature under a nitrogen atmosphere. The resulting mixture was stirred overnight at 90 °C under a nitrogen atmosphere. The reaction was monitored by LCMS. The mixture was allowed to cool to room temperature. The resulting mixture was concentrated under reduced pressure. The crude mixture was poured into saturated sodium bicarbonate (100 ml). The resulting mixture was extracted with EtOAc (3 x 100 ml). The combined organic layers were concentrated under reduced pressure. The residue was purified by silica gel column chromatography to yield the crude product.The crude product was purified by trituration with hexane (50 ml) to produce ethyl 7-bromo-6-methoxy-1,5-naphthyridine-3-carboxylate (3.50 g, 18.5% yield over three steps). LC-MS: (ES+H, m / z): [M+H]+=311.0 / 313.0; 1H NMR (400 MHz, DMSO-d6) d 9.22 (s, 1H), 8.78 (s, 1H), 8.58 (s, 1H), 4.42 (q, 2H), 4.12 (s, 3H), 1.39 (t 3H). Step 5: Preparation of ethyl 7-bromo-6-oxo-5H-1,5-naphthyridine-3-carboxylate:
[00217] A solution of ethyl 7-bromo-6-methoxy-1,5-naphthyridine-3-carboxylate (5.00 g, 16.07 mmol, 1.00 equiv.) in ACN (400 mL) was added dropwise to TMSI (13.8 mL, 96.42 mmol, 6.00 equiv.) at room temperature. The resulting reaction mixture was stirred for 2 hours at 80 °C under a nitrogen atmosphere. The mixture was allowed to cool to room temperature. The reaction was monitored by LCMS. The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography under the following conditions: column, silica gel; mobile phase, EA in DCM, gradient from 45% to 60% in 20 min; detector, UV 254 nm. The resulting mixture was concentrated under reduced pressure to yield ethyl 7-bromo-6-oxo-5H-1,5-naphthyridine-3-carboxylate (3.8 g, 79.5%). LC-MS: (ES+H, m / z): [M+H]+=296.95 / 298.95 Step 6: Preparation of 3-bromo-7-(hydroxymethyl)-1H-1,5-naphthyridin-2-one:
[00218] To a stirred solution of ethyl 7-bromo-6-oxo-5H-1,5-naphthyridine-3-carboxylate (450 mg, 1.51 mmol, 1.00 equiv.) in THF (8 ml), LiAlH4 (1.21 ml, 3.03 mmol, 2.00 equiv., 2.5M in THF) was added dropwise at 0 °C under a nitrogen atmosphere. The resulting mixture was stirred for 1 ha at 0 °C under a nitrogen atmosphere. The reaction was monitored by LCMS. The reaction was rapidly cooled by the addition of HCl (3.03 ml, 3.03 mmol, 2.00 equiv.) at 0 °C. The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to yield 3-bromo-7-(hydroxymethyl)-1H-1,5-naphthyridin-2-one (220 mg, 56.9%). LC-MS: (ES+H, m / z): [M+H]+ = 255.0 / 257.0. Step 7: Preparation of 3-bromo-7-(chloromethyl)-1H-1,5-naphthyridin-2-one:
[00219] To a stirred mixture of 3-bromo-7-(hydroxymethyl)-1H-1,5-naphthyridin-2-one (230 mg, 0.90 mmol, 1.00 equiv.) and DMF (6 mg, 0.09 mmol, 0.10 equiv.) in DCM (7 ml), SOCl2 (321 mg, 2.70 mmol, 3.00 equiv.) was added dropwise at 0 °C under a nitrogen atmosphere. The resulting mixture was stirred overnight at room temperature under a nitrogen atmosphere. The reaction was monitored by LCMS. The resulting mixture was concentrated under reduced pressure to yield 3-bromo-7-(chloromethyl)-1H-1,5-naphthyridin-2-one (220 mg, 89.2%). LC-MS: (ES+H, m / z): [M+H]+ =272.9 / 274.9. Step 8: Preparation of 6-{4-[(7-bromo-6-oxo-5H-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}pyridine-3-carbonitrile:
[00220] To a stirred solution of 3-bromo-7-(chloromethyl)-1H-1,5-naphthyridin-2-one (150 mg, 0.54 mmol, 1.00 equiv.), DIEA (354 mg, 2.74 mmol, 5.00 equiv.) and 6-(piperazin-1-yl)pyridine-3-carbonitrile (113 mg, 0.60 mmol, 1.10 equiv.) in MeCN (7 ml), KI (18 mg, 0.11 mmol, 0.20 equiv.) was added in portions at room temperature under a nitrogen atmosphere. The resulting mixture was stirred for 2 hours at 80 °C under a nitrogen atmosphere. The reaction was monitored by LCMS. The mixture was allowed to cool to room temperature. The resulting mixture was concentrated under reduced pressure. The crude product (120 mg) was purified by preparative HPLC, the pure fraction was concentrated and then lyophilized to produce 6-{4-[(7-bromo-6-oxo-5H-1,5-naphtiridine-3-yl)methyl]piperazin-1-yl}pyridine-3-carbonitrile (25.6 mg, 10.9%).LC-MS: (ES+H, m / z): [M+H]+=425.00 / 427.00; 1H NMR (400 MHz, DMSO-d6) d 12.41 (s, 1H), 8.47 (s, 3H), 7.85 (dd, J = 9.1, 2.4 Hz, 1H), 7.68 (s, 1H), 6.93 (d, J = 9.1 Hz, 1H), 3.78 - 3.59 (m, 6H), 2.48 (d, J = 4.7 Hz, 4H). Examples 68 and 69. Step 1: Preparation of ethyl 6-methoxy-7-(oxolan-2-yl)-1,5-naphthyridine-3-carboxylate:
[00221] To a stirred solution of ethyl 7-bromo-6-methoxy-1,5-naphthyridine-3-carboxylate (5.00 g, 16.07 mmol, 1.00 equiv.) and (4-methoxyphenyl)[4-(trifluoromethyl)phenyl]methanone (1.12 g, 4.01 mmol, 0.25 equiv.) in THF were added 5,5'-dimethyl-2,2'-bipyridine (0.74 g, 4.01 mmol, 0.25 equiv.), nickel acetylacetonate (1.03 g, 4.01 mmol, 0.25 equiv.) and Na2CO3 (1.70 g, 16.07 mmol, 1.00 equiv.) at room temperature under a nitrogen atmosphere. The resulting mixture was placed approximately ~3 cm away from two 40W blue LEDs and stirred for 7 days at room temperature under a nitrogen atmosphere. The reaction was monitored by LCMS. The resulting mixture was extracted with EtOAc (3 x 100 ml). The combined organic layers were washed with brine (50 ml) and dried with anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure.The residue was purified by silica gel column chromatography to yield ethyl 6-methoxy-7-(oxolan-2-yl)-1,5-naphthyridine-3-carboxylate (1.6 g, 32.93%). LC-MS: (ES+H, m / z): [M+H]+ = 303.15; 1H NMR (400 MHz, DMSO-d6) d 9.20 (d, J = 2.0 Hz, 1H), 8.57 (dd, J = 2.1, 0.8 Hz, 1H), 8.27 - 8.10 (m, 1H), 5.13 - 5.04 (m, 1H), 4.41 (q, J = 7.1 Hz, 2H), 4.18 - 4. 09 (m, 1H), 4.09 (s, 3H), 3.95 - 3.85 (m, 1H), 2.49 - 2.39 (m, 1H), 2.05 - 1.82 (m, 2H), 1.79 - 1.67 (m, 1H), 1.39 (t, J = 7.1 Hz, 3H). Step 2: Preparation of ethyl 6-oxo-7-(oxolan-2-yl)-5H-1,5-naphthyridine-3-carboxylate:
[00222] To a stirred solution of ethyl 6-methoxy-7-(oxolan-2-yl)-1,5-naphthyridine-3-carboxylate (1.30 g, 4.30 mmol, 1.00 equiv.) in MeCN, HBr in AcOH (0.25 mL, 33% by weight, 2.00 equiv.) was added at 0 °C under a nitrogen atmosphere. The resulting mixture was stirred for 0.5 h at 0 °C. The reaction was monitored by LCMS. The resulting mixture was diluted with water (20 mL) and basified to pH 8 with Et3N. The resulting mixture was extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with brine (50 mL) and dried with anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to yield ethyl 6-methoxy-7-(oxolan-2-yl)-1,5-naphthyridine-3-carboxylate (730 mg, 58.89%).LC-MS: (ES+H, m / z): [M+H]+ = 289,10; RMN de 1H (400 MHz, DMSO-d6) d 12,14 (s, 1H), 8,91 (d, J = 1,9 Hz, 1H), 8,18 (d, J = 1,9 Hz, 1H), 7,84 (d, J = 1,1 Hz, 1H), 4,96 - 4,87 (m, 1H), 4,39 (q, J = 7,1 Hz, 2H), 4. 12 - 4,04 (m, 1H), 3,91 - 3,79 (m, 1H), 2,48 - 2,32 (m, 1H), 1,99 - 1,81 (m, 2H), 1,74 - 1,63 (m, 1H), 1,36 (t, J = 7,1 Hz, 3H). Etapa 3: Preparação de 7-(hidroximetil)-3-(oxolano-2-il)-1H-1,5- naftiridina-2-ona:
[00223] To a stirred mixture of ethyl 6-oxo-7-(oxolan-2-yl)-5H-1,5-naphthyridine-3-carboxylate (730 mg, 2.53 mmol, 1.00 equiv.) in THF (8 ml), LiAlH4 (192 mg, 5.06 mmol, 2.00 equiv.) was added dropwise at 0 °C under a nitrogen atmosphere. The resulting mixture was stirred for 1 ha at 0 °C under a nitrogen atmosphere. The reaction was monitored by LCMS. The reaction was rapidly cooled by the addition of 1 M HCl (1 ml) at 0 °C. The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to yield 7-(hydroxymethyl)-3-(oxolan-2-yl)-1H-1,5-naphtiridine-2-one (280 mg, 44.90%). LC-MS: (ES+H, m / z): [M+H]+ = 247.00; 1H NMR (300 MHz, DMSO-d6) d 11.97 (s, 1H), 8.40 (d, J = 1.9 Hz, 1H), 7.80 (s, 1H), 7.64 (d, J = 1.9 Hz, 1H), 5.48 (t, J = 5.6 Hz, 1H), 4.98 - 4.84 (m, 1H), 4.63 (d, J = 5.3Hz, 2H), 4.18 - 4.01 (m, 1H), 3.91 - 3.75 (m, 1H), 2.45 - 2.31 (m, 1H), 2.02 - 1.78 (m, 2H), 1.74 - 1.58 (m, 1H). Step 4: Preparation of 7-(chloromethyl)-3-(oxolan-2-yl)-1H-1,5-naphthyridin-2-one:
[00224] To a stirred mixture of 7-(hydroxymethyl)-3-(oxolan-2-yl)-1H-1,5-naphtiridine-2-one (280 mg, 1.13 mmol, 1.00 equiv.) and DMF (8 mg, 0.11 mmol, 0.10 equiv.) in DCM, SOCl2 (0.25 ml, 3.41 mmol, 3.00 equiv.) was added dropwise at 0 °C under a nitrogen atmosphere. The resulting mixture was stirred for 5 h at room temperature under a nitrogen atmosphere. The reaction was monitored by LCMS. The resulting mixture was concentrated under reduced pressure to yield 7-(chloromethyl)-3-(oxolan-2-yl)-1H-1,5-naphtiridine-2-one (300 mg, crude). LC-MS: (ES+H, m / z): [M+H]+ =265.05. Step 5: Preparation of 6-(4-{[6-oxo-7-(oxolan-2-yl)-5H-1,5-naphthyridin-3-yl]methyl}piperazin-1-yl)pyridine-3-carbonitrile:
[00225] To a stirred mixture of 7-(chloromethyl)-3-(oxolan-2-yl)-1H-1,5-naphthyridin-2-one (150 mg, 0.56 mmol, 1.00 equiv) and 6-(piperazin-1-yl)pyridine-3-carbonitrile (106 mg, 0.56 mmol, 1.00 equiv) in MeCN (10 ml), DIEA (292 mg, 2.26 mmol, 4.00 equiv) and KI (18 mg, 0.11 mmol, 0.20 equiv) were added at room temperature under a nitrogen atmosphere. The resulting mixture was stirred for 2 h at 80 °C under a nitrogen atmosphere. The mixture was allowed to cool to room temperature. The reaction was monitored by LCMS. The resulting mixture was extracted with EtOAc (3 x 20 ml). The combined organic layers were washed with brine (20 ml) and dried with anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by reverse flash chromatography to yield 6-(4-{[6-oxo-7-(oxolan-2-yl)-5H-1,5-naftiridin-3-yl]methyl}piperazin-1-yl)pyridine-3-carbonitrile (88 mg, 37.29%). LC-MS: (ES+H, m / z): [M+H]+ = 417.10.The racemate (88 mg) was separated by prep-chiral HPLC under the following conditions: Column: CHIRALPAK IH, 2*25 cm, 5 µm; Mobile Phase A: Hex(10 mM NH3-MeOH), Mobile Phase B: EtOH: ACN=5:1; Flow rate: 20 mL / min; Gradient: 50% of B to 50% of B in 12 min; Wavelength: 218 / 282 nm; RT1(min): 4.62; RT2(min): 6.76; Sample Solvent: MeOH DCM=1:1--HPLC; Injection Volume: 0.75 mL; Number of Runs: 6, the pure fraction was concentrated under vacuum and then lyophilized to provide Example 68 (34.2 mg, 99.7% purity, ee=100%) and Example 69 (34.1 mg, 99.3% purity, ee=99.7%). Example 68: LC-MS: (ES+H, m / z): [M+H]+ = 417.10; 1H NMR (300 MHz, DMSO-d6) d 11.95 (s, 1H), 8.47 (d, J = 2.4 Hz, 1H), 8.43 (d, J = 1.8 Hz, 1H), 7.84 (dd, J = 9.1, 2.4 Hz, 1H), 7.80 (d, J = 1.3 Hz, 1H), 7.64 (d, J = 1.9 Hz, 1H), 6.93 (d, J = 9.2 Hz, 1H), 4,89 (t, J = 6,8 Hz, 1H), 4,10 - 4,03 (m, 1H), 3,87-3,79 (m, 1H), 3,73 - 3,62 (m, 6H), 2,58 - 2,49 (m, 4H), 2,43 - 2,30 (m, 1H), 2,02 - 1,77 (m, 2H), 1,73 - 1,57 (m, 1H). Exemplo 69: LC-MS: (ES+H, m / z): [M+H]+ =417,10; RMN de 1H (300 MHz, DMSO-d6) d 11,95 (s, 1H), 8,48 (d, J = 2,4 Hz, 1H), 8,43 (d, J = 1,8 Hz, 1H), 7,85 (dd, J = 9,1, 2,4 Hz, 1H), 7,82 - 7,77 (m, 1H), 7,64 (d, J = 1,9 Hz, 1H), 6,93 (d, J = 9,1 Hz, 1H), 4. 90 (t, J = 6,8 Hz, 1H), 4,15 - 4,00 (m, 1H), 3,92 - 3,76 (m, 1H), 3,74 - 3,59 (m, 6H), 2,50 - 2,45 (m, 4H), 2,44 - 2,31 (m, 1H), 2,02 - 1,78 (m, 2H), 1,74 - 1,57 (m, 1H). Exemplo 71. Etapa 1: Preparação de (2E)-N-(3-bromo-2-fluorofenil)-2-metil-3- fenilprop-2-enamida:
[00226] A solution of α-methylcinnamic acid (2.56 g, 15.78 mmol, 1.00 equiv.) in DCM (30 mL) was treated with DIEA (8.16 g, 63.15 mmol, 4.00 equiv.), T3P (15.07 g, 23.68 mmol, 1.50 equiv., 50% by weight in DCM) for 5 min at room temperature under a nitrogen atmosphere followed by the addition of 3-bromo-2-fluoroaniline (3.00 g, 15.78 mmol, 1.00 equiv.) at room temperature. The resulting mixture was stirred overnight at room temperature under a nitrogen atmosphere. The reaction was monitored by LCMS. The resulting mixture was diluted with water (100 mL). The resulting mixture was extracted with EtOAc (3 x 100 mL). The combined organic layers were washed with brine (2 x 100 ml) and dried with anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to yield (2E)-N-(3-bromo-2-fluorophenyl)-2-methyl-3-phenylprop-2-enamide (2.00 g, 37.9%).LC-MS: (ES+H, m / z): [M+H] +=333,95 / 335,95; RMN de 1H (400 MHz, DMSO-d6) d 9,89 (s, 1H), 7,62 -7,41 (m, 7H), 7,21 -7,13 (m, 1H), 6,85 -6,69 (m, 1H), 2,12 (d, J=1,4 Hz, 3H). Etapa 2: Preparação de 7-bromo-8-fluoro-3-metil-1H-quinolin-2-ona:
[00227] To a stirred solution of (2E)-N-(3-bromo-2-fluorophenyl)-2-methyl-3-phenylprop-2-enamide (2.00 g, 5.98 mmol, 1.00 equiv) in chlorobenzene (20 ml) was added AlCl3 (2.39 g, 17.95 mmol, 3.00 equiv) at 0 °C under a nitrogen atmosphere. The resulting mixture was stirred for 3 hours at 120 °C under a nitrogen atmosphere. The reaction was monitored by LCMS. The mixture was allowed to cool to room temperature. The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to yield 7-bromo-8-fluoro-3-methyl-1H-quinolin-2-one (1.00 g, 65.2%). LC-MS: (ES+H, m / z): [M+H]+=255.80 / 257.80; 1H NMR (400 MHz, DMSO-d6) d 11.94 (s, 1H), 7.82 (s, 1H), 7.44 - 7.34 (m, 2H), 2.09 (s, 3H). Step 3: Preparation of 8-fluoro-7-(hydroxymethyl)-3-methyl-1H-quinolin-2-one:
[00228] A solution of 7-bromo-8-fluoro-3-methyl-1H-quinolin-2-one (800 mg, 3.12 mmol, 1.00 equiv.) and (tributylstanyl)methanol (1.10 g, 3.43 mmol, 1.10 equiv.), 2nd Generation XPhos Precatalyst (123 mg, 0.15 mmol, 0.05 equiv.) in 1,4-dioxane (10 mL) was stirred overnight at 80 °C under a nitrogen atmosphere. The reaction was monitored by LCMS. The mixture was allowed to cool to room temperature. The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to yield 8-fluoro-7-(hydroxymethyl)-3-methyl-1H-quinolin-2-one (400 mg, 61.7%). LC-MS: (ES+H, m / z): [M+H]+ = 208.15 Step 4: Preparation of 7-(chloromethyl)-8-fluoro-3-methyl-1H-quinolin-2-one:
[00229] To a stirred mixture of 8-fluoro-7-(hydroxymethyl)-3-methyl-1H-quinolin-2-one (400 mg, 1.93 mmol, 1.00 equiv.) and DMF (14 mg, 0.19 mmol, 0.10 equiv.) in DCM (5 ml), SOCl2 (2.30 g, 19.30 mmol, 10.00 equiv.) was added dropwise at 0 °C under a nitrogen atmosphere. The resulting mixture was stirred for 2 h at room temperature under a nitrogen atmosphere. The reaction was monitored by LC-MS. The resulting mixture was concentrated under reduced pressure to yield 7-(chloromethyl)-8-fluoro-3-methyl-1H-quinolin-2-one (400 mg, 91.8%). LC-MS: (ES+H, m / z): [M+H]+ = 226.3 Step 5: Preparation of 6-{4-[(8-fluoro-3-methyl-2-oxo-1H-quinolin-7-yl) methyl] piperazin-1-yl} pyridine-3-carbonitrile:
[00230] A solution of 6-(piperazin-1-yl)pyridine-3-carbonitrile hydrochloride (229 mg, assumed 100% yield, 0.88 mmol, 1.00 equiv) in MeCN (10 ml) was treated with DIEA (573 mg, 4.43 mmol, 5.00 equiv) for 5 min at room temperature under a nitrogen atmosphere followed by the addition of KI (17 mg, 0.10 mmol, 0.10 equiv) and 7-(chloromethyl)-8-fluoro-3-methyl-1H-quinolin-2-one (200 mg, 0.88 mmol, 1.00 equiv). The resulting mixture was stirred for 2 hours at 100 °C under a nitrogen atmosphere. The reaction was monitored by LCMS. The mixture was allowed to cool to room temperature. The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to yield 6-{4-[(8-fluoro-3-methyl-2-oxo-1H-quinolin-7-yl)methyl]piperazin-1-yl}pyridine-3-carbonitrile (92.1 mg, 23.8%).LC-MS: (ES+H, m / z): [M+H] +=378.10; 1H NMR (400 MHz, DMSO-d6) d 11.77 (s, 1H), 8.47 (d, J = 4.0 Hz, 1H), 7.87 - 7.76 (m, 2H), 7.38 (d, J = 8.1 Hz, 1H), 7.18 (dd, J = 8.1, 6.4). Hz, 1H), 6.91 (d, J = 8.0 Hz, 1H), 3.66 - 3.65 (m, 6H), 2.51-2.48 (m, 4H), 2.10 (d, J = 1.3 Hz, 3H). 19F NMR (377 MHz, DMSO-d6) d - 135.84. Example 82. Step 1: Preparation of l-(tert-butyl) 3-ethyl 2-(5-bromo-3-nitropyridin-2- yl)malonate:
[00231] To a stirred mixture of potassium tert-butoxide (21.27 g, 189.52 mmol, 1.50 equiv.) in THF (500 ml), 1-tert-butyl-3-ethyl propanodioate (35.67 g, 189.52 mmol, 1.50 equiv.) was added dropwise at room temperature under a nitrogen atmosphere. To the above mixture, 5-bromo-2-chloro-3-nitropyridine (30.00 g, 126.34 mmol, 1.00 equiv.) in THF (50 ml) was added dropwise over 15 min at 60 °C. The resulting mixture was stirred for a further 3 h at 60 °C. The reaction was monitored by LCMS. The mixture was allowed to cool to room temperature. The resulting mixture was concentrated under vacuum. The resulting mixture was diluted with HCl (1M in water) (200 ml). The resulting mixture was extracted with EtOAc (3 x 300 ml). The combined organic layers were washed with brine (2 x 200 ml) and dried with anhydrous Na2SO4.After filtration, the filtrate was concentrated under reduced pressure to produce 1-(tert-butyl) 3-ethyl-2-(5-bromo-3-nitropyridin-2-yl)malonate (45 g, 91.5%). LC-MS: (ES-H, m / z): [MH]- = 387.1. Step 2: Preparation of ethyl 2-(5-bromo-3-nitropyridin-2-yl)acetate:
[00232] To a stirred solution of 1-(tert-butyl) 3-ethyl-2-(5-bromo-3-nitropiridin-2-yl)malonate (45.00 g, 115.62 mmol, 1.00 equiv.) in CH2Cl2 (300 mL), TFA (200 mL) was added at room temperature under a nitrogen atmosphere. The resulting mixture was stirred overnight at room temperature under a nitrogen atmosphere. The reaction was monitored by LCMS. The resulting mixture was concentrated under reduced pressure. The residue was diluted with saturated aqueous NaHCO3 solution (100 mL). The resulting mixture was extracted with EtO-Ac (3 x 500 mL). The combined organic layers were washed with brine (1 x 200 mL) and dried with anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure to yield ethyl 2-(5-bromo-3-nitropyridin-2-yl)acetate (35 g, crude). LC-MS: (ES+H, m / z): [M+H]+=290.9 Step 3: Preparation of ethyl 2-(3-amino-5-bromopyridine-2-yl)acetate:
[00233] To a stirred mixture of ethyl 2-(5-bromo-3-nitropyridin-2-yl)acetate (35.00 g, 121.07 mmol, 1.00 equiv.) and Fe (79.72 g, 1219.36 mmol, 7.50 equiv.) in EtOH (250 ml), a saturated aqueous solution of NH4Cl (250 ml) at room temperature was added under a nitrogen atmosphere. The resulting mixture was stirred for 2 hours at 80 °C under a nitrogen atmosphere. The reaction was monitored by LCMS. The mixture was allowed to cool to room temperature. The resulting mixture was diluted with EtOAc (300 ml). The resulting mixture was stirred for 10 min at room temperature. The resulting mixture was filtered, and the filter cake was washed with EtOAc (3 x 70 ml). The resulting mixture was extracted with EtOAc (3 x 300 ml). The combined organic layers were washed with brine (2 x 200 ml) and dried with anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure.The residue was purified by column chromatography on silica gel to yield 2-(3-amino-5-bromopyridin-2-yl)acetate (9.3 g, 29.7%) as a light yellow oil. LC-MS: (ES+H, m / z): [M+H]+ = 259.1. Step 4: Preparation of ethyl 2-(5-bromo-3-(2,2-dimethoxypropanamido)pyridin-2-yl)acetate:
[00234] To a stirred solution of methyl 2,2-dimethoxypropanoate (12.00 g, 80.99 mmol, 1.00 equiv) in MeOH (120 mL) was added NaOH (9.72 g, 242.98 mmol, 3.00 equiv) in H2O (120 mL) by dropwise at room temperature under a nitrogen atmosphere. The resulting mixture was stirred for 4 h at room temperature under a nitrogen atmosphere. The reaction was monitored by TLC. The mixture was acidified to pH 8 with HCl (2M in water). The resulting mixture was concentrated under reduced pressure. The resulting mixture was diluted with EtOH (500 mL). The resulting mixture was stirred for 2 h at room temperature. The resulting mixture was filtered, and the filter cake was washed with EtOH (3 x 100 mL). The filtrate was concentrated under reduced pressure to provide sodium 2,2-dimethoxypropanoate (8.5 g, 78.2%). 1H NMR (300 MHz, D2O) d 3.12 (d, J = 1.7 Hz, 6H), 1.33 (s, 3H).
[00235] To a stirred solution of sodium 2,2-dimethoxypropanoate (7.59 g, 48.63 mmol, 1.50 equiv.) in dioxane (100 ml) were added DIEA (12.57 g, 97.26 mmol, 3.00 equiv.) and T3P (30.95 g, 97.26 mmol, 3.00 equiv., 50% by weight in EtOAc) at room temperature under a nitrogen atmosphere. The resulting mixture was stirred for 1 h at room temperature under a nitrogen atmosphere. To the above mixture, ethyl 2-(3-amino-5-bromopyridine-2-yl)acetate (8.40 g, 32.42 mmol, 1.00 equiv.) was added at room temperature. The resulting mixture was stirred overnight at 100 °C. The reaction was monitored by LCMS. The mixture was allowed to cool to room temperature. The resulting mixture was diluted with water (100 ml). The resulting mixture was extracted with EtOAc (3 x 200 ml). The combined organic layers were washed with brine (1 x 100 ml), dried with anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure.The residue was purified by silica gel column chromatography to yield ethyl 2-(5-bromo-3-(2,2-dimethoxypropanamido)pyridin-2-yl)acetate (9.3 g, 79.4%). LC-MS: (ES+H, m / z): [M+H]+ = 375.1. Step 5: Preparation of ethyl 7-bromo-3-methyl-2-oxo-1,2-dihydro-1,5-naphthyridine-4-carboxylate:
[00236] To a stirred solution of 2-(5-bromo-3-(2,2-dimethoxypropanamido)pyridin-2-yl)ethyl acetate (7.00 g, 18.65 mmol, 1.00 equiv.) in TFA (100 mL) were added H2O (7 mL) followed by 2 drops of fresh I2 solution (30 mg of I2 were suspended in TFA (10 mL)) at room temperature under a nitrogen atmosphere. The resulting mixture was stirred overnight at 50 °C under a nitrogen atmosphere. The resulting mixture was concentrated under vacuum. The residue was dissolved in toluene (100 mL) and piperidine (6 mL). The resulting mixture was refluxed at 120 °C for 2 h, then concentrated under reduced pressure. The residue was purified by silica gel column chromatography to yield ethyl 7-bromo-3-methyl-2-oxo-1,2-dihydro-1,5-naphthyridine-4-carboxylate (3.3 g, 56.9%).LC- MS: (ES+H, m / z): [M+H] + =313,0; RMN de 1H (400 MHz, DMSO-d6) d 12,20 (s, 1H), 8,55 (d, J = 2,1 Hz, 1H), 7,86 (d, J = 2,1 Hz, 1H), 4,42 (q, J = 7,1 Hz, 2H), 2,06 (s, 3H), 1,33 (t, J = 7,1 Hz, 3H). Etapa 6: Preparação de 7-bromo-4-(hidroximetil)-3-metil-1,5-naftiridina- 2(1H)-ona: To a stirred solution of ethyl 7-bromo-3-methyl-2-oxo-1,2-dihydro-1,5-naphthyridine-4-carboxylate (3.00 g, 9.64 mmol, 1.00 equiv.) in THF (50 ml), LiEt 3BH (30 ml, 1M in THF) was added dropwise at 0°C under a nitrogen atmosphere. The resulting mixture was stirred for 2 hours at 0°C under a nitrogen atmosphere. The reaction was monitored by LCMS. The reaction was rapidly cooled by the addition of water / ice (6 ml) at 0°C. The resulting mixture was concentrated under vacuum. The residue was purified by silica gel column chromatography, eluted with CH2Cl2 / MeOH (gradient from 0 to 10:1 in 30 min) to yield 7-bromo-4-(hydroxymethyl)-3-methyl-1,5-naphthyridin-2(1H)-one (1.8 g, 69.4%). LC-MS: (ES-H, m / z): [M+H]+=267.0 / 269.0; 1H NMR (300 MHz, DMSO-d6) d 11.95 (s, 1H), 8.57 (d, J = 2.1 Hz, 1H), 7.83 (d, J = 2.1 Hz, 1H), 5.04 (t, J = 5.5 Hz, 1H), 4.90 (d, J = 5.2 Hz, 2H), 2.21 (s, 3H). Step 7: Preparation of 7-bromo-3-methyl-2-oxo-1,2-dihydro-1,5-naphthyridine-4-carbaldehyde:
[00237] To a stirred mixture of 7-bromo-4-(hydroxymethyl)-3-methyl-1,5-naphthyridin-2(1H)-one (1.80 g, 6.68 mmol, 1.00 equiv.) in THF (20 ml) was added 1,1-bis(acetyloxy)-3-oxo-3H-1 l A[5] ,2-benziodaoxol-1-yl acetate (3.40 g, 8.02 mmol, 1.20 equiv.) at room temperature under a nitrogen atmosphere. The resulting mixture was stirred for 2 h at room temperature under a nitrogen atmosphere. The reaction was monitored by LCMS. The resulting mixture was diluted with water (10 ml). The precipitated solids were collected by filtration and washed with water (3 x 5 ml). The residue was purified by reverse combi-flash chromatography to yield 7-bromo-3-methyl-2-oxo-1,2-dihydro-1,5-naphthyridine-4-carbaldehyde (760 mg, 42.5%). LC-MS: (ES-H, m / z): (MH)- = 264.9; 1H NMR (300 MHz, DMSO-d6) d 12.28 (s, 1H), 10.88 (s, 1H), 8.62 (d, J = 2.1 Hz, 1H), 7.89 (d, J = 2.1 Hz, 1H), 2.25 (s, 3H). Step 8: Preparation of 7-bromo-4-(difluoromethyl)-3-methyl-1,5-naphthyridin-2(1H)-one:
[00238] To a stirred solution of 7-bromo-3-methyl-2-oxo-1,2-dihydro-1,5-naphthyridine-4-carbaldehyde (750 mg, 2.80 mmol, 1 equiv.) in THF (5 ml) were added BAST (2.49 g, 11.23 mmol, 4 equiv.) by drop at 0°C under a nitrogen atmosphere. The resulting mixture was stirred for 2 hours at 50°C under a nitrogen atmosphere. The reaction was monitored by LCMS. The mixture was allowed to cool to room temperature. The reaction was rapidly cooled with NH4Cl (aq.) sat. (3 ml) at 0°C. The resulting mixture was extracted with EtOAc (3 x 20 ml) and dried with anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to yield 7-bromo-4-(difluoromethyl)-3-methyl-1,5-naphthyridin-2(1H)-one (320 mg, 39.4%). LC-MS: (ES-H, m / z): [MH]-=287.0 Step 9: Preparation of 4-(difluoromethyl)-7-(hydroxymethyl)-3-methyl-1,5-naphthyridin-2(1H)-one:
[00239] To a stirred solution of 7-bromo-4-(difluoromethyl)-3-methyl-1H-1,5-naphthyridin-2-one (360 mg, 1.24 mmol, 1.00 equiv.) and 2nd Generation XPhos Precatalyst (195 mg, 0.24 mmol, 0.20 equiv.) in dioxane (5 ml) were added (Tributylstanyl)methanol (959 mg, 2.98 mmol, 2.40 equiv.) at room temperature under a nitrogen atmosphere. The resulting mixture was stirred for 2 hours at 80 °C under a nitrogen atmosphere. The reaction was monitored by LCMS. The resulting mixture was concentrated under vacuum. The residue was purified by silica gel column chromatography to yield 4-(difluoromethyl)-7-(hydroxymethyl)-3-methyl-1,5-naphtiridine-2(1H)-one (195 mg, 65.2%). LC-MS: (ES+H, m / z): [M+H]+ = 241.1. Step 10: Preparation of 7-(chloromethyl)-4-(difluoromethyl)-3-methyl-1,5-naphthyridin-2(1H)-one:
[00240] To a stirred mixture of 4-(difluoromethyl)-7-(hydroxymethyl)-3-methyl-1,5-naphthyridine-2(1H)-one (185 mg, 0.25 mmol, 1.00 equiv.) and DMF (2 mg, 0.02 mmol, 0.10 equiv.) in CH2Cl2 (3 ml), SOCl2 (183 mg, 1.54 mmol, 6.00 equiv.) was added dropwise at 0 °C under a nitrogen atmosphere. The resulting mixture was stirred overnight at room temperature under a nitrogen atmosphere. The reaction was monitored by LCMS. The resulting mixture was concentrated under vacuum to yield 7-(chloromethyl)-4-(difluoromethyl)-3-methyl-1,5-naphthyridine-2(1H)-one (195 mg, crude). The crude product was used directly in the next step without further purification. LC-MS: (ES+H, m / z): [M+H]+=259.0 Step 11: Preparation of 6-(4-((8-(difluoromethyl)-7-methyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)nicotinonitrile:
[00241] To a stirred mixture of 7-(chloromethyl)-4-(difluoromethyl)-3-methyl-1,5-naphthyridine-2(1H)-one (104 mg, 0.40 mmol, 1.00 equiv) and 6-(piperazine-1-yl)pyridine-3-carbonitrile (91 mg, 0.48 mmol, 1.20 equiv) in MeCN (5 ml), DIEA (260 mg, 2.01 mmol, 5.00 equiv) and KI (13 mg, 0.08 mmol, 0.20 equiv) were added at room temperature under a nitrogen atmosphere. The resulting mixture was stirred for 3 hours at 80 °C under a nitrogen atmosphere. The reaction was monitored by LCMS. The mixture was allowed to cool to room temperature. The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to yield 6-(4-((8-(difluoromethyl)-7-methyl-6-oxo-5,6-dihydro-1,5-naphtiridine-3-yl)methyl)piperazine-1-yl)nicotinonitrile (crude).The crude product was further purified by trituration with MeOH (6 mL) to yield 6-(4-((8-(difluoromethyl)-7-methyl-6-oxo-5,6-dihydro-1,5-naphtiridine-3-yl)methyl)piperazine-1-yl)nicotinonitrile (28.3 mg, 16.6%). LC-MS: (ES+H, m / z): [M+H] + =411.10; 1H NMR (300 MHz, DMSO-d6) d 12.25 (s, 1H), 8.48 (t, J = 1.8 Hz, 2H), 8.14 - 7.74 (m, 2H), 7.70 (d, J = 1.9 Hz, 1H), 6.94 (d, J = 9.1 Hz, 1H), 3.39-3.67 (m, 6H), 2.50-2.48 (m, 4H), 2.33 (t, J = 2.8 Hz, 3H). 19F NMR (282 MHz, DMSO-d6) d-117.71. Example 83. Step 1: Preparation of (2E)-N-(3-bromo-2-fluorophenyl)-3-ethoxyprop-2-enamide:
[00242] To a stirred mixture of 3-bromo-2-fluoroaniline (20.00 g, 105.25 mmol, 1.00 equiv.) in DCM (300 ml), pyridine (14.99 g, 189.45 mmol, 1.80 equiv.) was added dropwise at room temperature under a nitrogen atmosphere. The resulting mixture was stirred for 5 min at room temperature under a nitrogen atmosphere. To the above mixture, (2E)-3-ethoxyprop-2-enoyl chloride (21.24 g, 157.88 mmol, 1.50 equiv.) was added dropwise over 5 min at room temperature. The resulting mixture was stirred for a further 2 h at room temperature. The reaction was monitored by LCMS. The resulting mixture was concentrated under reduced pressure. The residue was dissolved in EtOAc (500 ml). The resulting mixture was washed with water (3 x 500 ml). The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to yield (2E)-N-(3-bromo-2-fluorophenyl)-3-ethoxyprop-2-enamide (24.6 g, 81.1%).LC-MS: (ES+H, m / z): [M+H]+ =288.0 / 290.0. Step 2: Preparation of 7-bromo-8-fluoro-1H-quinolin-2-one:
[00243] A mixture of (2E)-N-(3-bromo-2-fluorophenyl)-3-ethoxyprop-2-enamide (17.00 g, 59.00 mmol, 1.00 equiv.) in H2SO4 (85 ml) was stirred for 3 h at room temperature under a nitrogen atmosphere. The resulting mixture was added to ice water (1 l) by drop and stirred for 1 h. The precipitated solids were collected by filtration and washed with water (3 x 200 ml). The resulting mixture was concentrated under reduced pressure to yield 7-bromo-8-fluoro-1H-quinolin-2-one (14.30 g, crude). LC-MS: (ES+H, m / z): [M+H]+ =242.0 / 244.0. Step 3: Preparation of 7-bromo-3-chloro-8-fluoro-1H-quinolin-2-one:
[00244] To a stirred mixture of 7-bromo-8-fluoro-1H-quinolin-2-one (3.00 g, 12.39 mmol, 1.00 equiv.) and NCS (2.65 g, 19.83 mmol, 1.60 equiv.) in CH3COOH (50 ml), 2,2-dichloroacetic acid (0.32 g, 2.47 mmol, 0.20 equiv.) was added dropwise at room temperature under a nitrogen atmosphere. The resulting mixture was stirred overnight at 100 °C under a nitrogen atmosphere. The reaction was monitored by LCMS. The mixture was allowed to cool to room temperature. The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to yield 7-bromo-3-chloro-8-fluoro-1H-quinolin-2-one (2.48 g, crude). LC-MS: (ES+H, m / z): [M+H]+=275.9 / 277.9. 1H NMR (400 MHz, DMSO-d6) d 12.52 (s, 1H), 8.38 (d, J = 1.6 Hz, 1H), 7.52-7.42 (m, 2H). Step 4: Preparation of 3-chloro-7-ethenyl-8-fluoro-1H-quinolin-2-one:
[00245] To a stirred mixture of 7-bromo-3-chloro-8-fluoro-1H-quinolin-2-one (2.48 g, 8.97 mmol, 1.00 equiv.), CsF (4.09 g, 26.91 mmol, 3.00 equiv.), Pd(dppf)Cl2 (0.33 g, 0.44 mmol, 0.05 equiv.) and 2-ethenyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (1.38 g, 8.97 mmol, 1.00 equiv.) in dioxane (50 ml), H2O (5 ml) was added dropwise at room temperature under a nitrogen atmosphere. The resulting mixture was stirred for 2 hours at 100 °C under a nitrogen atmosphere. The reaction was monitored by LCMS. The mixture was allowed to cool to room temperature. The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to yield 3-chloro-7-ethenyl-8-fluoro-1H-quinolin-2-one (750 mg, 37.3%). LC-MS: (ES+H, m / z): [M+H] + =224.0; 1H NMR (300 MHz, DMSO-d6) d 12.38 (s, 1H), 8.34 (d, J = 1.6 Hz, 1H), 7.53-7.46 (m, 2H), 6.95 (dd, J = 17.7, 11.2 Hz, 1H), 6.07 (dd, J = 17.7, 1.0 Hz, 1H), 5.57 (dd, J = 11.2, 1.0 Hz, 1H). Step 5: Preparation of 3-chloro-8-fluoro-2-oxo-1H-quinoline-7-carbaldehyde:
[00246] To a stirred mixture of 3-chloro-7-ethenyl-8-fluoro-1H-quinolin-2-one (750 mg, 3.35 mmol, 1.00 equiv.), K2OsO2(OH)4 (123 mg, 0.33 mmol, 0.10 equiv.), NaIO4 (2.87 g, 13.41 mmol, 4.00 equiv.) and 2,6-dimethylpyridine (718 mg, 6.70 mmol, 2.00 equiv.) in THF (15 ml), H2O (1.5 ml) was added dropwise at room temperature under a nitrogen atmosphere. The resulting mixture was stirred overnight at room temperature under a nitrogen atmosphere. The reaction was monitored by LCMS. The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to yield 3-chloro-8-fluoro-2-oxo-1H-quinoline-7-carbaldehyde (630 mg, 83.2%). LC-MS: (ES-H, m / z): [MH]- =224.1. Step 6: Preparation of 6-{4-[(3-chloro-8-fluoro-2-oxo-1H-quinolin-7-yl)methyl]piperazin-1-yl}pyridine-3-carbonitrile:
[00247] A mixture of 3-chloro-8-fluoro-2-oxo-1H-quinoline-7-carbaldehyde (150 mg, 0.66 mmol, 1.00 equiv.) and 6-(piperazine-1-yl)pyridine-3-carbonitrile (137 mg, 0.73 mmol, 1.10 equiv.) in DCM (2 mL) was stirred for 10 min at room temperature. The resulting mixture was concentrated under reduced pressure. HOAc (19 mg, 0.33 mmol, 0.50 equiv.) in EtOH (3 mL) was added to the resulting mixture and stirred for 4 ha at 50 °C under a nitrogen atmosphere. The mixture was allowed to cool to room temperature. NaBH3CN (83 mg, 1.33 mmol, 2.00 equiv) was added to the stirred mixture in portions at 0 °C under a nitrogen atmosphere. The resulting mixture was stirred overnight at room temperature under a nitrogen atmosphere. The precipitated solids were collected by filtration and washed with EtOH (3 x 2 mL). The residue was purified by silica gel column chromatography.The resulting mixture was concentrated under reduced pressure to produce 6-{4-[(3-chloro-8-fluoro-2-oxo-1H-quinolin-7-yl)methyl]piperazin-1-yl}pyridine-3-carbonitrile (69.3 mg, 26.2%). LC-MS: (ES+H, m / z): [M+H] + =398.10; 1H NMR (400 MHz, DMSO-d6) d 12.46 (s, 1H), 8.47 (d, J = 2.0 Hz, 1H), 8.36 (d, J = 1.5 Hz, 1H), 7.85 (dd, J = 9.1, 2.4 Hz, 1H), 7.49 (d, J = 8.1 Hz, 1H), 7.28 (dd, J = 8.1, 6.3 Hz, 1H), 6.97 - 6.87 (m, 1H), 3.71 - 3.63 (m, 6H), 2.50 - 2.44 (m, 4H); 19F NMR (282 MHz, DMSO-d6) d -134.50.
[00248] The following compound was synthesized as described above. Table 2. Characterization Data Example A: Cell growth inhibition assay
[00249] Cell proliferation was measured using the cell viability assay with DLD-1 BRCA2(- / -) and parental isogenic pair and MDA-MB-436 cell lines (BRCA1 mutated). The CellTiter-Glo (CTG) based cell viability assay is designed to determine the number of viable cells in culture due to the compound effect, quantifying ATP, which indicates the presence of metabolically active cells.
[00250] DLD-1 BRCA2 (- / -) and the parental isogenic pair were cultured in RPMI 1640 supplemented with 10% fetal bovine serum (FBS), and MDA-MB-436 cells were cultured in DMEM supplemented with 10% FBS. Both were cultured at 37°C with 5% CO2. The compounds of the invention were dispensed into the 384-well plate (Corning, 3764) using the Echo acoustic liquid manipulator to form a final 1:3 serial dilution concentration with a top dose of 10 or 30 µM. Cells were inoculated into the plate at a density of 50 cells / well (parental DLD-1), 200 cells / well (DLD-1 BRCA 2- / -) or 500 cells / well (MDA-MB-436). After a short centrifugation, the cells were cultured in a well-hydrated incubator at 37 °C with 5% CO2 for 7 days without disturbance. Cell viability was measured using the CellTiter Glo 2 assay kit.0 (Promega, G9243), and the growth inhibition rate was calculated and plotted against the final concentration of the compound, and the data were fitted in Xfit to generate IC50 values. Example B: Biochemical assay (FA)
[00251] Fluorescent polarization ("FP") based assays have been widely used in drug discovery due to their homogeneous format, robust performance, and lack of interference observed in other assays. The compounds were characterized using an assay that measures the displacement of a commercially available fluorescently labeled PARP 1 / 2 inhibitor (PARRPi-FL, Tocris Biosciences, No. 6461) as exemplified in the assays performed in documents WO2014 / 064149 and WO2021 / 013735A1. The assay was performed using the following method: the compounds were dissolved in DMSO, an Echo550 liquid handler was used to perform serial dilutions in the desired concentration range in Optiplate-384F plates. 100% DMSO was used for the high (with protein) and low (without protein) control samples. 20 nl of compound or DMSO alone were added to individual assay plate wells.
[00252] PARP1 and PARP2 proteins were expressed, purified, and diluted in assay buffer containing 50 mM Tris pH 8.0, 0.001% Triton X-100, 10 mM MgCl2, and 150 mM NaCl to a final concentration of 20 nM. PARP1-FL was then added to a final concentration of 3 nM.
[00253] The test plate was centrifuged at 1000 rpm for 1 min and incubated for 4 h at room temperature.
[00254] Fluorescent polarization was read using an Envision plate reader with the following settings: excitation filter - FITC FP 480-Ex Slot 3; emission filter - FITC FP P-pol 535-Em Slot 4; 2nd emission filter - FITC FP S-pol 535-Em Slot 3; mirror module - FITC FP Dual Enh-Slot 1
[00255] The inhibition rate was calculated using the percentage of permuted Mahalanobis distances greater than the control samples (mP value) following the equation below:
[00256] XLFit (equation 201) is used to calculate a reported IC50 for each compound.
[00257] The data for examples A and B are provided in Table 3. Table 3 Example C: In Vitro Human Carrier Efflux
[00258] Canine Madin-Darby (MDCKII) kidney cells expressing MDR1 and BCRP were seeded onto 96-well Corning HTS Transwell® permeable polycarbonate supports (0.4 µm pore size) at a density of 545,000 cells / cm². Cells were incubated for 4–8 days prior to assay, and monolayer integrity was assessed by measuring transepithelial electrical resistance (TEER). Test and reference compounds were diluted with transport buffer (HBSS HEPES pH 7.4) to concentrations of 10 and 1 µM, respectively. The final organic solvent concentration was 0.5% (v / v). The bidirectional flow (apical to basolateral and basolateral to apical) of the test and reference compounds was determined over a 2-hour incubation at 37 °C and 5% CO2 with a relative humidity of 95%. At the end of the incubation, samples from the apical and basolateral sides were taken and then precipitated with an internal standard containing acetonitrile.After centrifugation at 3200 xg, the supernatants were diluted 1:1 (v / v) with water and subjected to analysis via HPLC-MS / MS. The integrity.
[00259] The apparent permeability (Papp, units of x 10-6 cm / s) was calculated using the following equation: Where dQ / dt was the drug transport rate (pmol / s), A was the membrane surface area (0.143 cm2), and D0 was the initial donor concentration (nM or pmol / cm3). Where Papp(B^A) is the apparent permeability in the basolateral-to-apical direction, and Papp(A^B) is the apparent permeability in the apical-to-basolateral direction. Example D: In vivo determination of Kp,uu in rats Determination of the Unbound Fraction in Plasma (Pu)
[00260] The equilibrium dialysis method was used to investigate the in vitro binding of test articles and reference compounds to plasma proteins. Plasma samples containing 5 µM test article or blank dialysis buffer solution (PBS, pH 7.4) were added to separate dialysis well chambers of the High-Throughput Equilibrium Dialysis (HTD) device. The dialysis plate was sealed and placed in an incubator at 37 °C with 5% CO2 with agitation at approximately 100 rpm for 6 hours. All experiments were performed in duplicate. Ketoconazole (5 µM) was used as the reference compound. After incubation, the seal was removed and 50 µL of post-dialysis samples were pipetted from both the buffer and plasma chambers into fresh 96-well plates. The samples were made equal by adding blank plasma to buffer samples or by adding blank buffer to plasma samples.Subsequently, 400 µL (4 volumes) of acetonitrile-containing internal solution were added to all samples to precipitate proteins prior to UPLC-MS / MS analysis to determine the relative concentrations of the test items. The unbound fractions in plasma were calculated using the concentrations of test items in buffer and plasma samples according to the following equation: Determination of the Unbound Fraction in Brain Homogenate (Bu)
[00261] The equilibrium dialysis method was used to investigate the in vitro binding of test articles and reference compounds to rodent brain homogenate. Brains collected from unexposed animals were weighed and homogenized in 4 volumes of PBS, pH 7.4. Samples of brain homogenate containing 1 µM of test article or blank dialysis buffer solution (PBS, pH 7.4) were added to separate dialysis well chambers of the High-Throughput Equilibrium Dialysis (HTD) device. The dialysis plate was sealed and placed in an incubator at 37 °C with 5% CO2 with agitation at approximately 100 rpm for 6 hours. Experiments were performed in duplicate. Telmisartan (5 µM) was used as the reference compound. After incubation, the seal was removed and 50 µL of post-dialysis samples were pipetted from both buffer chambers and homogenized into fresh 96-well brain plates.The samples were equimatized by adding blank homogenate to buffer samples or by adding blank buffer to homogenate samples. Subsequently, 400 µL (4 volumes) of acetonitrile-containing internal solution was added to all samples to precipitate proteins before UPLC-MS / MS analysis to determine the relative concentrations of the test subjects. The unbound fractions in diluted brain homogenate were calculated using the concentrations of test subjects in buffer and homogenate samples according to the following equation:
[00262] The correction for the unbound percentage in undiluted brain was achieved with the following equation: Determination of the Brain-Plasma Partition Coefficient of the Drug (Kp) and Kp Unbound to the Drug (Kp,uu) in Rats
[00263] The compounds were formulated individually or in a cassette (as a mixture) at a concentration of 0.1 mg / mL / compound in sterile water containing 0.5% (w / v) methylcellulose 400 cP and administered to male Sprague-Dawley rats via oral gavage at a dose volume of 10 mL / kg. One animal was sacrificed at each of the following time points: 0.5, 1, 2, 4, 8, and 24 hours post-dose, and brain and blood samples were collected. Plasma was prepared from blood by refrigerated centrifugation, and plasma samples were stored frozen at -80 °C until bioanalysis. Brain samples were rinsed with saline solution to remove residual blood and dried with a tissue. Brain samples were then weighed and homogenized with 3 volumes (v / w) of water and stored frozen at -80 °C until bioanalysis.
[00264] Prior to bioanalysis, plasma and brain samples were extracted with 4 volumes of acetonitrile containing an internal standard and centrifuged for 15 minutes. The supernatants were diluted with 2 volumes of water and injected for analysis via HPLC-MS / MS. Plasma and brain homogenate drug concentrations were determined against calibration curves generated by adding blank rat plasma or drug-containing brain homogenate across an appropriate concentration range. The brain homogenate concentration was corrected for the dilution factor of the homogenization buffer, yielding total brain drug concentrations.
[00265] The brain-plasma partition coefficient (Kp) was determined for each compound, calculated as: Brain AUC:Plasma AUC, provided that the tlast was identical in each matrix. If the drug concentration versus time profile for one matrix fell below the lower limit of quantification at a time point earlier than in the other matrix, then the brain Kp was calculated as the average of the ratios of the total brain drug concentration to the total plasma drug concentration measured at each time point where the drug concentrations in both matrices were quantifiable.
[00266] The Kp,uu was then calculated from the Kp using the following equation: Kp,uu = Kp * (unbound fraction in brain homogenate / unbound fraction in plasma).
[00267] The data for examples A and B are provided in Table 4. Table 4
Claims
CLAIMS 1. A compound of Formula (I) or a pharmaceutically acceptable salt, solvate or stereoisomer thereof: Formula (I) wherein: R1 is hydrogen, deuterium, halogen, -CN, -ORa, -NRcRd, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C1-C6heteroalkyl, C2C6alkenyl, C2-C6alkynyl, cycloalkyl or heterocycloalkyl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl and heterocycloalkyl is optionally substituted by one or more R; R2 is hydrogen, deuterium, halogen, -CN, -ORa, -NRcRd, C1-C6alkyl, C1-C6haloalkyl, or C1-C6deuteroalkyl; X is N or CR3; Y is N or CR4; Z is N or CR5; R3 is hydrogen, deuterium, halogen, -CN, -ORa, -NRcRd, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C1-C6heteroalkyl, C2C6alkenyl, C2-C6alkynyl, cycloalkyl, or heterocycloalkyl;wherein alkyl, alkenyl, alkynyl, cycloalkyl, and heterocycloalkyl is optionally substituted by one or more R; R4 is hydrogen, deuterium, halogen, -CN, -ORa, -NRcRd, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C1-C6heteroalkyl, C2C6alkenyl, C2-C6alkynyl, cycloalkyl, or heterocycloalkyl; wherein Petition 870250039377, dated 05 / 14 / 2025, page 168 / 372 2 / 19 alkyl, alkenyl, alkynyl, cycloalkyl, and heterocycloalkyl is optionally substituted by one or more R; R5 is hydrogen, deuterium, halogen, -CN, -ORa, -NRcRd, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C1-C6heteroalkyl, C2C6alkenyl, C2-C6alkynyl, cycloalkyl or heterocycloalkyl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl and heterocycloalkyl is optionally substituted by one or more R;each R6 is independently hydrogen, deuterium, halogen, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C1-C6heteroalkyl, cycloalkyl, or heterocycloalkyl; wherein the alkyl, cycloalkyl, and heterocycloalkyl is optionally substituted by one or more R; or two R6 are combined to form a cycloalkyl or a heterocycloalkyl; each optionally substituted by deuterium, halogen, -CN, -OH, -ORa, -NRcRd, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, or C1-C6heteroalkyl; each R7 is independently deuterium, halogen, -CN, OH, -ORa, -NRcRd, C1-C6alkyl, C1-Cehaloalkyl, C1-Cedeuteroalkyl, C1-C6hydroxyalkyl, C1-Ceaminoalkyl, C1-Ceheteroalkyl, C2-Cealkenyl, or C2-Cealkynyl; or two R7 on the same carbon combine to form an oxo; or two R7 on the same carbon or different carbons combine to form a cycloalkyl or a heterocycloalkyl;each optionally substituted by one or more R; n is 0 to 4; T is N or CR8; U is N or CR9; Petition 870250039377, dated 05 / 14 / 2025, page 169 / 372 3 / 19 R8 is hydrogen, deuterium, halogen, -CN, -OH, -ORa, NRcRd, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C1-C6heteroalkyl, C2C6alkenyl, C2-C6alkynyl, cycloalkyl or heterocycloalkyl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl and heterocycloalkyl is optionally substituted by one or more R; R9 is hydrogen, deuterium, halogen, -CN, -OH, -ORa, NRcRd, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C1-C6heteroalkyl, C2C6alkenyl, C2-C6alkynyl, cycloalkyl or heterocycloalkyl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl and heterocycloalkyl is optionally substituted by one or more R;R10 is hydrogen, deuterium, halogen, -CN, -OH, -ORa, NRcRd, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C1-C6heteroalkyl, C2C6alkenyl, C2-C6alkynyl, cycloalkyl or heterocycloalkyl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl and heterocycloalkyl is optionally substituted by one or more R; R11 is hydrogen, deuterium, halogen, -CN, -OH, -ORa, NRcRd, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C1-C6heteroalkyl, C2C6alkenyl, C2-C6alkynyl, cycloalkyl or heterocycloalkyl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl and heterocycloalkyl is optionally substituted by one or more R; R12 is cyano or halogen;each Ra is independently C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C1-C6heteroalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6alkylene(cycloalkyl), C1-C6alkylene(heterocycloalkyl), C1-C6alkylene(aryl), or Petition 870250039377, dated 05 / 14 / 2025, p. 170 / 372 4 / 19 Ci-C6alkylene(heteroaryl); wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently and optionally substituted by one or more R; each Rb is independently hydrogen, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C1-C6heteroalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6alkylene(cycloalkyl), C1-C6alkylene(heterocycloalkyl), C1-C6alkylene(aryl), or C1-C6alkylene(heteroaryl);wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently and optionally substituted by one or more R; and each Rc and Rd are independently hydrogen, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C1-C6heteroalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6alkylene(cycloalkyl), C1-C6alkylene(heterocycloalkyl), C1-C6alkylene(aryl), or C1-C6alkylene(heteroaryl); wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently and optionally substituted by one or more R; or Rc and Rd are considered together with the atom to which they are attached to form a heterocycloalkyl optionally substituted by one or more R;each R is independently deuterium, halogen, -CN, OH, -OC1-C6alkyl, -NH2, -NHC^alkyl, -N(C1-C6alkyl)2, NHC(=O)OC1-C6alkyl, -C(=O)C1-C6alkyl, -C(=O)OH, C(=O)OC1-C6alkyl, -C(=O)NH2, -C(=O)N(C1-C6alkyl)2, C(=O)NHC1-C6alkyl, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, or C1-C6heteroalkyl; or two Rs on the same atom combine to form Petition 870250039377, dated 05 / 14 / 2025, p. 171 / 372 5 / 19 an oxo; since when X is CR3, Y is CR4, and Z is CR5; then one of R3, R4, and R5 is not hydrogen and R4 is not -OMe; and since when X is CH, Y is CH, and Z is CH; then R2 is not hydrogen.; 2. The compound of claim 1, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, characterized in that X is N.
3. The compound of claim 1, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, characterized in that X is CR3.
4. Compound according to any one of claims 1 to 3, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, characterized in that Y is N.
5. Compound according to any one of claims 1 to 3, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, characterized in that Y is CR4.
6. Compound according to any one of claims 1 to 5, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, characterized in that Z is N.
7. Compound according to any one of claims 1 to 5, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, characterized in that Z is CR5.
8. The compound of claim 1, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, characterized in that the compound has Formula (Ia): Formula (Ia); Petition 870250039377, dated 05 / 14 / 2025, p. 172 / 372 6 / 19 or in that the compound has Formula (Ib): or in that the compound has Formula (Ic): Formula (Ic); or in that the compound has Formula (Id): in which one of R3, R4, and R5 is not hydrogen and R4 is not OMe; or in that the compound has Formula (Ie): in which R2 is deuterium, halogen, -CN, -ORa, -NRcRd, C1-C6alkyl, C1-C6haloalkyl, or C1-C6deuteroalkyl.
9. Compound according to any one of claims 1 to 8, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, characterized in that R1 is halogen, C1-C6alkyl, Petition 870250039377, dated 05 / 14 / 2025, page 173 / 372 7 / 19 C1-C6haloalkyl, C2-C6alkynyl, or cycloalkyl; or in that R1 is C1-C6alkyl, or cycloalkyl; or in that R1 is C1-C6alkyl; or in that R1 is cycloalkyl; or in that R1 is halogen.
10. A compound according to any one of claims 1 to 9, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, characterized in that R2 is hydrogen or halogen; or in that R2 is halogen.
11. A compound according to any one of claims 1 to 10, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, characterized in that R3 is hydrogen or halogen, or C1-C6alkyl; or in that R3 is hydrogen or halogen, or in that R3 is hydrogen.
12. A compound according to any one of claims 1 to 11, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, characterized in that R4 is hydrogen or halogen, or C1-C6alkyl; or in that R4 is hydrogen or halogen; or in that R4 is hydrogen.
13. The compound of any one of claims 1 to 12, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, characterized in that R5 is hydrogen or halogen, or C1-C6alkyl; or in that R5 is hydrogen or halogen; or in that R5 is hydrogen.
14. The compound according to any one of claims 1 to 13, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, characterized in that each R6 is independently hydrogen, deuterium, or C1-C6alkyl; or in that one R6 is hydrogen and the other R6 is C1-C6alkyl; or in that each R6 is deuterium; or in that each R6 is independently C1-C6alkyl; or in that each R6 is hydrogen.
15. The compound of any one of claims 1 to 14, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, characterized in that each R7 is independently C1-C6alkyl; or in that two R7 on the same carbon or different carbons are combined to form a cycloalkyl.
16. The compound of any one of claims 1 to 15, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, characterized in that n is 0 or 1; or in that n is 1 or 2.
17. A compound according to any one of claims 1 to 16, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, characterized in that it is or that R10 R11 R12 18. Compound according to any one of claims 1 to 17, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, characterized in that R8 is hydrogen, halogen, -CN, -ORa, C1-C6alkyl, or C1-C6haloalkyl. Petition 870250039377, from 05 / 14 / 2025, page 175 / 372 9 / 19 19. The compound of any one of claims 1 to 18, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, characterized in that R9 is hydrogen, halogen, C1-C6alkyl, C1-C6haloalkyl, or cycloalkyl.
20. The compound of any one of claims 1 to 19, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, characterized in that R10 is hydrogen, halogen, C1-C6alkyl, or C1-C6haloalkyl.
21. The compound of any one of claims 1 to 20, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, characterized in that R11 is hydrogen, halogen, C1-C6alkyl, or C1-C6haloalkyl.
22. The compound of any one of claims 1 to 21, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, characterized in that R12 is cyano; or in that R12 is halogen; or in that R12 is fluorine or chlorine.
23. Compound according to claim 1, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, characterized in that it is selected from: Petition 870250039377, of 05 / 14 / 2025, p. 176 / 372 10 / 19 Petition 870250039377, of 05 / 14 / 2025, p. 177 / 372 11 / 19 Petition 870250039377, of 05 / 14 / 2025, p. 178 / 372 12 / 19 Petition 870250039377, of 05 / 14 / 2025, p. 179 / 372 13 / 19 Petition 870250039377 of 14 / 05 / 2025, p. 180 / 372 14 / 19 Petition 870250039377 of 14 / 05 / 2025, p. 181 / 372 15 / 19 Petition 870250039377 of 14 / 05 / 2025, p. 182 / 372 16 / 19 Petition 870250039377 of 14 / 05 / 2025, p. 183 / 372 17 / 19 Petition 870250039377 of 14 / 05 / 2025, p. 184 / 372 18 / 19 Example Structure 84 ,.croir 24 Pharmaceutical composition, characterized by comprising a compound as defined in any one of claims 1 to 23 or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, and a pharmaceutically acceptable excipient.
25. Use of a compound as defined in any one of claims 1 to 23, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, or of a composition as defined in claim 24, characterized in that it is for the manufacture of a medicament for treating cancer.
26. Use according to claim 25, characterized in that the cancer is breast cancer, ovarian cancer, pancreatic cancer, prostate cancer, a hematologic cancer, gastrointestinal cancer, or lung cancer; optionally wherein the cancer is a cancer comprising a BRCA1 and / or BRCA2 mutation; optionally wherein the cancer is a cancer comprising a mutation in a gene that confers homologous repair deficiency; optionally wherein the mutation in a gene that confers homologous repair deficiency comprises ATM, BRCA1, BRCA2, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, RAD51B, RAD51C, RAD51D, or RAD54L, or any combinations thereof; or where the cancer is bladder cancer, brain and CNS cancers, breast cancer, cervical cancer, colorectal cancer, esophageal cancer, Hodgkin's lymphoma, non-Hodgkin's lymphoma, kidney cancer, leukemia, lung cancer, melanoma, myeloma, cancer of Petition 870250039377, dated 05 / 14 / 2025, page.185 / 372 19 / 19 oral cavity, ovarian cancer, pancreatic cancer, prostate cancer, skin cancer, stomach cancer, thyroid cancer or uterine cancer; or where the cancer is metastatic cancer; or because the cancer has metastasized to the brain; or where the cancer is a cancer that is present in the brain; or where the cancer is a brain cancer.
